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The rapid development of antimicrobial resistance over the past three decades 
represents a critical public health threat and urgent challenge. 
In this context, in order to establish lead compounds or identify novel modes of 
action one approach is to re-investigate drugs that affect eukaryotic processes for 
antimicrobial activity, particularly if their drug targets have homologies with 
bacterial proteins. In this study, regioisomers of LY2183240, a potent inhibitor of 
anandamide transport and fatty acid amide hydrolase were selected after a small 
screening study.  
The 2,5-LY2183240 regioisomer was shown to possess potent antimicrobial activity 
selective towards certain Gram-positive bacteria, which included Staphylococcus 
aureus and Bacillus subtilis, but not Enterococcus faecalis or Streptococcus 
pneumoniae. Conversely, the 1,5-LY2183240-regioisomer had no anti-bacterial 
activity strongly implicating the position of the carbamoyl on the tetrazole in the 
structure-activity relationship of the molecule.  
Investigation of the mechanism of antimicrobial activity suggested that while 2,5-
LY2183240 had bacteriostatic activity this was probably not due to inhibition of 
protein or teichoic acid synthesis. Nevertheless, this activity may be related to the 
inhibition of bacterial fatty acid synthesis. Supporting this hypothesis, addition of 
exogenous fatty acids within Tween 80 was able to compromise 2-5-LY2183240 
anti-staphylococcal activity. Based on the spectrum of activity and known 
redundancies at each of the steps in the fatty acid synthesis pathway, the most likely 
target was deduced to be FabI. However, characterization of a 2,5-LY2183240-
resistant mutant revealed no alteration to the deduced amino acid sequence of FabI or 
relevant changes to FabI protein expression, an observation confirmed by analysis of 
the fabI promoter region and western blot studies. Since resistance to 2,5-
LY2183240 could be mediated through non-target related factors such as drug efflux 
or drug entry into the cell, FabI could not be ruled out as a potential target. In 
addition, whole cell protein profiling revealed the 2,5-LY2183240-mutant to have 
differences in the expressions of several proteins, suggesting resistance may occur 
through a more global effect. Due to the promiscuous nature of LY2183240, the 
 iii 
possibility of having multiple targets in S. aureus that collectively exhibit a 
bacteriostatic effect cannot be ruled out.  
This study also showed that the LY2183240 regioisomers are specific inhibitors of 
class C β-lactamases with optimum inhibitory activity dependent upon the position 
of the carbonyl on the tetrazole heterocyclic group (Ki values of 1.8 and 2.45 µM for 
1,5- and 2,5-LY2183240, respectively). Molecular modelling suggested that 
LY2183240 regioisomers bind within the catalytic site of class C β-lactamases, 







by the substrate nitrocefin and β-lactamase inhibitors. The results substantiate the 
competitive inhibition model determined by enzyme kinetic studies. Furthermore, 
mass spectrometry data revealed non-covalent interactions between AmpC β-
lactamase and LY2183240 regioisomers, which together with the non-reversible 
inhibitory activity, may indicate that both regioisomers present a high affinity 
towards this cephalosporinase and dissociate very slowly from the enzyme. 
LY2183240 may prove useful as a chemical scaffold for the development of novel 




















Antimicrobial resistance is a fluid and constantly evolving challenge. The dimension 
of the problem worldwide and the influence of antimicrobial resistance on public 
health, and on costs to the health-care sector and social impact are still largely 
unknown. With the relative absence of new antimicrobials coming to market and 
with new threats arising from either Gram-positive or Gram-negative bacteria, the 
number of drug options is worryingly close to none or only a single effective agent 
for some life-threatening infections. In addition, several of β-lactam-degrading 
enzymes are rapidly disabling key β-lactam antimicrobial agents, particularly 
amongst Gram-negative bacteria. 
This project gives significant insight into the antimicrobial and resistance-modifying 
properties of LY2183240 regioisomers and is the first study examining the activity of 
these agents towards prokaryotic systems. The 2,5-LY2183240 regioisomer had 
significant and potent activity against certain bacteria, which included multi-drug 
resistant staphylococci. Both regioisomers were also found to be specific inhibitors 
of class C β-lactamases. These findings suggest that LY2183240 provides a suitable 
scaffold for the design and development of compounds aimed specifically towards 
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 Basic Modes of Antibiotic Action 1.1
 
To reach the large cells numbers observed during an infection or on the surfaces of 
the body, microorganisms have to grow and divide, replicating repeatedly. There is 
immense variation across pathogen species in the number of cells required to give 
rise to an infection. For instance, species such as Shigella and Giardia lamblia 
require about 10 cells to infect a host. In contrast, species such as Staphylococcus 
aureus require 10
3
 –108 cells in order for an infection to develop (Leggett et al., 
2012). To make this possible, they must synthesize several kinds of biomolecules. 
Antimicrobial agents interfere with specific processes that are vital for growth and 
division (Neu & Gootz, 1996). 
Moreover, antimicrobial agents may be either bactericidal, killing the 
microorganism, or bacteriostatic, inhibiting its growth. In general, bactericidal agents 
result in irreversible damage to a cell, in contrast, bacteriostatic agents, although they 
do not kill the cell, they can be extremely useful since they prevent further 
replication of the pathogen and allow the immune system time to mount its defences 
against the infection (Lee & Bishop, 2012). 
Antibiotics may be categorized into 5 major modes of action: (i) interference with 
cell wall synthesis, (ii) inhibition of protein synthesis, (iii) interference with nucleic 
acid synthesis, and (iv) inhibition of a metabolic pathway and (v) membrane 
disruption (Tenover, 2006; Džidić et al., 2008). 
 
1.1.1 Inhibition of Cell Wall Synthesis 
 
The bacterial cell wall is a complex structure composed of a range of 
macromolecules, many of which are not found elsewhere in nature (Gale et al., 
1981). Peptidoglycan is a polymer found in the cell walls of both Gram-positive and 
Gram-negative bacteria that is considered to be essential for survival of bacteria. β-
lactam agents inhibit synthesis of the bacterial cell wall by interfering with the 
enzymes, penicillin-binding protein (PBPs), required for the formation of the 
peptidoglycan layer; this category includes penicillins, cephalosporins, carbapenems, 
monobactams, glycopeptides, such as vancomycin and teicoplanin that bind to the 
cell wall pentapeptide substrate and block transglycosylation (Walsh et al., 1993; 




Figure 1.1. Chemical structures of β-lactam agents of different categories. (A) Penicillin core 
structure, “R” is the variable group; (B) Amoxicillin; (C) Cefotaxime; and (D) Meropenem. 
 
1.1.2 Inhibition of Protein Synthesis 
 
Many compounds have been shown to inhibit protein synthesis selectively. 
Definitely the preponderance of antibiotics, which act against protein synthesis do so 
by inhibiting functions of ribosomes – the multi-macromolecular complexes on or in 
which decoding of the genetic message occurs (Gale 1981). Protein synthesis is 
achieved by the pairing between a triplet of nucleotide bases in the incoming 
aminoacyl-tRNA and the complementary triplet in messenger RNA (mRNA) and 
subsequent joining of amino acids to form a polypeptide. 
Macrolides, for instance, bind to the 50S ribosomal subunit and interfere with the 
polypeptide chain elongation. Aminoglycosides inhibit polypeptide chain initiation 
binding to the 30S ribosomal subunit. Tetracyclines bind to 30S subunit of ribosome, 
thereby weakening the ribosome-tRNA interaction. Chloramphenicol binds to the 
50S ribosomal subunit blocking the peptidyltransferase reaction (Džidić et al., 2008). 
Differing from others protein synthesis inhibitors that bind to the ribosomal subunits, 
mupirocin possess a unique mode of action. This compound reversibly binds to the 
isoleucyl tRNA synthetase, especially against staphylococci and streptococci, thus 
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blocking protein synthesis and indirectly inhibiting RNA synthesis (Sutherland et al., 
1985; Slocombe & Perry, 1991). 
 
1.1.3 Interference with Nucleic Acid Synthesis 
 
Antimicrobial agents can target nucleic acid (RNA or DNA) synthesis in several 
different ways. One of the mechanisms is at the level of nucleotide metabolism, 
usually by blocking de novo synthesis of nucleotides or by rearranging the balance of 
reactions concerned with interconversion of nucleotides. Other compounds may act 
at the level of polymerization reactions, which can directly interfere with 
polymerases or other enzymatic processes involved in the replication and 
transcription of DNA (Gale, 1980). 
1.1.4 Inhibition of a Metabolic Pathway 
 
Chemotherapeutic agents may disrupt particular metabolic pathways within the 
bacterial cell. Sulphonamides, for example, interrupt the folate biosynthesis pathway, 
which is a cofactor in nucleotide synthesis, leading to the ultimate depletion of folate 
and arresting cell growth (Patel et al., 2003). 
1.1.4.1 Inhibition of Fatty Acid Synthesis 
 
Within the metabolic pathway inhibition category, bacterial fatty acid synthesis 
represents a relevant target for potential antimicrobial agents research. The 
biosynthesis of fatty acids for the formation of membranes is an energy-intensive and 
essential aspect of cell physiology. Bacteria achieve this task employing an 
extremely conserved group of enzymes named the type II fatty acid synthase system 
(FASII) (Rock & Jackowski, 2002).  
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Figure 1.2. Type II fatty acid synthesis pathway in bacteria (adapted from Schiebel et al. 2012). 
This system contrasts immensely with the type I FAS of eukaryotes, which is a dimer 
of a particular large and multifunctional polypeptide. Therefore, the bacterial 
pathway offers many different single sites for specific inhibition by antimicrobial 
agents (Heath et al., 2001). 
The enzymes that regulate this pathway are generally called Fab (fatty acid 
biosynthesis) enzymes (Janßen & Steinbüchel, 2014). Figure 1.2 shows a simple 
scheme of the pathway of the bacterial FASII and some of the inhibitors previously 
reported (Schiebel et al., 2012). Briefly, the growth of a new acyl chain is originated 
by the acetyl-CoA carboxylase complex (ACC). This complex is one of the key 
enzymes in the fatty acid biosynthesis pathway and belongs to the family of enzymes 
that catalyze the intermolecular transfer of carboxyl groups via the transient 
formation of a carboxyphosphate intermediate covalently linked to a biotin prosthetic 
group (Freiberg et al., 2004). Malonyl-CoA formed is transformed to malonyl-ACP 
(acyl-carrier protein) where it is condensed with acyl-CoA by the enzyme FabH. The 
subsequent acetoacyl-ACP feeds into the elongation module where it is extended by 
2 carbons with each round of the cycle by a condensation reaction with malonyl-
ACP via FabF. The resulting acyl-ACP can be used by glycerol-3-phosphate 
acyltransferases to synthesize phospholipids (Parsons & Rock, 2011). 
There are several inhibitors of FASII formerly reported in literature. Many of them 
are natural products that have been established as targeting ACC, as well as the 
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condensing enzymes FabF and FabH or the enoyl-ACP reductase FabI (D’Agnolo et 
al., 1973; Freiberg et al., 2006; Young et al., 2006; Zheng et al., 2007; Zheng et al., 
2009; Kwon et al., 2009; Kwon et al., 2011). Moreover, some natural products have 
demonstrated in vivo efficiency in Gram-positive and Gram-negative murine 
infection models (Miyakawa et al., 1982; Freiberg et al., 2006; Wang et al., 2007; 
Wang et al., 2006).  
One of the most significant FASII inhibitors is triclosan, which is a synthetic 
compound that has been used for decades as an antibacterial agent and has extensive 
use as an additive in a variety of antibacterial consumer products (Bhargava & 
Leonard, 1996; Rock & Jackowski, 2002). This compound specifically inhibits the 
enzyme FabI in the bacterial fatty acid biosynthesis pathway (Gomez Escalada et al., 
2005). Moreover, it is found in formulations as diverse as toothpastes, cosmetics, 
antiseptic soaps, carpets, plastic kitchenware and toys (Levy et al., 1999). 
Biomonitoring studies have detected triclosan in human urine, plasma, and breast 
milk suggesting health concerns (Adolfsson-Erici et al., 2002; Allmyr et al., 2006; 
Dayan, 2007; Wolff et al., 2007; Calafat et al., 2007). Nevertheless, a more recent 
report revealed that the exposure to triclosan in consumer products is not estimated 
to cause adverse health effects in children or adults who utilize these products as 
originally proposed (Rodricks et al., 2010). 
In 2009, Brinster and coworkers published a contentious research paper claiming that 
bacterial fatty acid synthesis (FASII) is not a suitable antimicrobial target for Gram-
positive pathogens. The authors demonstrated that in general, Gram-positive 
microorganisms, including streptococci, pneumococci, enterococci and 
staphylococci, defeated drug-induced FASII pathway inhibition when provided with 
external fatty acids, such as those found in human serum. This report triggered a 
commotion among bacterial fatty acid synthesis researchers; Balemans et al. (2010) 
responded presenting in vitro and in vivo data revealing that former observations are 
not valid for S. aureus, one of the most relevant Gram-positive pathogen causing 
numerous human infections. Moreover, the detected divergences among Gram-
positive pathogens within FASII systems suggest a variety either in fatty acid 
biosynthesis enzymes or in the capacity for fatty acid uptake from the environment 
(Balemans et al., 2010). 
More recently, Yao & Rock (2016) also debated about this topic presenting 
arguments that the situation is more complex since not all Gram-positive 
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microorganisms possess similar fatty acid structures as mammals. In addition, the 
hypothesis stated by Brinster et al. (2009) is not consistent with experimental 
observations that show the efficacy of FASII therapeutics against S. aureus using in 
vivo models (Freiberg et al., 2006; Escaich et al., 2011; Banevicius et al., 2013).  
To summarize, there is still no agreement in the literature about the significance of 
developing FASII inhibitors as antibacterial drugs against Gram-positive pathogens. 
Notwithstanding, the efficiency of fatty acid synthesis inhibitors in S. aureus 
infection models should not be overlooked and there is a need to have a detailed 
understanding of lipid metabolism in clinically relevant pathogens (Parsons & Rock, 
2011). 
 
1.1.5 Membrane disruption 
 
Some agents can affect the membrane permeability of the cell. Usually they have no 
distinction between microbial and mammalian membranes, however the fungal cell 
membrane demonstrated to be more flexible to selective action (Chopra, 2010). Until 
recently, polymyxin was the only membrane-active antibacterial agent used in 
human medicine, however, daptomycin, a cyclic lipopeptide, has now been 
introduced.  
These agents act by disrupting the Gram-negative bacterial cytoplasmic membrane, 
potentially by attacking the exposed phosphate groups of the membrane 
phospholipid. This action results in a leakage of cytoplasmic contents and death of 
the cell (Gilleland et al., 1984). 
 Antimicrobial Resistance 1.2
 
Antimicrobial resistance is not a threat to public health but a reality. A recent report 
by the World Health Organization reveals that this issue is no longer a prediction for 
the future, it is happening right now in every region of the world and has the 
potential to affect anyone, of any age, in any country (WHO, 2014).  
From time to time, microorganisms in general develop a natural resistance to 
antibiotics, and this process has been accelerated by the overuse of antimicrobials for 
trivial infections as well as those widely employed for animal farming and 
agricultural purposes (Baquero et al., 2008; Spellberg et al., 2008; Martinez, 2009). 
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Moreover, the pharmaceutical industry has not prioritized the development of new 
antimicrobial agents due to the fact that the process is expensive and any new drugs 
will produce limited profits when compared to other drug classes (Torjesen, 2014). 
Consequently, there was an antimicrobial drugs discovery gap from late 70’s until 
beginning of 2000’s (Figure 1.3), which led to a significant impact on the antibiotic 
resistance crisis (Lewis, 2017). 
 
 
Figure 1.3. The timeline of antibiotic discovery and introduction into the clinic. This figure was 
adapted from Lewis (2017) and does not comprise a comprehensive listing of antibiotics, several 
examples have been omitted to achieve clarity. In blue, the year of introduction into clinical practice; 
in red, year of discovery of a major antibiotic class. The last class to be discovered, lipopeptides 
(daptomycin) is an exception, the compound does not hit a specific target, but rather increases 
membrane permeability. 
To combat drug-resistant bacteria novel strategies and new targets are necessary to 
keep pace with ever-evolving bacterial resistance. There are recent reports 
mentioning different approaches to tackle this public health threat. Proteases, for 
instance, are essential for the proliferation and growth of bacteria and are also known 
to contribute to bacterial virulence. Some authors discuss that bacterial proteases, 
such as transpeptidases, make suitable candidates as therapeutic targets for the 
treatment of infectious diseases (Kaman et al., 2014; Culp & Wright, 2017). More 
specifically, serine hydrolases play crucial roles in prokaryotes, including pathogen 
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life cycle, virulence and drug resistance (Damblon et al., 1996; Silver, 2007; Steuber 
& Hilgenfeld, 2010; White et al., 2011; Bachovchin & Cravatt, 2012). A classic 
example of drug resistance mediated by serine hydrolases is β-lactamases. These 
enzymes are capable of inactivating β-lactam agents and they are associated with 
some of the most serious infectious disease issues that are currently encountered 
(Bush, 2013). The potential to inhibit these enzymes still remains an interesting 
approach and a resurgence in this topic with the focus on agents with novel 
mechanisms of action against a wide range of β-lactamases is currently being 
addressed (Drawz et al., 2014). 
 
1.2.1 The Social Impact of Antimicrobial Resistance 
 
Bacteria have existed on this planet for about 3.5 billion years and in that time have 
become adept at resisting the toxic substances that have threatened their survival 
(Bennett, 2008). Microbial adaptation stems from their genetic plasticity and rapid 
replication, making microorganisms one of the most diverse and adaptable life forms 
on the planet (Spellberg et al., 2008). From this framework, it seems recognizable 
that these organisms do not need help in creating antibiotic resistance. Nevertheless, 
the increase in antimicrobial resistance currently occurs due to the extensive, 
uncontrolled and in many cases inappropriate use of antimicrobials worldwide 
(Levy, 2002). 
From the perspective of public health, considering the impact of microbial resistance 
on health and economy, it is observed that antibiotic-resistant infections double the 
duration of hospital stays, double mortality as well as morbidity (and presumably the 
costs) when compared with drug-susceptible infections (Levy & Marshall, 2004). A 
cost comparison of treating methicillin-resistant (MRSA) versus methicillin-
susceptible (MSSA) Staphylococcus aureus in New York City found almost a 
threefold increase in mortality (21 % versus 8 %) and an economic cost increase of 
22 % associated with MRSA. For all hospitalized individuals with MRSA in New 
York City, such costs would translate into millions of dollars (Levy, 2002). 
According to the WHO (2014), microbial infections cause more than 25 % of deaths 
worldwide, while in developing countries the rate may reach 45 %. Furthermore, 
over 50 % of prescriptions are inappropriate and in many countries two thirds of 
antibiotics are used without a prescription. Additionally, more than 50 % of the 
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budget of drugs is allocated to the purchase of antimicrobials; antibiotics represent 
12 % of all ambulatory requirements, which corresponds to 15 % of the 100 billion 
dollars spent annually on medicines (WHO, 2013; Dye, 2014). Most of these studies 
have been conducted within the United States of America and are based on hospital 
data and include the costs related to additional hospital stays and treatment, but not 
to early mortality. Within the USA, there are 160 million prescriptions of antibiotics, 
corresponding to 25 tons of antibiotics, of which about 50 % are intended for patients 
with the remaining being used in animals and agriculture (Wenzel & Edmond, 2000). 
In the UK, after the severe increase of extended-spectrum β-lactamase (ESBL)-
producing organisms such as Escherichia coli and Klebsiella pneumoniae in the 
1980’s and 90’s, from 2001 henceforth, the situation seems to have stabilized, with 
similar levels of ESBLs being detected in 2006 and 2007 (Reynolds, 2009). 
Likewise, it is noted that there has been a marked reduction in the number of 
methicillin-resistant S. aureus (MRSA) infections in England since 2005, and a 
decrease in the occurrence of MRSA in comparison to the total number of S. aureus 
isolated (Reynolds, 2009). This positive result may be the outcome of the strategies 
implemented by the UK government in recent years, which includes improving 
infection prevention and control practices, optimising prescriptions, developing new 
drugs, treatments and diagnostics, improving professional education, training and 
public engagement, amongst others. (Department of Health & UK Government 
2013). 
Thus, it seems clear that large-scale production and use of antibiotics in clinical and 
veterinary medicine, poor infection control in hospitals and communities, 
uncontrolled use of antimicrobials in agriculture and aquaculture as well as the 
physician’s misuse of antibiotics, are all major reasons that promote selective 
pressure and aggravate antibiotic resistance (Spellberg et al., 2008; Aminov, 2009; 
Giedraitienė et al., 2011). Whilst measures may be implemented to control antibiotic 
resistance development and spread, issues still remain, particularly amongst Gram-
negative bacteria and the possible re-emergence of drug-resistant Gram-positive 
bacteria. 
1.2.2 Antimicrobial Resistance Mechanisms 
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Since the discovery and consequently extensive use of antimicrobials, a diversity of 
bacterial species from different sources and origins have developed numerous 
mechanisms that provide microorganisms resistance to some, and in certain cases to 
almost all antimicrobial agents (Džidić et al., 2008).  
1.2.2.1 Genetic Mechanism of Resistance 
 
Resistance to any antimicrobial agent may be inherent or acquired by 
microorganisms. Inherent or intrinsic resistance is a stable genetic attribute encoded 
within chromosomal DNA and shared by all members of the genus, such as the 
AmpC β-lactamases of Gram-negative bacteria and many multi-drug resistant efflux 
systems (Alekshun & Levy, 2007). On the other hand, acquired resistance comprises 
mutations in genes targeted by the antibiotic and the transfer of resistance 
determinants that express a novel phenotypic feature carried on plasmids, 
bacteriophages, transposons, and other mobile genetic elements (McManus, 1997; 
Alekshun & Levy, 2007). A single mutation that gives full clinical resistance in only 
one step is comparatively rare, but it has been well documented for certain agents, 
such as quinolones, sulphonamides, streptomycin and trimethoprim (Shafran, 1990). 
Despite the low probability, these types of mutations persist and commonly result in 
an altered protein that is less susceptible to the antibiotic. For instance, this has been 
seen in gonococci; the ability of penicillin G to reach PBPs in the cell wall has 
gradually diminished, leading to low-level resistance. However, this essentiality 
represents an evolutionary process, and resistance by this method is relatively rare 
(McManus, 1997; Franklin & Snow, 2005) (McManus, 1997; Franklin & Snow, 
2005). It is important to note that most of the genetic elements involved are 
commonly carriers of multifactorial determinants. In other words, the appearance of 
a new antimicrobial resistance gene must occur as a result of combined genetic 
processes and it is not likely to be an independent event (Dougherty & Projan, 2003). 
Genes coding for extended-spectrum β-lactamases (ESBLs) in Gram-negative 
bacteria are an interesting example of the requirement of multifactorial mutations 
(Gniadkowski, 2008). 
Bacterial pathogens that have obtained mutations presenting antibiotic resistance 
frequently have a lower growth rate and are less invasive or transmissible initially 
than their susceptible counterparts (Wiesch et al., 2010). Nevertheless, fitness costs 
of resistance mutations can be enhanced by secondary site mutations. Compensatory 
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mutations may restore fitness in the absence and/or presence of antimicrobial agents 
(Brown et al., 2010; Melnyk et al., 2015). 
The clear benefit to a bacterial species of acquiring new DNA is mainly because it 
provides a selective advantage when a new resistance attribute is acquired and 
expressed phenotypically. New resistance genes are transferred among bacteria and 
can be integrated into the bacterial chromosome and stably inherited from generation 
to generation, or they may be preserved on a bacterial plasmid. Plasmids may carry 
genes for a variety of traits, including antimicrobial resistance (Davies, 1997; 
McManus, 1997; Franklin & Snow, 2005; Alekshun & Levy, 2007). 
New genes encoding resistance from chromosomal or plasmid DNA can be 
transferred among microorganisms by transduction, transformation and conjugation. 
In transduction, these genes can be transported from one microbe to another through 
bacteriophages (bacterial viruses). Bacteriophages have a very restricted host range 
and are consequently much less successful in spreading resistance within a bacterial 
population (Goodman et al., 2011; McManus, 1997).  
Bacteria can acquire DNA from their environment in a process called transformation. 
Like transduction, the compatibility range between donor and recipient is limited. 
Transformation is the least important mechanism for antibiotic resistance 
development, nonetheless it is the molecular basis of penicillin resistance in some 
species like pneumococci (Stratton, 1997). It is believed that they have been 
introduced from viridans group streptococci and integrated into the resident 
penicillin binding protein genes by homologous recombination, although it has 
proven difficult to identify the source or sources of the divergent region (Spratt, 
1994). Lastly, conjugation is by far the most important process that implicates the 
dissemination of antimicrobial resistance including the majority of reports of 
bacterial gene transfer in the environment (Llosa & de la Cruz, 2005). 
 
1.2.2.2 Biochemical Mechanisms of Resistance 
 
Bacterial resistance genes are expressed phenotypically as biochemical interference 
with an antimicrobial’s mode of action, ensuing decreased activity against the strain 
with the resistant trait. There are several types of resistance mechanisms that bacteria 
have acquired over the years in order to survive (McManus, 1997). The prevalence 
of these mechanisms depends on the nature of the antibiotic, its target site, the 
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bacterial species and whether it is mediated by a resistance plasmid or by a 
chromosomal mutation (Džidić et al., 2008). 
Some of the mechanisms are the direct inactivation of the active antibiotic molecule, 
including the production of enzymes that degrade or modify the drug itself. 
Biochemical strategies are hydrolysis, group transfer, and redox mechanisms 
(Wright, 2005; Džidić et al., 2008). Several enzymes are known to destroy antibiotic 
activity by targeting and cleaving hydrolytically susceptible chemical bonds. A 
typical example is the β-lactamases, which cleave the β-lactam ring of the penicillin 
and cephalosporin antibiotics. A wide range of Gram-negative and Gram-positive 
bacteria produce such enzymes, and more than 200 different β-lactamases have been 
identified (Richmond & Sykes, 1973; Bush & Jacoby, 2010). This mechanism of 
resistance is addressed in more detail below (See Section 1.1.2.3). 
Alterations in the target sites of antibiotics are also a common mechanism of 
resistance whereby the antimicrobial agents are no longer able to bind to their target 
effectively. Target site changes frequently arise as a consequence of spontaneous 
mutation of an encoding gene and selection in the presence of an antibiotic. 
Mutations in RNA polymerase and DNA gyrase genes are examples of resistance to 
rifamycins and quinolones, respectively. In some cases, genetic exchange such as 
conjugation, transduction and transformation may be involved in the acquisition of 
resistance. The mecA gene, encoding PBP2a enzyme, conferring methicillin 
resistance in Staphylococcus aureus was acquired through genetic acquisition from 
an unconfirmed organism (Lambert, 2005). Another example is the mechanism of 
resistance of sulphonamides. These antimicrobial agents, including trimethoprim, 
inhibit the enzyme dihydrofolate reductase (DHFR) by competitively binding to its 
catalytic site (Van Hoek et al., 2011). High-level resistance is commonly 
accomplished by a bypass mechanism through the action of an acquired gene 
encoding an alternative enzyme, which is a non-allelic and drug-insusceptible variant 
of a chromosomal DHFR. These plasmid-mediated DHFRs emerged in Gram-
negative bacteria within several years of the clinical introduction of the drug 
(Huovinen et al., 1995; Sköld, 2000; Sköld, 2001).  
Another category of resistance mechanisms is associated with transport of the agent 
into the cell. Reduced outer membrane permeability results in reduced antibiotic up-
take. Generally, this type of resistance is mediated by modifications in the lipid or 
protein composition of the outer membrane of the bacterial cell (Delcour, 2009). 
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Moreover, efflux pumps, for instance, which are membrane proteins, export 
antibiotics out of the cell and keep their intra-cellular concentrations at low levels. 
The reduced uptake and active efflux give rise to low-level resistance in many 




The development of bacterial enzymes with the ability to hydrolyse β-lactams 
remains one of the most substantial threats to the effectiveness of this essential class 
of antimicrobial agents (Bush et al., 2011; Drawz et al., 2014). In 1940, even before 
the clinical use of penicillin, the first β-lactamase was identified in Escherichia coli 
and it was defined as an enzyme capable of destroying penicillin (Abraham & Chain, 
1940). Notwithstanding, this report was not recognized as a significant threat to drug 
development since penicillin was utilized only for Gram-positive bacterial-related 
infections. Four years later, a β-lactamase was reported from S. aureus, and 
subsequently became a significant clinical problem until the development of β-
lactamase stable anti-staphylococcal penicillin-derivatives (Kirby, 1944). More 
recently, the number of distinctive protein sequences for these enzymes, amongst a 
wide range of organisms, surpassed 890, and more than 1300 diverse -lactamases 
have now been identified in clinical isolates  (Bush et al., 2011; Bush, 2013; Farina 
et al., 2014). 
 
 
Figure 1.4. General scheme of the catalytic mechanism of serine β-lactamases adapted from 
Stojanoski et al. (2016). The β-lactam ring is shown in blue. The serine nucleophile is activated via a 
general base and attacks the carbonyl of the β-lactam ring in the acylation step. This results in 
formation of the covalent acyl-enzyme complex. In the deacylation step the complex is resolved by a 





The classification of β-lactamases is a constant research topic and two classification 
schemes are currently in use. 
The molecular classification, also known as the Ambler classification, is based on the 
amino acid sequence and divides β-lactamases into classes A, B, C, and D enzymes. 
Classes A, C and D utilize a serine residue in the catalytic site for β-lactam ring 
hydrolysis (Figure 1.4). Conversely, class B enzymes, also known as metallo-β-
lactamases, require divalent zinc ions for substrate hydrolysis (Ambler, 1980; Bush 
& Jacoby, 2010). Notably, serine β-lactamases belong to the serine hydrolases super 
family and represent the largest group of β-lactamases of relevant research interest. 
The second classification system is based on functional characteristics and it was 
presented by Bush, Jacoby and Medeiros (1995) as a refinement of earlier schemes. 
There are three main clusters of enzymes that are defined by their substrate and 
inhibitor profiles. For example, Group 1 are cephalosporinases that are not well 
inhibited by clavulanic acid; Group 2 penicillinases, cephalosporinases, and broad 
spectrum β-lactamases that are normally inhibited by active site-directed β-lactamase 
inhibitors; and finally, Group 3 are metallo-β-lactamases that hydrolyse penicillins, 
cephalosporins, and carbapenems and that are weakly inhibited by almost all β-
lactam-containing molecules. Within each group there are sub-groups denoting an 
extension of hydrolytic activity, e.g., Group 2be, with the letter "e" for extended 
spectrum of activity, represents the ESBLs, which are able of inactivating third-
generation cephalosporins (Bush et al., 1995). 
The molecular classification is more frequently used among β-lactamase researchers, 
and consequently adopted in this study. 
1.2.2.3.1.1 Class A 
 
Normally, class A enzymes are susceptible to the commercially available β-
lactamase inhibitors such as clavulanic acid and tazobactam. Nonetheless the 
carbapenemase KPC from K. pneumoniae is a significant exemption to this 
generality (Papp-Wallace et al., 2010). In 1965, the first plasmid-mediated β-
lactamase in E. coli was reported and denoted “TEM” derived from the first three 
letters of the patient’s name from whom the organism was isolated (Datta & 
Kontomichalou, 1965). Another β-lactamase named, SHV, from the term sulfhydryl 
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reagent variable, is commonly found in K. pneumoniae (Drawz et al., 2010).  The 
name’s origin indicates that p-chloromercuribenzoate (which binds sulfhydryl 
groups) inhibits hydrolysis of cephaloridine but not of benzylpenicillin (Matthew, 
1979). However, currently, many of the three letter β-lactamases names have lost 
their historical meanings (Livermore, 1995). These two β-lactamases are usually 
identified in clinical isolates of E. coli and K. pneumoniae, pathogens responsible for 
urinary tract, hospital-acquired respiratory tract, and bloodstream infections 
(Thomson & Amyes, 1993; Gorbach, 1994; Buynak, 2006). Although SHV-1 and 
TEM-1 share almost 70% sequence homology, the catalytic site of SHV-1 is about 
0.7 to 1.2 Å broader than that of TEM-1, which may have essential structural 
implications, especially related to the substrate profiles of SHV variants 
(Tzouvelekis & Bonomo, 1999).  
It is noteworthy that these enzymes may exist as extended-spectrum β-lactamase 
(ESBL) variants.  
ESBLs are a family of enzymes capable of hydrolyzing penicillins, cephalosporins, 
and monobactam antibiotics, whereas the host bacteria would still be sensitive to 
cephamycins, carbapenem antibiotics, and inhibitors of the enzymes (Han et al., 
2016). The most common ESBL genotypes include the class A, TEM, SHV and 
CTX-M, as well as the class D, OXA enzymes (Paterson & Bonomo, 2005; Perez et 
al., 2007; Liakopoulos et al., 2016). 
A typical hydrolytic reaction mechanism of a class A β-lactamase involves several 
steps. Briefly, after formation of the Henri-Michaelis complex, the active-site serine 
executes a nucleophilic attack on the carbonyl of the β-lactam agent, which results in 
a high-energy tetrahedral acylation intermediate. This intermediate transitions into a 
lower-energy covalent acyl-enzyme following protonation of the β-lactam nitrogen 
and cleavage of the C-N bond. After that, an activated water molecule attacks the 
covalent complex and leads to a high-energy tetrahedral deacylation intermediate, 
and consequently the hydrolysis of the bond between the β-lactam carbonyl and the 
oxygen of the nucleophilic serine regenerates the active enzyme and releases the 
inactive β-lactam. The acylation and deacylation processes (Figure 1.4) require the 
activation of the nucleophilic serine and hydrolytic water, respectively (Strynadka et 
al., 1992; Damblon et al., 1996; Drawz et al., 2010). 
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1.2.2.3.1.2 Class B (Metallo-β-Lactamases) 
 
Metallo-β-lactamases are metallo-enzymes that require one or two zinc ions within 
the active site for their activity. In general, these enzymes use the hydroxyl group 
from a water molecule that is coordinated by Zn
2+
 to hydrolyze the amide bond of a 
β-lactam. They belong to the molecular classification of class B β-lactamases 
according to their amino acid sequence homology, and to Group 3 according to the 
Bush-Jacoby-Medeiros classification scheme, which is based on their substrate 
profiles (imipenem hydrolysis), universal inhibition by ethylene diamine tetra-acetic 
acid (EDTA) and absence of inhibition by serine β-lactamase-susceptible inhibitors 
(Ambler, 1980; Bush et al., 1995; Rasmussen & Bush, 1997; Maltezou, 2009).  
These types of β-lactamases can hydrolyze all classes of β-lactams agents, excluding 
monobactams, and they are unique for their continuous and effective carbapenem-
hydrolyzing activities. This represents a distressing feature not only because 
carbapenems still are stable against the majority of serine β-lactamases, but also due 
to the fact they are the antimicrobial agents with the widest range of activities 
(Bebrone, 2007). 
The first report of this type of enzyme was in a Bacillus cereus species in 1966 when 
it was demonstrated that EDTA inhibited the cephalosporinase activity produced by 
this organism (Sabath & Abraham, 1966). Very few studies involving more selective 
metallo-β-lactamases inhibitors were performed during the next two decades, 
possibly because this class of enzymes was not considered to be a dangerous clinical 
threat (Mojica et al., 2016). Nevertheless, this situation dramatically changed in the 
late 1980’s, with the emergence of metallo-β-lactamases in clinically relevant 
pathogens, including Bacteroides fragilis, Pseudomonas aeruginosa, Aeromonas 
hydrophila, Serratia marcescens, and Elizabethkingia meningoseptica (Rasmussen et 
al. 1990; Watanabe et al. 1991; Massidda et al. 1991; Osano et al. 1994). 
Furthermore, a silent gene coding for a metallo-enzyme was discovered in Bacillus 
anthracis as well as Klebsiella pneumoniae clinical isolates from Japan (Senda et al. 
1996; Rossolini et al. 1998; Cornaglia et al. 1999). 
The rise and propagation of acquired metallo-β-lactamases among general Gram-
negative pathogens such as members of the family Enterobacteriaceae, P. 
aeruginosa, and Acinetobacter species turned the circumstances more grave and 
intricate (Walsh et al., 2005; Bebrone, 2007). Additionally, many of the metallo-
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enzyme genes are present in environmental species, which consequently comprise 
reservoirs of β-lactam resistance genes (Rossolini et al., 2001; Simm et al., 2001; 
Stoczko et al., 2006).  
The metallo-β-lactamases are divided into three subclasses (B1, B2, B3) based on 
primary amino acid sequence homologies (Galleni et al., 2001; Garau et al., 2004). 
Subclass B1 encompasses a more prevalent number of identified metallo-enzymes 
and embraces the well-studied Bacillus cereus BcII enzyme and the clinically 
relevant and transferable IMP-, VIM-, and NDM-type enzymes (Palzkill, 2013).  
More specifically, the increasing occurrence of carbapenem-resistant K. pneumoniae 
is of primary concern and have been reported globally (Lee et al., 2016). The New 
Delhi Metallo-β-lactamase, NDM-1, was first identified in a Swedish patient 
returning from India (Yong et al., 2009). Since then, it has been shown to be present 
at increased frequency within Enterobacteriaceae in India and has successively been 
revealed to be present in clinical isolates in a number of countries worldwide 
(Palzkill, 2013). The blaNDM-1 gene has been located on numerous plasmid types and 
it can be transferred among Gram-negative bacteria by conjugation (Göttig et al., 
2010).  
To summarize, metallo-β-lactamases are now considered a therapeutic challenge and 
the understanding of their alarming attributes is essential in the fight to overcome 
them. 
1.2.2.3.1.3 Class C 
 
AmpC β-lactamases are clinically significant cephalosporinases encoded on the 
chromosome of many Enterobacteriaceae species, including E. coli, C. freundii and 
E. cloacae and a few other organisms. They can give rise to resistance to several β-
lactams such as cephalothin, cefazolin, cefoxitin, most penicillins, and β-lactamase 
inhibitor/β-lactam combinations (Jacoby, 2009). In many bacteria species, AmpC 
enzymes are inducible and can be expressed at high levels by mutation. 
Overexpression gives resistance to broad-spectrum cephalosporins becoming a 
serious problem particularly in infections with E. aerogenes and E. cloacae, where 
an isolate originally susceptible to these antimicrobial agents may develop resistance 
upon therapy (Chow & Shlaes, 1991; Lee et al., 1991; de Champs et al., 1993; 
Tzouvelekis et al., 1994; Yigit et al., 2002; Thiolas et al., 2005; Jacoby, 2009). 
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In several organisms, including C. freundii and E. cloacae, but not E. coli, β-
lactamase expression may increase in the presence of certain β-lactam antibiotics, in 
a process referred to as induction. β-Lactamase induction by β-lactams, such as 
cefoxitin, imipenem and meropenem, occurs by the drugs crossing the outer 
membrane through porins, entering the periplasmic space, and interacting with target 
PBPs that form stable covalent complexes leading to inactivation (Beadle et al., 
2001). An increase in pools of 1,6-anhydromuropeptides is then observed, and 
AmpD is unable to efficiently process the higher levels of cell wall fragments 
(Figure 1.5). The anhydro-MurNAc-peptides replace UDP-MurNAc-pentapeptides 
bound to AmpR, causing a conformational change in the protein. AmpR is converted 
into a transcriptional activator, AmpC is expressed at higher levels, and AmpC 
accumulates in the periplasmic space. When the amount of β-lactam decreases below 
“inducing levels,” the cytoplasmic pool of anhydroMurNAc-peptides also decreases, 
and AmpD is able to efficiently cleave these peptides, restoring wild-type AmpC 
expression (Figure 1.5). 
 
 
Figure 1.5. Mechanisms involved in regulation of AmpC expression. This figure is adapted from 
Lister et al. (2009) and portrays the present information acquired from studies with members of the 
Enterobacteriaceae family. 
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The fundamental evidence regarding the class C hydrolytic mechanism indicates that 
the residue Tyr
150
 acts as a general base by increasing the nucleophilicity of Ser
64
 for 
acylation (Oefner et al., 1990). Previous studies of the deacylation mechanism 
indicated that Tyr
150
 also acts as the catalytic base, accepting a proton from the 
deacylating water (Dubus et al., 1994; Dubus et al., 1996). In a study conducted 
using a molecular simulation method, more specifically employing mixed quantum 
mechanics/molecular mechanics calculations suggested that Tyr
150
 interacts with 
Lys
67
 in a conjugate base fashion (Gherman et al., 2004). Nevertheless, the crystal 
structure of the E. coli AmpC in complex with a deacylation transition state analog 
revealed that Tyr
150
 remains protonated throughout the reaction and therefore is 
unlikely to be the anionic base. 
Figure 1.6 depicts the active site of an AmpC β-lactamase showing the main catalytic 





Figure 1.6. Hydrogen bond interactions into the catalytic site of E. cloacae P99 adapted from 
Fenollar-Ferrer et al. (2002). All the interactions are valid for β-lactams and derivatives. 
1.2.2.3.1.4 Class D 
 
Among the classes of β-lactamases, class D is the least studied so far despite its 
significance in the clinic (Maveyraud et al., 2000). This class was firstly classified as 
oxacillinases due to their capability to hydrolyze oxacillin at a rate of at least 50 % of 
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that of penicillin G, as compared to the slow hydrolysis of oxacillin by classes A and 
C β-lactamases (Danel et al., 2007).  
The most representative feature of this β-lactamase class appears to be the presence 
of a conserved carboxylated lysine residue in the active site (Golemi et al., 2001; 
Fisher et al., 2005). Moreover, some OXA enzymes have been established to form 
dimers, demonstrating a biphasic kinetic behavior, e.g., it is dependent on the 
enzyme existing as a highly active dimer at high concentration and as a less active 
monomer at low concentration (Danel et al., 2001; Vercheval et al., 2010).  
 
1.2.2.4 β-Lactamases Inhibitors 
 
Two main approaches have been accepted to overcome the fast increase in β-
lactamase-mediated resistance. The first strategy is the discovery or design of new β-
lactam antibiotics able to avoid enzymatic inactivation by β-lactamases. The second 
strategy is the finding and design of β-lactamase inhibitors that can be used in 
combination with traditional β-lactam antibiotics, allowing the β-lactam antibiotics 
to inhibit penicillin-binding proteins (PBPs) (Farina et al., 2014). The latter strategy 
is effective using agents designed to bind especially at the active site of the enzyme. 
This approach can take two forms: (1) design substrates that reversibly and/or 
irreversibly bind to the enzyme with high affinity but form unfavourable steric 
interactions as an acyl-enzyme; or (2) create mechanism-based or irreversible, also 
called “suicide inhibitors” (Drawz et al., 2010). 
Reversible inhibitors can be divided into three main types: competitive, non-
competitive and uncompetitive (Segel, 1975; Cornish-Bowden et al., 2002).  
A number of graphic methods have been described for determining the mode of 
inhibition of a particular molecule. Of these, the double reciprocal or Lineweaver-
Burk plot is the most straightforward means of diagnosing inhibitor modality (See 
Chapter 2, section 2.3.13.3) (Copeland, 2000). Figure 1.7 illustrates these types of 
inhibition as well as the graphic representations of each effect within Lineweaver-
Burk plots. Competitive inhibition denotes the case of the inhibitor binding 
particularly to the free enzyme and not at all to the enzyme-substrate complex. In 
other words, the inhibitor and substrate compete for the same enzyme form and 
normally bind in a mutually exclusive manner; which means the free enzyme binds 
either a molecule of inhibitor or a molecule of substrate, but not both concomitantly 
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(Copeland, 2000). This type of inhibition can be overcome by sufficiently high 
concentrations of substrate (Vmax remains constant), for instance, by surpassing the 
inhibitor. Nevertheless, the Michaelis-Menten constant (Km) will increase as it takes 
a higher concentration of the substrate to reach the Km, or half the Vmax.  
In non-competitive inhibition, the inhibitor displays binding affinity for both the free 
enzyme and the enzyme-substrate complex. As a result, the extent of inhibition 
depends only on the concentration of the inhibitor. Vmax (maximum velocity) will 
decrease due to the inability for the reaction to proceed as efficiently, but Km will 
remain the same, as the actual binding of the substrate, by definition, will still 
function properly. 
Lastly, uncompetitive inhibitors bind solely to the enzyme-substrate complex, rather 
than to the free enzyme form (Figure 1.7). This mode of inhibition decreases Vmax as 
a result of removing activated complex and Km decreases due to better binding 
efficiency and the effective elimination of the ES complex hence decreasing the Km, 
which indicates a higher binding affinity. 
For reversible inhibition, the reaction can be described as indicated below in 
Equation 1, where an enzyme (E) binds to its substrate (S) to form the enzyme-
substrate binary complex ES. During catalysis, this complex breaks down to release 
product (P) and free the enzyme. The inhibitor (I) can bind to either E or ES with the 




As mentioned before, irreversible “suicide inhibitors” can permanently inactivate the 
β-lactamase via secondary chemical reactions in the enzyme catalytic site. Equation 






The rate constants for each step are represented by k1, k-1, k2, and k3. More 
specifically, k1 and k-1 are the association and dissociation rate constants for the pre-
acylation complex, respectively; k2 is the acylation rate constant, and k3 is the 
deacylation rate constant (Drawz et al., 2010). 
Figure 1.7. Graphic representations of basic enzyme-substrate interactions. (A) Normal binding, (B) 
competitive inhibition, (C) non-competitive inhibition, and (D) uncompetitive inhibition. The red 




The first β-lactamase inhibitor introduced into clinical medicine was clavulanic acid 
(Figure 1.8 A), being isolated from the microorganism Streptomyces clavuligerus in 
the 1970s, almost 50 years ago (Reading et al., 1977). This inhibitor revealed no 
significant antimicrobial activity alone, but when combined with amoxicillin it 
lowered considerably the amoxicillin MICs against a wide range of pathogens 
including S. aureus, K. pneumoniae, Proteus mirabilis, and E. coli (Brown, 1986). 
 
 
Figure 1.8. Chemical structures of the main β-lactamases inhibitors currently used. (A) Clavulanic 
acid; (B) Tazobactam; (C) Sulbactam and (D) Avibactam. 
 
Sulbactam and tazobactam (Figure 1.8B and C) are penicillinate sulfones that were 
subsequent developed as synthetic compounds in the late 1970’s and beginning of 
1980’s (English et al., 1978; Fisher et al., 1980). All three β-lactamase inhibitors 
have a β-lactam ring and share structural similarity with the antimicrobial agent 
penicillin (See Figure 1.1A). They are effective against many susceptible organisms 
expressing class A β-lactamases, including CTX-M and the ESBL derivatives of 
TEM-1, TEM-2, and SHV-1, but they are usually less efficient against class B, C, 
and D β-lactamases (Bush, 1988; Philippon et al., 1989; Paterson & Bonomo, 2005; 
Buynak, 2006; Cantón & Coque, 2006; Drawz et al., 2010).  
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Avibactam is a novel non-β-lactam inhibitor with higher potency when compared to 
clavulanic acid, sulbactam, and tazobactam. This inhibitor has remarkable low IC50 
values and decreased reactivation rates for the clinically relevant class A and C β-
lactamases including TEM-1, KPC-2, and P99 and the AmpC from P. aeruginosa as 
well as the ESBL CTX-M-15 (Ehmann et al., 2012; Ehmann et al., 2013; Lahiri et 
al., 2013; Drawz et al., 2014; Choi et al., 2016). 
Table 1 depicts the kinetic properties of some relevant β-lactamases in the presence 
these inhibitors. This table was adapted from Drawz et al. (2010), with avibactam 
activity included. 
Currently, there are clinically available β-lactam/β-lactamase inhibitor combinations 
including amoxicillin-clavulanate, ticarcillin-clavulanate, ampicillin-sulbactam, 
cefoperazone-sulbactam, piperacillin-tazobactam and more recently ceftazidime-
avibactam (Fass & Prior, 1989; Corbella et al., 1998; Chetchotisakd et al., 2001; 
Geddes et al., 2007; Zhanel et al., 2013). 
More specifically, the inhibitors clavulanic acid, tazobactam, and sulbactam have 
found widespread clinical use; still, poor activity has been demonstrated against class 
D ESBLs and AmpC enzymes, with exception of avibactam combinations (Bassetti 
et al., 2008; Levasseur et al., 2012). The combination of ceftazidime-avibactam is a 
novel β-lactam-β-lactamase inhibitor with activity against carbapenem-resistant 
Enterobacteriaceae that produce carbapenemases (Zhanel et al., 2013; Shields et al., 
2017). Nonetheless, there are already reports of cases of ceftazidime-avibactam 
resistance developed during treatment of carbapenem-resistant Enterobacteriaceae 
infections (Humphries et al., 2015; Livermore et al., 2015; Haidar et al., 2017). 
In this context, it is necessary continually to develop new strategies and compounds 
to tackle the spread of β-lactam-resistant pathogens and the increasing number of 







Table 1. Kinetic properties of clinically relevant β-lactamases in the presence of inhibitors, adapted from Drawz et al. (2010). 
 β-lactamase Class Clavulanate Sulbactam Tazobactam Avibactam 
Ki (μM) IC50 (nM) Ki (μM) IC50 (nM) Ki (μM) IC50 (nM) Ki (μM) IC50 (nM) 
TEM-1 A 0.1 60 1.6 900 0.01 97  8
c
 
SHV-1 A 1 12 8.6 12,000 0.07 150   
SHV-4 A        3
d
 
SHV-5 A  20  1,800  80   
PC1 A  30  80  27   
CTX-M-2 A  200  2,100  20   
CcrA B  > 500,000  > 500,000  400,000   





CMY-2 C 4,365  101  50  26
b
  
OXA-1 D  1,800  4,700 380 1400   
OXA-2 D   1,400 0.1 140   10    
a
 Ehmann et al. (2013) 
b
 Papp-Wallace et al. (2014) 
c
 Bonnefoy et al. (2004). 
d
 Stachyra et al. (2010) 
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 Natural Products: ‘Legal Highs’ 1.3
 
In general, phytochemicals are a rational natural product alternative for investigation 
as potential antibacterial and resistance-modifying agents. Plants are known to 
produce abundant antibacterial metabolites as part of their protective mechanism 
against microorganisms in their environment (Ahuja et al., 2012). Moreover, 
antimicrobial agents from plants have a large prospect for biotechnological 
applications and have enlarged significantly in recent years with new information on 
their distribution, synthesis, regulation, in vivo function, and mechanism of action. 
With more than a quarter of a million species and a particularly diverse specialized 
metabolism, the richness of plant antimicrobials has barely been explored (Sampedro 
& Valdivia, 2014). 
‘Legal highs’ are natural products from plant or fungal sources as well as synthetic 
compounds (tablets or powders) used as recreational drugs (Arunotayanun & 
Gibbons, 2012). These products are extensively available online resulting in the rise 
of the sales and enlarging consumption of these materials worldwide (EMCDDA, 
2011). Nonetheless, a survey made in several databases revealed little information 
about the phytochemical composition, biological activities, and toxicology of these 
products. Most of the work that has been described has focused on the influence of 
these agents on the central nervous system. Their applications in other areas such as 
antimicrobial and resistance-modifying activities have yet to be explored in detail. 
Previous studies have shown that plants with psychoactive properties have proven to 
possess antimicrobial properties. Datura metel, a member of the Solanaceae family, 
contains tropane alkaloids, which are exploited traditionally for their hallucinogenic 
characteristics. Studies have found compounds derived from this species possess 
antibacterial action against a wide range of microbes. For instance, aqueous and 
ethanol leaf extracts are shown to have an MIC of 20 µg/mL against S. aureus, P. 
aeruginosa and E. coli (Akharaiyi, 2011).  
Trichocereus peruvianus and Trichocereus pachanoi popularly known as Peruvian 
Torch cacti and San Pedro, respectively, are South American species belonging to 
the Cactaceae family (Figure 1.9). They are well-known psychoactive mescaline-
containing cacti and commonly used in shamanistic treatments by decoction of sliced 
pieces of the plants. The few reports found in the literature indicate that mescaline is 
a major component and key constituent for their psychoactive activities (Halpern, 
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2044; Arunotayanun & Gibbons, 2012).  
 
 
Figure 1.9. Photograph by Jason Langley (Font: Reciprocity Images
®
) of (A) Trichocereus 
peruvianus, also known as Peruvian Torch cactus. (B) Trichocereus pachanoi photographed by Cal 
Lemke (Font: University of Oklahoma, Department of Microbiology and Plant Biology), (C) 
mescaline, the major component present in these species and responsible for psychoactive activities. 
 
 Kratom is the popular name of the species Mitragyna speciosa (Rubiaceae). 
Mitragynine is the major alkaloid in this psychoactive plant grown in Southeast Asia, 
present in concentrations up to 66% in crude extracts and possesing analgesic 
properties (Figure 1.10) (Takayama, 2004; Arunotayanun & Gibbons, 2012).  
  
Figure 1.10. (A) Photograph of kratom (Mitragyna speciosa) by Dr István Ujváry, and mitragynine 
(B), the main compound. 
 
Argyneia nervosa also known as Hawaiian Baby Woodrose is a species used in 





Ayurvedic medicine (Figure 1.11), and some reports indicate that the seed extracts 
show hypoglycemic, anti-fungal (Mishra, 1978) and antibacterial activity against 
both Gram-positive and Gram-negative organisms (Akhtar, 1992; Arunotayanun & 
Gibbons, 2012).  
 
 
Figure 1.11. (A) Argyneia nervosa photographed by Patricia Howell (Font: Atlas of Florida Vascular 
Plants). (B) Lysergic Acid Amide (LSA), precursor of Lysergic Acid Diethylamide (LSD), a potent 
hallucinogenic compound. 
 
Banisteriopsis caapi is one of the main ingredients of the sacred drink Ayahuasca 
(Figure 1.12). It is an Amazon native species and belongs to the Malpighiaceae 
family. The major components reported in this plant are β-carboline alkaloid 
derivatives, which mainly include harmine, harmaline, and tetrahydroharmine 









Figure 1.12. (A) Photograph of Ayahuasca (Banisteriopsis caapi) an Amazon native species by David 
Lorence (Font: National Tropical Botanical Gardens), (B) Harmine, and (C) Harmaline. 
 
Some species of mushroom present psychoactive compounds as well. Amanita 
muscaria also known as Fly Agaric, has been used throughout history for medicinal, 
ritual and recreational purposes (Figure 1.13). Alkaloids like ibotenic acid and 
muscimol are the main constituents responsible for central nervous system activity. 
Furthermore, A. muscaria also contains muscarine, a potent cholinergic agonist 




Figure 1.13. (A) Photograph by Geoffrey Kibby (Kew Royal Botanical Gardens) of Amanita 
muscaria, also known as Fly Agaric, (B) muscarine, the main psychoactive compound. 
 
Salvia divinorum (Lamiaceae) is one of the most consumed legal highs in the UK. 
This plant is a Mexican native species, which the key psychoactive compound is a 
non-nitrogenous neoclerodane diterpene named salvinorin A (Figure 1.14). It is 
believed that its hallucinogenic effect is due to its selective k-opioid receptor agonist 








Figure 1.14. (A) Salvia divinorum (Font: Zurich Botanical Gardens / Botanischer Garten Zürich), (B) 
salvinorin A, the key compound responsible for the psychoactive properties. 
 
Leonotis leonurus (Lamiaceae) is a robust shrub widespread throughout South Africa 
(Figure 1.15). The plant is widely used in oriental medicine and reports showed the 
presence of anticonvulsant, anti-nociceptive, anti-inflammatory and hypoglycemic 
activities. Some countries consider this species a legal high due to the orange colored 
flowers that are reported to have hallucinogenic properties (Agnihotri et al., 2009).  
 
 
Figure 1.15. (A) Photograph of Leonotis leonurus by Alvaro Villjoen (Font: Tshwane University of 
Technology), (B) leonurine, the main compound present in this species. 
 
 LY2183240 Regioisomers 1.4
 
LY2183240 (N,N-dimethyl-5-[(4-biphenyl)methyl] tetrazole–1 carboxamide) is a 










considered as a cannabinoid-type new psychoactive substance despite its chemical 
structure and mechanism of action on the cannabinoid system being different from 
those of other synthetic cannabamimetics on the market. Contrasting the emerging 
synthetic cannabinoids that act as direct agonists to cannabinoid receptors, 
LY2183240 elevates endogenous cannabinoid levels by disrupting the cellular 
uptake of a principal endocannabinoid, anandamide and arachidonoylglycerol, as 
well as inhibiting the main endocannabinoid degrading enzymes (Moore et al., 
2005). Anandamide is a naturally occurring amide of arachidonic acid with 
ethanolamine, which it is released on demand by stimulated neurons and plays a 
significant role in both central and peripheral nervous system, becoming a useful 
therapeutic approach for pain, inflammation, insomnia, depression and anxiety 
management (Devane et al., 1992; Di Marzo et al., 1994; Piomelli et al., 1999; 
Kathuria et al., 2002).  
Initial studies reported in literature on LY2183240 aimed to investigate the ability of 
this compound to inhibit the reuptake of anandamide. A study using a rodent model 
confirmed the analgesic property of LY2183240 without alteration in behaviour or 
motor responses of the subjects, unlike other cannabinoid receptor agonists, which 
generally cause undesirable adverse effects (Moore et al., 2005). 
Moreover, LY2183240 was reported as a potent irreversible inhibitor of fatty acid 
amide hydrolase (FAAH), the key enzyme involved in the degradation of 
anandamide. Regarding the mechanism of action, it is believed that LY2183240 
inactivates FAAH by covalently binding to the enzyme’s serine nucleophile (Figure 
1.16) (Alexander & Cravatt, 2006). Curiously, the test compound in this particular 
study was discovered later to be a mixture of LY2183240, 1,5 disubstituted 
carbamoyl tetrazole and its 2,5 regioisomer (Figure 1.17). Following studies reported 
that 2,5-LY2183240 behaves similarly to its isomer, but with relatively inferior 
pharmacological effect (Ortar et al., 2007; Ortar et al., 2008; Asada et al., 2015). The 
only difference between them is the position of the carbamoyl group in the tetrazole. 
Ortar et al. (2007) demonstrated that apart from the high potency against FAAH, 1,5-
LY2183240 showed a moderate activity towards a monoacylglycerol lipase 
(MAGL), a degradative enzyme of another main endocannabinoid, 2-
arachidonoylglycerol while 2,5-LY2183240 proved to be two times as active against 
MAGL than FAAH (Ortar et al., 2007; Ortar et al., 2008; Zvonok et al., 2008; 




Figure 1.16 Predicted mode of irreversible inactivation of FAAH by LY2183240, involving 
carbamylation of the enzyme’s serine nucleophile (Ser241) (Alexander & Cravatt, 2006). 
 
Intriguingly, Alexander and Cravatt (2006) revealed the identification of several 
additional serine hydrolases that were also inactivated by LY2183240 using 
functional proteomic screens. This finding indicates that this compound possesses 
rather promiscuous activity against this large and diverse enzyme class, becoming a 
relevant subject of study in many fields involving hydrolases. 
More recently, both regioisomers were detected in herbal blend products as designer 
drugs in Japan. Concomitantly, two analogues of LY2183240 were also identified 
(Asada et al., 2015). 
There have only been limited studies conducted on LY2183240 to date, especially 
regarding prokaryotic systems. This study aimed to explore the antimicrobial 




Figure 1.17. Chemical structures of the LY2183240 regioisomers design by ChemDraw
®
 software 
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 Plant Materials 2.2
 
Plant species, namely Trichocereus peruvianus, Trichocereus pachanoi, Mitragyna 
speciosa, Argyreia nervosa, Banisteriopsis caapi, Salvia divinorum, Amanita 
muscaria, and Morning Glory seeds, were purchased on-line from various websites 
(listed in Table 2), with the exception of Leonotis leonurus, which was collected in 
the Shannon, South Africa, and kindly donated for this research project. 
 
Table 2. The source of the legal highs samples tested. 
Sample Website Quantity 
Salvia divinorum leaves http://partyherbals.co.uk/index.php/  3.5g 
Argyreia nervosa http://partyherbals.co.uk/index.php/  10g 
Banisteriopsis caapi http://www.avalonmagicplants.com/  10g 
Mitragyna speciosa http://azarius.net/smartshop/  25g 
Trichocereus peruvianus http://azarius.net/smartshop/  8g 




Morning Glory seeds http://salviaonline.co.uk/ 25g 
 
2.2.1.1 Chemical Material 
 
During the screening phase of this study, synthetic compound LY2183240, 
purchased from the website “Buy Any Chem” at the average price of £ 10.00 per 500 
mg (2013), was also investigated.  
The 1,5-regioisomer of LY2183240 5-([1,1’-biphenyl]-4-ylmethyl)-N,N-dimethyl-
1H-tetrazole-1-carboxamide (Figure 1.17A) was obtained from Santa Cruz 
Biotechnology, Inc., Dallas, Texas, USA and 2,5-regioisomer of LY2183240 5-
([1,1’-biphenyl]-4-ylmethyl)-N,N-dimethyl-2H-tetrazole-1-carboxamide (Figure 
1.17B) from Cayman Chemical, Ann Arbor, Michigan, USA. Both compounds were 
stored at -20°C, protected from light and moisture. 
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2.2.2 Bacteria 
 
Table 3. The microorganisms tested. 




S. aureus 12981 + NCTC MSSA Control Strain 
S. aureus 13373 + NCTC MRSA Standard Strain 
MRSA 80415G + Clinical Isolate MRSA - 
MRSA 80415R + Clinical Isolate MRSA - 
MRSA 80415S + Clinical Isolate MRSA - 
MRSA 80415K + Clinical Isolate MRSA - 
EMRSA 15 + NCTC MRSA - 
S. aureus 1199b + ATCC Norfloxacin NorA efflux pump 
S. aureus RN4220 + Clinical Isolate MRSA From S. aureus 8325 
S. aureus XU212 + (Gibbons & Udo, 
2000) 
Tetracycline TetK efflux pump 
S. epidermidis 12228 + ATCC MSSA Standard Strain 
S. pneumoniae 12695 + NCTC  Standard Strain 
B. subtilis 15 + NCTC Susceptible Control Strain 
E. faecalis 12967 + NCTC Susceptible Control Strain 
E. faecalis 13379 + NCTC Gentamicin Standard Strain 
Stenotrophomonas sp. - NCTC Susceptible Standard Strain 
E. coli 10418 - NCTC Susceptible Control Strain 
E. coli G69 - Clinical Isolate MDR - 
C. freundii 382010 - NCTC Susceptible Standard Strain 
K. pneumoniae 17 - NCTC MDR - 
P. aeruginosa 10662 - NCTC Susceptible - 
Micrococcus 
lysodeikticus 4698  




2.3.1 Ultrasound-Assisted Extraction of Plant Material 
 
The plant materials were pulverised into fine powder with a blender. Ten grams (10 
g) of each powder of the plant was macerated in 100 mL of different solvents: n-
hexane, ethyl acetate and methanol. Extracts were prepared by an ultrasound-assisted 
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process for 1h at room temperature and filtered through Whatman No. 2 filter paper. 
Filtrates obtained from each extraction were exposed to nitrogen gas to remove any 
residual solvent, except the methanol extract, which was concentrated under vacuum 
(Buchi R-114, Switzerland). The extracts obtained were stored at 4C until further 
use. 
Twenty-five grams of L. leonurus was extracted with 250 mL of n-hexane, 
chloroform, methanol and dichloromethane in sequence, by use of a Soxhlet 
apparatus. The extract was filtered through Whatman paper filter No. 2, concentrated 
at 55 ± 3C under reduced pressure. Again, the extracts obtained were preserved at 
4C prior to use. 
2.3.2 Chemical Characterization 
 
In this study, the chemical characterisation was performed only on samples that 
previously revealed antimicrobial activity. Various types of techniques were used 
including Thin Layer Chromatography and High Performance Liquid 
Chromatography, as well as spectroscopic approaches like Nuclear Magnetic 
Resonance, and Mass Spectroscopy. 
2.3.2.1 Chromatographic Techniques 
 
2.3.2.1.1 Thin Layer Chromatography (TLC) 
 
Thin layer chromatography (TLC) was performed on LY2183240 to assess the purity 
of the compound purchased. The LY2183240 powder was dissolved in methanol (1 
mg/mL) and placed on a 10 x 10 cm silica gel TLC plate (Sigma Aldrich, UK). The 
mobile system was developed with hexane: ethyl acetate (30:70) and UV light (254 
nm and 366 nm) was used for visualization of the bands in the plate. 
 
2.3.2.1.2 High Performance Liquid Chromatography (HPLC) 
 
HPLC is a sophisticated technique of liquid chromatography used to separate the 
intricate mixture of molecules in both chemical and biological systems, offering a 
combination of speed, reproducibility and sensitivity (McMaster, 2007).  
After the TLC test, further characterisation of samples of LY2183240 (mixture, -1,5 
and -2,5) were performed by HPLC with a Agilent 1200 series instrument supplied 
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with a binary solvent manager, sample manager and photodiode array detector 
(PDA) coupled with a Q-TOF mass spectrometer. An XTerra column, 2.5 μm 
particle size, 4.6 x 50 mm (Waters, Milford, MA, United States) was utilized at a 
temperature of 40°C with a flow rate of 1 mL/min. The gradient system is 
summarized in Table 4.  
 
Table 4. Gradient system used in HPLC analysis. 
  Solvent A Solvent B 
Time (minutes) 0.1% formic acid 
0.1% formic acid in 
acetonitrile 
1 90% 10% 
8 5% 95% 
10 5% 95% 




2.3.2.2 Spectroscopic Methods 
 
2.3.2.2.1 Nuclear Magnetic Resonance (NMR) Analysis 
 
Samples of LY2183240 (5 mg) were dissolved in 0.7 mL methanol-d4, transferred to 
5 mm NMR tubes and subjected to NMR spectroscopy analysis. NMR experiments 
were performed on a Bruker Avance 400 spectrometer operating at 400 MHz (Bruker 




C and DEPT), as well as two-dimensional 
(COSY, HMQC, HMBC and NOESY) analysis. The data generated were processed 
and visualized by the software TopSpin v2.1. Chemical shifts were presented in part 
per million (ppm), which were generally scaled from 0 to 15 ppm for 
1
H-NMR 
spectra and from 0 to 220 ppm for 
13
C NMR spectra, while coupling constant (J 
values) were reported in Hertz (Hz).  
2.3.2.2.2 Mass Spectrometry Analysis 
 
Samples of LY2183240, including regioisomers -1,5 and -2,5, were dissolved in 
acetonitrile (100 %) to reach a concentration of 5 mg/mL, transferred to a glass vial 
and submitted to analysis. 
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Mass determinations were conducted by the structural analysis team at the UCL 
School of Pharmacy. Electrospray ionization mass spectrometry (ESI-MS) was 
performed on a Finnigan Navigator instrument. The mass spectra were plotted as 
arrays of vertical lines (ion peaks) of relative abundance of the ions in % (x-axis) 
against the ratio of mass-to-charge (m/z) value (y-axis). The highest peak represented 
the most abundant ion which typically was the most stable ion generated during the 
ionization process. 
2.3.3 Biological Evaluation 
 
2.3.3.1 Minimum Inhibitory Concentration (MIC) Assay 
 
The antibacterial activity of the extracts and synthetic compound LY2183240 were 
tested by the broth microdilution assay according to Andrews (2001). Briefly, all 
bacterial strains were cultured on nutrient agar (Sigma-Aldrich, UK) plates and 
incubated for 24 hours at 37°C prior to MIC determination. In addition, known 
quantities of each test sample were dissolved in DMSO and then diluted in ISB (Iso-
Sensitest Broth, Oxoid, UK) to give a range concentration of 512 – 0 μg/ml, unless 
stated differently. The DMSO concentrations employed in all experiments showed 
no inhibitory effect towards bacterial growth. Finally, the overnight cultures of each 
of the tested strains were suspended to an inoculum density of approximately 1.0 × 
10
8 
CFU/mL in the Phosphate Buffered Saline (PBS), consisting of 137 mM NaCl, 3 
mM KCl, 8 mM Na2HPO4, and 15 mM KH2PO4 (Oxoid, UK). The cell suspensions 
were standardized by adjusting the optical density to 0.1 at 600 nm (Thermo 
Scientific UV-Vis Spectrophotometer, UK) before being diluted 1:100 in ISB prior 
to inoculation. Antimicrobial agents such as penicillin, norfloxacin, and amoxicillin 
were used as positive controls for the assay. 
The assays were performed by microdilution using 96-well microtiter plates with a 
final inoculum of 5x10
5
 CFU/mL and each sample was tested in duplicate in at least 
two independent experiments in order to confirm the reliability of the data. Results 
were determined by visual inspection of the wells and the presence of an evident 
opaque medium or white pellets were indicative of bacterial growth. The MIC values 
were recorded as the lowest concentration at which no bacterial growth was detected 
(Figure 2.1).  
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Figure 2.1. Representative illustration of the microbroth dilution technique. 
 
2.3.3.2 Minimum Bactericidal Concentration (MBC) Assay 
 
The minimum bactericidal concentration (MBC) is the lowest concentration of an 
antimicrobial agent necessary to reduce the viability of the initial bacterial inoculum 
by ≥ 99.9 %. The MBC along with the MIC assist in the determination of the 
mechanism of action of the antimicrobial agents, e.g., bacteriostatic or bactericidal 
effect.  
After MIC determination, the wells showing no growth were sub-cultured onto 
nutrient agar and incubated overnight at 37°C to determinate the number of viable 
CFU present (Lorian, 2005). 
 
2.3.3.3 Antimicrobial Potentiation Assay 
 
To assess the antibiotic resistance modifying activity of the extracts and synthetic 
compounds, the MICs of antibiotics were determined in the presence or absence of 
the test samples using the broth microdilution technique as aforementioned 
(Andrews, 2001). All bacterial strains were cultured on nutrient agar for 24 h at 37°C 
prior to MIC determination. The test samples (modulators) and antimicrobial agents 
were prepared by dissolving in DMSO. The concentration of the modulators was 
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fixed throughout the experiment whilst antimicrobial agents were serially diluted 
across the 96-well microtiter plates. The MIC of the antimicrobial agents was 
determined in combination with sub-inhibitory concentrations of the modulators.  
 
2.3.3.4 Bioautographic Agar Overlay Method 
 
Bioautography has been considered one of the most effective procedures for the 
detection of antimicrobial agents, because it permits the location of the activity 
especially in a complex matrix, hence allows a target-directed isolation of the active 
components (Rahalison et al., 1991). 
The bioautographic agar overlay method was performed based on the procedure of 
Hamburger & Cordell (1987), with modifications. Firstly, the TLC plates (10 × 10 
cm) containing LY2183240 bands were developed as described in section 2.3.2.1.1. 
Afterwards the TLC plates were carefully cleaned with ethanol and placed into a 
square Petri dish (Thermo Scientific, UK). A suspension of S. aureus 12981 to 




 was added to 200 mL of molten 
nutrient agar. A sample of around 25 mL of the inoculated nutrient agar was 
dispersed evenly over the TLC plate. The plates were incubated overnight at 37°C. 
Clear inhibition zones observed against a black background indicated an active 
compound. 
 
2.3.3.5 Inhibition Zone Determination by Disc Diffusion Assay 
 
The antimicrobial activity of LY2183240 was also assessed by a disc diffusion 
method. Briefly, LY2183240 was dissolved in dimethyl sulphoxide (DMSO, Merck, 
Germany). Iso-Sensitest Agar (Oxoid, UK) was prepared and autoclaved at 121°C 
for 20 minutes. Twenty millilitres of the sterilised agar medium were poured into 
sterile Petri dishes under aseptic conditions and allowed to set. 
Overnight cultures of S. aureus 12981 and B. subtilis were prepared for the inocula 
and suspended in PBS. The cell suspensions were standardized by adjusting the 
optical density to 0.1 at 600 nm (Thermo Scientific UV-Visible Spectrophotometer, 
UK). One hundred (100 μL) microlitres of cell suspension with approximately 108 
CFU/mL were placed in Petri dishes and dispersed over the agar. Hereafter, sterile 
paper discs were saturated with 10 μL of the different compounds extracted from the 
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LY2183240 mixture and allowed to dry at 37°C for 1 hour before being placed onto 
the agar. A disc prepared under the same conditions containing DMSO was used as a 
solvent control (Tekwu et al. 2012). 
2.3.3.6 Plasmid Conjugation Assay 
 
The broth-mating for E. coli assay employed in this study was described by Rice and 
Bonomo (2005) with modifications. McConkey agar and LB broth were prepared 
and autoclaved. The appropriate antibacterial agents were added to McConkey agar 
depending on the plasmid tested (Table 5). 
Table 5 Antibiotics used for the preparation of donor and transconjugant selection 
plates. 
Test plasmid 
Agar plates for donor 
growth 
Agar plates for 
transconjugant growth 
TP114 
kanamycin (10 μg/ml) 
 
kanamycin (10 μg/mL) + 
streptomycin (20 μg/mL) 
 
pKM101 
amoxicillin (30 μg/ml) 
 
amoxicillin (30 μg/mL) + 
streptomycin (20 μg/mL) 
 
pUB307 
kanamycin (30 μg/ml) 
 
kanamycin (30 μg/mL) + 
streptomycin (20 μg/mL). 
 
R7K 
amoxicillin (30 μg/ml) 
 
amoxicillin (30 μg/mL) + 
nalidixic acid (30 μg/mL) 
 
 
In the mating experiment, the donor and a recipient strain carrying different resistant 
determinants are mixed together. Subsequently, the transconjugants were selected on 
a selective agar plate containing two antimicrobial agents. It is possible to apply 
selective conditions that inhibit both the recipient and the donor and allow the 
growth only of the recipients that acquired the transferable plasmid from the donor 
(transconjugants). In this context, the addition of LY2183240 in the mating broth 
evaluated the compound’s inhibitory activity against plasmid transfer, in comparison 
with a drug free control. Two or three colonies of an overnight culture of each strain 
were inoculated to different flasks containing 5 mL of LB broth and incubated for 16 
h at 37°C. This was followed by the mating of the strains, which included the 
addition of 450 μL of PBS, 250 μL of a donor, 250 μL of the recipient and 2.5 mL of 
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the test sample or in LB broth alone (control) in the same flask. The flask containing 
the different combinations of donors and test samples were incubated overnight at 
37°C. A serial dilution of the mixture were prepared and plated to the selective agar 
plates. All plates were incubated overnight at 37°C and eventually the colonies 
grown on each plate were counted and the transfer frequency in the presence and 
absence of LY2183240 was determined. The transfer frequency was calculated as the 
number of transconjugant, to the number of the donor colonies, both expressed as 
CFU/mL. 
 
2.3.3.7 Bacterial Cell Morphology Assay 
 
The goal of this experiment was to identify potential target or targets of LY2183240 
in Gram-positive strains, especially B. subtilis and S. aureus. Consequently, due to 
the capacity of LY2183240 to inhibit eukaryotic hydrolases, an assessment of the 
effect of the agent on bacterial hydrolases was performed.  
The process of cell division involves the association of a large number of proteins at 
the mid-point of the cell. These enzymes catalyze the separation of nucleoids, the 
formation of a septum, and the division of the cell into two daughter cells (Robichon 
et al., 2008). Bacterial peptidoglycan hydrolases constitute an ample and immensely 
diverse group of enzymes, those whose main functions include the regulation of cell 
wall growth, the turnover of peptidoglycan during growth, the separation of daughter 
cells during cell division and autolysis (Vollmer et al., 2008).  
The effect of LY2183240 mixture on cell morphology was examined over time and 
compared to the effect that the antimicrobial agent cefotaxime exhibits on bacterial 
cell shape. Inocula were incubated to reach the appropriate optical density at 600 nm. 
100 µL of S. aureus 12981 or Bacillus subtilis 13 were then added to 900 µL ISB 
containing various concentrations of cefotaxime (0.01, 0.1 and 1 µg/mL) or 
LY2183240 (16, 160 and 1.6 µg/mL). The resulting solutions were left in an 
incubator-shaker (GenLab) for 90 minutes at 37°C. Around 0.5 µL of the cell 
suspensions were spread onto a glass slide, 76 x 26 mm (Thermo Scientific, UK) and 
fixed by passing through a Bunsen flame twice, and then examined with the aid of a 
phase-contrast microscope (Zeiss light imaging, Axio Cam MR). Sequential photos 
were taken, using Zen Pro 2012 software. Between time points the solutions were 
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left in the incubator to allow continuation of the exponential growth of the cells. 
Control experiments in the absence of cefotaxime or LY2183240 were performed for 
comparison. 
2.3.3.8 Modulation of Penicillin-Induced Cell Lysis 
 
The ability of LY2183240 to inhibit cell lysis was assessed with penicillin G as the 
cell lysing-inducing agent. A M. lysodeikticus ATCC 4698 (Sigma – Aldrich, UK) 
suspension was prepared in PBS (0.1% w/v) and mixed with penicillin G (128 to 
0.125 µg/mL) or LY2183240 (800 to 12.5 µg/mL). The optical density (600nm) was 
measured in a microplate spectrophotometer (BioTek, UK) at 37°C, over a period of 
120 minutes at 5 minute intervals.  
2.3.3.9 Modulation of Triton X-100-Induced Cell Lysis  
 
Assessment of the capacity of LY2183240 to affect Triton X-100-induced cell lysis 
was accomplished by the method of Mani et al. (1993), with modifications. Briefly, 5 
mL cultures of S. aureus 12981 (MSSA) growing exponentially in ISB medium were 
collected by centrifugation (8,000  g, 4C, 15 min). Cells were washed twice with 5 
mL of cold distilled water and re-suspended in 5 mL of 0.05 M Tris-HCl (pH 7.4) 
containing 0.05 % (v/v) Triton X-100 (Sigma-Aldrich, UK). The cells were 
incubated at 37C with shaking and the absorbance was measured (630 nm) at 30-
min intervals for 3 h.  
2.3.3.10 Inhibition of Lysozyme 
 
The inhibitory activity of LY2183240 mixture against lysozyme (EC 3.2.1.17, 
Sigma-Aldrich, UK) was assessed by a cell lysis assay employing a cell suspension 
of M. lysodeikticus ATCC 4698 in PBS, pH 7.2. The cell suspension was mixed with 
PBS containing 400 units/mL of lysozyme and LY2183240 mixture. The 
concentration of LY2183240 was 170 mM. Imidazole (Sigma – Aldrich, UK) was 
used as a positive control of lysozyme inhibition at the same concentration. 
The reaction mix was incubated at 37°C and lysozyme activity was quantified by 
measuring the absorbance (630 nm) at different times with a 96-well microtiter plate 
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spectrophotometer (Biotek, UK) with plate shaking function. Analytical data were 
processed by Gen5 v1.07 software. 
2.3.3.11 Detection of Lytic Activity in SDS-PAGE Gels 
 
The lytic activity of enzyme extracts was determined as described by Mani et al. 
(1993). Briefly, a 10 % polyacrylamide-sodium dodecyl sulfate (SDS) gel containing 
0.1 % (w/v) crude cell walls from S. aureus 12697 was prepared. Purified cell walls 
and crude cell walls were prepared from exponential-phase cultures of S. aureus 
strains grown in LB medium as described by Jayaswal et al. (1990). The enzyme 
extracts were mixed with loading buffer (control) and 2,5-LY2183240 (128 µg/ml). 
Imidazole was used as positive control at the same concentration. Samples were 
heated at 98°C for 3 min in a thermo cycler (Fisher Scientific, UK) prior to 
polyacrylamide gel electrophoresis (PAGE). After electrophoresis the gels were 
incubated for 12 to 16 h at 37°C in 25 mM Tris-HCl (pH 7.4) containing 1 % Triton 
X-100 to allow protein renaturation. Bands with lytic activity were observed as clear 
zones in the opaque gel. Gels were stained with 1 % methylene blue in 0.01% KOH 
prior to photography. For total protein profile analysis, SDS-15% PAGE gels were 
used, and bands were visualized by staining with coomassie blue dye. 
 
2.3.4 In Vitro Protein Synthesis Assay 
 
The in vitro protein synthesis experiments were performed using the commercially 
available cell-free transcription-translation system composed of purified components 
PURExpress (New England BioLabs Inc., UK). The protocol was followed 
according with the manufacturer instructions using a template DNA of dihydrofolate 
reductase (DHFR). To evaluate the potential protein synthesis inhibition, 128 µg/ml 
of 2,5-LY2183240 was added into the reaction. A positive control using 
chloramphenicol was performed.  
After in vitro transcription/translation, reactions could be analyzed by SDS-PAGE 
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2.3.5 Effect of Cell Membrane Permeabiliser, PEI, on the Anti-Gram-Negative 
Activity of 2,5-LY2183240  
 
Gram-negative bacteria typically are enclosed by an outer membrane (Nikaido, 
2003). This barrier protects bacteria against austere environments and consequently 
have a major influence on the susceptibility to external agents such as antibiotics, 
which, in most of cases, are targeted at intracellular processes (Koebnik et al., 2000; 
Delcour, 2009).  
In this respect, the main objective of this assay was to evaluate the effect of the 2,5-
regioisomer towards Gram-negative bacteria in the presence of the permeabilising 
agent polyethyleneimine (PEI). 
The susceptibility of E. coli 10418 to 2,5-regioisomer was tested by broth 
microdilution procedure with and without PEI supplementation (at 256 µg/mL). 
Novobiocin was used as a standard reference under the same conditions. Likewise, 
polyethyleneimine was evaluated alone and in combination with novobiocin.  
 
2.3.6 Wall Teichoic Acid (WTA) Extraction 
 
Bacteria are surrounded by a complex cell envelope that performs a variety of 
functions (Silhavy et al., 2010). In many Gram-positive bacteria, the peptidoglycan 
layers are densely functionalized with anionic glycopolymers called wall teichoic 
acids (WTAs). These polymers play vital roles in cell shape determination, 
regulation of cell division, as well as other fundamental aspects of cell physiology. 
Moreover, WTAs are important in the pathogenesis of infection and play key roles in 
antibiotic resistance (D’Elia et al., 2006; Atilano et al., 2011; Brown et al., 2013). 
In this respect, the primary goal of this assay is to examine if the biosynthesis of 
staphylococcal wall teichoic acid could be a potential target of 2,5-LY2183240.  
The assay was divided into two parts, namely WTA extraction and WTA PAGE 
analysis. 
 
2.3.6.1 Wall Teichoic Acid Extraction 
 
The extraction of the wall teichoic acid was conducted according to Meredith et al. 
(2008) and Endl et al. (1983), with modifications. Briefly, WTA was extracted from 
a 20-mL culture of S. aureus NCTC 12981 grown in ISB overnight at 37°C. The 
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cells were collected by centrifugation (5,000 × g) for 10 min. Afterwards, they were 
subjected to washing with 30 mL of buffer 1 [50 mM 2-(N-morpholino) 
ethanesulfonic acid (MES), pH 6.5], and re-suspended in 30 mL of buffer 2 (4 % 
[wt/vol] sodium dodecyl sulfate (SDS), 50 mM MES; pH 6.5). Samples were boiled 
for 1 h, and the cells collected by centrifugation (8,000 × g) for 10 min. The pellet 
was re-suspended in buffer 2, transferred to a 1.5-ml eppendorf tube, and sedimented 
at 14,000 × g for 10 min. Subsequently, the pellet was washed once with buffer 2, 
one more time with buffer 3 (2% NaCl, 50 mM MES, pH 6.5), and finally with 
buffer 1. After the last wash, samples were treated with proteinase K (20 mM Tris-
HCl, pH 8.0; 0.5% wt/vol SDS, and 20 µg of proteinase K in 1 mL) and incubated at 
50°C for approximately 4 hours. Following digestion, samples were washed once 
with buffer 3 and then at least three times with distilled water to remove the SDS. 
Samples were carefully re-suspended in 1 mL of 0.1 M NaOH and shaken at room 
temperature for 16 h to hydrolyse the WTAs. Insoluble cell wall debris was removed 
by centrifugation (14,000 × g, 10 min), and the supernatant containing the 
hydrolysed WTA was directly analysed by polyacrylamide gel electrophoresis 
(PAGE). 
 
2.3.6.2 Wall Teichoic Acid PAGE Analysis 
 
The WTA PAGE technique was performed according to Pollack & Neuhaus (1994) 
and Meredith et al. (2008). Electrophoresis was performed utilising a Mini-Protean 
Tetra cell (Bio-Rad, Hercules, California, USA) at a constant current of 80 mA to 
achieve separation.  
WTA samples were diluted 1:3 in loading buffer (Sigma-Aldrich, UK) to obtain a 
final volume of 10 μL and loaded in a 20%-gel (total acrylamide). Gels were 
developed at ~4°C for about 18 hours using the running buffer (0.25 M Tris-base, 
1.92 M glycine, and 1 % SDS w/v). WTA bands were visualized using a coomassie 
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2.3.6.3 Lipoteichoic Acid (LTA) Potential Target Analysis 
 
The main objective of this assay was to verify if the synthesis of lipoteichoic acid is a 
potential target of 2,5-LY2183240 anti-staphylococcal activity. An agar well 
diffusion test was performed according to Magaldi et al. (2004). Briefly, 2,5-
LY2183240 (5 µg/mL) was added to a well containing 100 µg of LTA. Two controls 
containing only the regioisomer and LTA were also prepared.  
 
2.3.7 Fatty Acid Biosynthesis Inhibition Assay 
 
MICs were determined in accordance with the broth microdilution technique (section 
3.3.7). In addition, a filtered solution of 0.1 % Tween 80 was supplemented to wells 
containing the 2,5-LY2183240 (0 – 128 µg/mL) and Triclosan (0 – 32 µg/mL). 
Modulation of activity was defined as a greater than or equal to a 10-fold decrease in 
CFU mL
-1
 for the combination compared to the agent alone. All the experiments 
were conducted in triplicate. 
 
2.3.8 Selecting Drug-Resistant Mutants 
 
The traditional and classic technique of selecting mutants capable to grow in the 
presence of a toxic concentration of a novel identified compound continues to be a 
useful target identification strategy (Farha & Brown, 2016). 
A paper-disc diffusion method was used to select the drug-resistant mutants. A high-
density culture of S. aureus 12981 was applied on the agar plate and left to dry. 
Afterwards, 100 µg/ml of 2,5-LY2183240 and 10 µg/ml of triclosan were added on 
paper discs and fixed on the agar. The plates were incubated for 48 hours at 37°C.  
 
2.3.9 DNA Extraction and PCR Amplification of the fabI Gene 
 
DNA extraction was performed using DNeasy UltraClean Microbial Kit (Qiagen, 
Hilden, Germany) and the protocol was followed according to manufacturer 
instructions. PCR amplification of the fabI genes of S. aureus drug-susceptible and -
resistant mutants were performed with primers: 
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5'–CGGACGATACAGAGTTAGTTGATTC–3'  
5'–GCTAAATTTTTCAAAGGTGAACGTA–3' 
Amplification primers were designed based on the extracted sequence 919,754 (1) to 
920,994 (1,241) from Staphylococcus aureus subsp. aureus NCTC 8325 complete 
genome (accession number CP000253). Primers were identified with Primer3 
(default settings); target sequence was 919,873 (120) to 920,853 (1,100 bp). PCR 
amplification conditions were: 1 min at 98ºC for 1 cycle; 30 sec at 98ºC, 30 sec at 
65ºC and 1 min at 72ºC for 30 cycles; and 10 minutes at 72ºC for 1 cycle. The 
enzyme used was Phusion High-Fidelity DNA polymerase (NEB, UK). The PCR 
products (1103 bp) were purified utilizing a QIAquick PCR Purification Kit (Qiagen, 
Hilden, Germany) and sent for sequencing at UCL Sequencing Facility. The data 
were processed using Geneious software version 6.1.6. 
 
2.3.9.1 Western Blotting of FabI Expression 
 
The level of FabI protein expression in S. aureus strains was quantified by western 
blotting by means of polyclonal rabbit antibodies raised against recombinant S. 
aureus enoyl-[acyl-carrier-protein] reductase [NADPH] FabI protein (LifeSpan 
BioSciences, Inc., Seattle, USA).  
Bacterial protein extraction was performed using B-PERTM reagents (ThermoFisher, 
UK) with the addition of 200 units of lysostaphin (Sigma-Aldrich, UK). Briefly, an 
exponentially growing culture of S. aureus was pelleted by centrifugation at 5000 × g 
for 10 minutes. 4 mL of B-PER reagent containing lysozyme (50mg/mL), DNase I 
(2500U/mL) and lysostaphin (200 U/mL) was added for each gram of cell pellet and 
incubated for 15 minutes at room temperature. Lastly, the lysates were centrifuged at 
15,000 × g for 5 minutes to separate soluble proteins from the insoluble cell debris. 
The protein concentration in the lysates was determined by using a Bio-Rad DC kit 
in accordance with the manufacturer’s instructions. 
Western blot processing was performed with the WesternBreeze™ Chromogenic Kit, 
anti-rabbit (Thermo Scientific, UK), using anti-FabI as a primary antibody. 
MagicMark™ XP Western was used as a protein standard marker. 
After running the SDS-PAGE gel, the proteins were transferred to a PVDF 
membrane. The membrane was then placed in 10 mL of the appropriate Blocking 
Solution in a covered, plastic dish and incubated for 30 minutes on a rotary shaker. 
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The Blocking Solution was then decanted and the membrane was rinsed with 20 mL 
of water for 5 minutes, twice. Afterwards, the membrane was incubated with 10 mL 
of Primary Antibody Solution for 1 hour, then decanted and washed for 5 minutes 
with 20 mL of prepared Antibody Wash, 3 times. Subsequently, the membrane was 
incubated in 10 mL of Secondary Antibody Solution for 30 minutes, and subjected to 
the same washing procedure as aforementioned. Lastly, the membrane was incubated 
with 5 mL of Chromogenic Substrate until purple bands developed on the membrane, 
at which point the membrane was rinsed and dried on a clean piece of filter paper. 
 
2.3.10 β-Lactamase AmpC Purification 
 
2.3.10.1 Affinity Chromatography 
 
The purification of the AmpC β-lactamase from Enterobacter cloacae was 
performed by the method of Cartwright and Waley (1984) with modifications. A 
boronic acid column with a hydrophilic spacer arm (Figure 2.2) was prepared as 
follows.  20 mL of Affi-Gel 10 was washed with propan-2-ol and then water at 4°C 
and transferred to 20 mL of 1 M-KHCO3 containing 2 g of m-aminophenylboronic 
acid hemisulphate and 2 g of sorbitol under agitation at room temperature for 1h. The 
gel was poured into a column 10 cm high x 2.5 cm diameter and washed 
consecutively with 1 M-NaCI/0.5M-sorbitol, pH 7 (200 mL), 0.5 M-borate, pH 7 
(200 ml), and lastly 20 mM-triethanolamine hydrochloride/0.5 M-NaCl (loading 
buffer), pH 7.0. The column was then ready for use. 
 
 
Figure 2.2. A typical boronic acid column with a hydrophilic spacer arm. 
 
Crude protein extract containing 0.2 - 0.6 units/mg protein of β-lactamase P99 
(Sigma-Aldrich, UK) was dissolved in loading buffer and ran through a column at a 
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flow rate of 30 mL/h. The column was washed with loading buffer until the OD280 of 
washings was zero. The AmpC β-lactamase was then eluted with 0.5 M-borate/0.5 
M-NaCl, pH7. The columns were regenerated by washing with this borate buffer, 
stored at 4°C, and re-used repeatedly with no loss of binding capacity detected. The 
use of buffers of high ionic strength minimizes ionic interactions (Cartwright and 
Wiley, 1984). The samples were then analysed by SDS-PAGE electrophoresis. 
 
2.3.10.2 SDS-PAGE Electrophoresis Analysis 
 
SDS-PAGE is a consistent method for determining the purity and molecular weight 
of a particular protein; the migration position of a protein coated with SDS is 
inversely proportional to the logarithm of its molecular weight.  
A 10 μL aliquot of each fraction was loaded with SDS sample buffer (New England 
BioLabs, UK) and heated at 98°C for 3 min in a thermocycler (Fisher Scientific, UK) 
before loading into a well of a 10 % acrylamide gel (16 cm x 14 cm x 3 mm). 
Electrophoresis was performed in a Mini-Protean Tetra cell using 130 V and 500 mA 
for the separation. The running buffers contained 0.25 M Tris-base, 1.92 M glycine, 
and 1% (w/v) SDS. Proteins were stained with coomassie blue (Bio-Rad) for 60 
minutes with gentle shaking and subsequently washed with distilled water for 15 
minutes at least 3 times. 
 
2.3.10.3 Protein Concentration and Content Determination 
 
The fractions containing a ~39-kDa protein, corresponding to the P99 β-lactamase, 
were pooled and concentrated with a Vivaspin 500 centrifugal concentrator (10 kDa 
MW cut-off; Vivascience, Hannover, Germany) in sterile-filtered PBS and total 
protein content determined by the Bradford method (Ramagli & Rodriguez, 1985). 
All extracts were combined and stored at – 20°C until needed. 
 
2.3.10.4 Fast Protein Liquid Chromatography (FPLC) 
 
Fast protein liquid chromatography (FPLC) is a frequently employed liquid 
chromatographic method for macromolecules in gel separation at low pressure and 
with high capacity. The adsorbents, composed within a gel matrix with functional 
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ligands, are one of the most essential features of this chromatography technique 
(Madadlou et al., 2011). Commonly, FPLC chromatography is performed on material 
that has already been exposed to some preliminary chromatographic steps. Gel 
filtration, for instance, is frequently used as a final step to eliminate minor impurities 
from a partially purified protein (Madadlou et al., 2011). 
The FPLC gel filtration of the sample previously semi-purified was performed in 
0.05 M KH2PO4 buffer (pH 5.0), at a flow rate of 1 mL/min and using a Superdex 75 
column, which had been calibrated with molecular mass standards (GE Healthcare 
Life Science, UK). 
 
2.3.11 β-Lactamase Mass Characterisation 
 
The molecular mass of the AmpC β-lactamase from Enterobacter cloacae sp. was 
determined according to Stachyra et al. (2010) in positive-ion mode by electrospray 
ionization mass spectrometry on a Q-TOF Voyager-DE PRO with Data Explorer 
processing software. Samples were prepared with sinapinic acid at 10 mg/mL in 
50:50 ACN/H2O + 0.1 % trifluoroacetic acid (TFA). 
 
2.3.12 β-lactamase Induction Assay 
 
To determine the influence of LY2183240 on β-lactamase induction, a colorimetric 
assay employing nitrocefin was used. Nitrocefin is a chromogenic cephalosporin that 
changes colour (yellow to red) on hydrolysis, providing a sensitive test for most β-
lactamases (O’Callaghan et al., 1972) (See Figure 2.3). 
Cultures of Citrobacter freundii 382010 growing exponentially were mixed with 
meropenem (10 times above the MIC to induce β-lactamase expression) (positive 
control) and LY2183240 regioisomers (0 - 420 µM) during a 1-hour period. 
Clavulanic acid was used as a standard inhibitor control. Subsequently, 20 µL of 
nitrocefin (100 µM, final concentration) were added to assess β-lactamase activity at 
486 nm using an UV-visible spectrophotometer (Thermo-Scientific, UK). 
β-Lactamase activity was indicated by a red colour change within 1-3 min (Figure 
2.3). Reactions taking more than 10 minutes were not considered, as they may reflect 
the secondary β-lactamase activity of penicillin-binding proteins that form unstable 
acyl complexes (Livermore & Brown, 2001). 
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Figure 2.3. The reaction scheme for the hydrolysis of nitrocefin by β-lactamases. The cuvettes show 
the difference in the colour visually perceptible before (top, yellow) and after hydrolysis (bottom, 
red). 
 
2.3.13 β-Lactamase Inhibition Studies 
 
Class A and B β-lactamase activities were assessed spectrophotometrically by 
hydrolysis of the substrate nitrocefin according to O’Callaghan et al. (1972), with 
modifications. The assay mixture contained the β-lactamase (2.5 nM, TEM-1 or the 
growth medium supernatant of K. pneumoniae expressing NDM-1) and 100 μM of 
nitrocefin in a final volume of 1 mL of 50 mM phosphate buffer (PBS). β-Lactamase 
activity was monitored by measuring the absorbance at 486 nm for 3 min at 25°C. 
Both LY2183240 regioisomers were incorporated into the assay mixture separately 
and the β-lactamase activity measured as described above. Clavulanic acid was used 
as reference inhibitor for the class A enzyme. 
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2.3.13.1 Determination of IC50  
 
The inhibitor concentration that caused a 50 % reduction in enzyme activity (IC50) 
was determined according to Bush et al. (1993), with modifications. Briefly, the 
activity data were obtained after 10 min of pre-incubation of 10 to 50 µL of the 
enzyme and LY2183240 regioisomers in different concentrations (0 – 420 µM) at 
25°C. The enzymatic reaction started with the addition of the substrate nitrocefin at a 
fixed concentration of 100 µM in a volume of 1 mL. The data was determined 
graphically using GraphPad Prism version 7 software. Clavulanic acid, tazobactam 
and avibactam were used as standards.  
 
2.3.13.2 Progressive Inhibition Determinations 
 
The progressive inhibition determinations were performed according to Bush et al. 
(1993), with modifications. Briefly, the purified AmpC enzyme from Enterobacter 
cloacae (2.5 nM) and different concentrations of LY2183240 regioisomers were 
incubated together at 25°C in a total volume of 100 µL. A control containing PBS 
buffer was also prepared. At fixed time points, samples were promptly diluted 
(1:100) in reaction buffer containing 100 µM of nitrocefin. Hydrolysis rates were 
monitored over 3 to 5 minutes using a UV-visible spectrophotometer at 486 nm. All 
experiments were performed in triplicate. Tazobactam and avibactam were used as 
standards.  
 
2.3.13.3 Kinetic Interactions Studies 
 
For the kinetic studies, the inhibitory activity of the purified AmpC β-lactamase from 
E. cloacae sp. previously obtained was assessed using the chromogenic substrate 
nitrocefin as described above (O’Callaghan et al., 1972). Enzyme preparations were 
diluted in Phosphate-Buffered Saline (PBS), pH 7.0, in different sterile tubular 
universal flasks. A five-fold concentrated stock of nitrocefin was prepared in 30 % 
DMSO. Experiments employed a range of substrate concentrations (2.5 – 40 μM) 
and the enzyme AmpC (2.5 nM). The class A TEM-1 β-lactamase (0.25 μM) was 
used for method validation and comparison purposes. After incubating the enzyme at 
room temperature for 5 minutes in the presence of inhibitor, reactions were initiated 
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(6) 
by the addition of nitrocefin in a final volume of 1 mL. Nitrocefin hydrolysis was 
monitored at 486 nm using a UV-visible spectrophotometer (Thermo Scientific, UK) 
controlled by the software package VisionPro (Thermo Scientific, UK). Reaction 
rates were linear from 0 – 3 minutes at room temperature (~ 25°C). All the main 
kinetic parameters were determined by non-linear regression analysis applying 
Michaelis-Menten equation: 
 
𝑣 =  
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 +  [𝑆]
=  
𝑉𝑚𝑎𝑥





This equation plots the reaction velocity (v) as a function of the substrate 
concentration [S] for an enzyme showing that the maximal velocity (Vmax) is 
approached asymptotically. The Michaelis-Menten constant (Km) is the substrate 
concentration yielding a velocity of Vmax/2. 
 




















𝑉𝑚𝑎𝑥 =  𝐾𝑐𝑎𝑡  [𝐸𝑡] 
 
Reported values for Ki were determined using a model for mixed inhibition. The 
mixed inhibition model is a general equation that includes competitive, 
uncompetitive and non-competitive inhibition as special cases (Copeland, 2000; 
Copeland, 2013):  
 
𝑣 =  
𝑉𝑚𝑎𝑥





[𝑆] +  𝐾𝑚  (
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The model possesses one more parameter compared to the others, and this parameter 
indicates the potential mechanism of inhibition. Once the mechanism of inhibition 
was determined, the model of competitive inhibition was applied: 
𝑣 =  
𝑉𝑚𝑎𝑥 [𝑆]





All the data were conducted in triplicate and calculated using GraphPad Prism 7 
software for fitting of data, statistical and error analysis. 
 
2.3.14 In Silico Study 
2.3.14.1 Molecular Modelling 
 
Computer-based techniques for predicting the structure of ligand–protein complexes 
as well as docking algorithms can be used in both drug design and the elucidation of 
biochemical processes, including the understanding of the mode of action of a drug 
towards an enzyme target (Mcconkey et al., 2002). 
Usually, the main purpose of molecular docking is estimating the ligand-protein 
complex structure using computational approaches. A docking can be achieved by 
three interconnected elements: identification of the binding site, a search algorithm to 
successfully sample the search space, e.g., the range of potential ligand positions and 
conformations on the protein surface, and a scoring function. Preferably, sampling 
algorithms should be able to replicate the experimental binding form and the scoring 
function should identify the most favourable complex or those with the highest 
affinity amongst all conformations provided (Meng et al., 2011; Mcconkey et al., 
2002). The package software iGEMDOCK requires entry of the coordinates of the 
target protein atoms from the PDB (Protein Data Bank) format file and consecutively 
the atom coordinates of a ligand from the prepared ligand database. In this study, the 
ligands and the cephalosporinase were prepared and progressively used in the 
flexible docking mode for each ligand by using the genetic algorithm implemented in 
GEMDOCK (Yang & Chen, 2004; Barata et al., 2016). Its energy function comprises 
electrostatic, steric, and hydrogen-bonding potentials. The last two functions utilize a 
linear model, which is simple and distinguishes probable complexes promptly (Hsu 
et al., 2011). 
(7) 
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2.3.14.2 Preparation of Proteins and Compounds 
 
The structures of all ligands assessed were prepared with Avogadro 1.90.0. Protein 
crystal structures were obtained from the Protein Data Bank (PDB), 
http://www.rcsb.org/; β-lactamase from Enterobacter cloacae P99 is PDB entry 
1xx2. The protein structure was verified and optimized with the Preparation Wizard 
(Prep Wiz) tool from Maestro 10.3. For validation purposes, two different standard 
β-lactamase inhibitors, tazobactam and avibactam, were also used as ligands in 
docking. 
 
2.3.14.3 Water Molecules 
 
Molecular docking accuracy and enrichment results can be affected by the treatment 
of explicit water molecules, as formerly revealed by some researchers (Wong & 
Lightstone, 2011; Corbeil & Moitessier, 2009; Verdonk et al., 2005; de Graaf et al., 
2006; Myrianthopoulos et al., 2013). Nevertheless, the determination of which 
waters to preserve is challenging, mainly considering that the free energy of a water 
molecule is not precisely related to the crystallographic occupancy (Michel et al., 
2009). Since the main purpose of this part of the study was to assess the performance 
of LY2183240 regioisomers towards class C β-lactamases and not to 
comprehensively investigate each possible treatment of water molecules, it was only 
considered whether or not to retain the water molecules in the β-lactamase structure 
for the hydrogen bond optimization and enzyme minimization stages. Possibly, with 
no water molecules, the hydrogen-bonding arrangements necessary for ligand 
binding could be disturbed or the β-lactamase could collapse. Conversely, in most 
cases, water molecules can raise several complications, such as the process of finding 
poses and calculating binding affinity (Wong & Lightstone, 2011). In addition, 
solvation is frequently neglected in docking scoring functions, making potential 
biased scoring results. In this sense, all water molecules were removed with Maestro 
10.3 preceding molecular docking. 
2.3.14.4 Protein-Ligand Molecular Docking 
 
All the molecular dockings were performed using iGEMDOCK software (Hsu et al., 
2011). This flexible and easy-to-use software adopts a genetic evolutionary method 
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and an empirical scoring function (Hsu et al., 2011; Yang & Chen, 2004; Barata et 
al., 2016). The scoring function is given as:  
 
𝐸𝑡𝑜𝑡  =  𝐸𝑏𝑖𝑛𝑑  +  𝐸𝑝ℎ𝑎𝑟𝑚𝑎  +  𝐸𝑙𝑖𝑔𝑝𝑟𝑒 ,  
 
where Ebind accounts for inter- and intra-molecular energies and ligand is outside the 
search box, and fixed value is 10,000. The Epharma term is the sum of all hot-spot 
atoms of the interaction between ligand and protein: 
 








where wj is the pharmacophore weight of the hot-spot atom j, 𝑟𝑖𝑗
𝐵𝑖𝑗
 is the distance 
between the atoms i and j with the interaction type Bij forming by the pair-wise heavy 
atoms between ligands and proteins; Bij is either a hydrogen bond or a steric state; lig 
is the number of heavy atoms in the ligand; and hs is the number of hot-spot atoms in 
the receptor. The value of f (wj, Bij) is wj or 0. f (wj, Bij) is wj if the interaction type 
(Bij) equals the type of hotspots found on the target receptor. The ligand preferences 
include electrostatic (i.e., the number of electrostatic atoms) and hydrophilic 
characteristic (i.e., the atom numbers of hydrogen donor and acceptor). The Eligpre is 
a penalty value for a ligand, which is unable to satisfy the ligand preferences and is 
defined as  
 
𝐸𝑙𝑖𝑔𝑝𝑟𝑒 =  𝑊𝑃𝑒𝑙𝑒𝑐 +  𝑊𝑃ℎ𝑏 
 
where WPelec and WPhb are the penalties for the electrostatic and hydrophilic 
preferences, respectively (Hsu et al., 2011; Yang & Chen, 2004; Barata et al., 2016; 
Yang, 2004).  
The docking used a customized protocol by setting a population size of 500, with 
100 generations and 20 solutions. After the completion of the docking, post-docking 
analysis was performed to find the docking pose and its energy values. Confirmation 
of the scoring process was performed by the software package VEGA ZZ version 
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All the results were processed using the software packages Maestro 10.3, Pymol 1.3 
(Schrödinger, LLC, New York, NY, USA) and Discovery Studio Visualizer 4.0 
(Biovia, San Diego, CA, USA). 
 
2.3.15 Characterization of the Enzyme-Inhibitor Complex 
 
The purified AmpC enzyme from E. cloacae (40 μM) was incubated for 15 min at 
37°C in the presence and absence of 4 mM avibactam, 1,5-LY2183240 or 2,5-
LY2183240, dialyzed at 4°C and analysed by MALDI (Matrix Assisted Laser 
Desorption/Ionization) –TOF (Time of Flying) mass spectrometry (MS) (Stachyra et 
al., 2010). 
For all the analyses Voyager-DE PRO with Data Explorer processing software was 
used. Samples were prepared for MALDI-TOF with sinapinic acid at 10 mg/mL in 
50:50 ACN/H2O + 0.1 % trifluoroacetic acid (TFA). Table 8 summarizes the details 
of the parameters used. 
 
Table 6. MALDI-TOF parameters. 
Mode of operation: Linear 
Polarity: Positive 
Extraction mode: Delayed 
Accelerating voltage: 25000V 
Grid Voltage 92 % 
Guide wire: 0.3 % 
Extraction delay time: 750-1500 nsec 
 
2.3.16 Crystallographic Study 
 
The crystallization techniques were conducted according to those described by 
Professor Knox’s research group (Lobkovsky et al., 1993; Lobkovsky et al., 1994; 
Crichlow et al., 1999).  
 
 
  82 
2.3.16.1 Crystallisation 
 
Crystals of the 39,134 Da β-lactamase were grown at room temperature by the 
sitting-drop vapour diffusion method using 1:1 or 3:2 ratios of protein to reservoir 
solutions. Protein at 6.2 mg/mL was diluted with reservoir solution containing 20 % 
PEG 8,000 (Sigma-Aldrich, UK) and 0.1-M KH2PO4 at pH 5.0.  
 
2.3.16.2 Preliminary X-ray Data Collection 
 
Crystallographic data were collected at the Diamond LightSource on beam line Io4-
1, at a wavelength of 0.9785 Å, and 100 K. Processing and data reduction were 
carried out on site using Xia2, an automated data processing tool within CCP4 (Wei 





























































3 CHAPTER 3 
Mini-Screening of “legal high” natural products and 
synthetic compound LY2183240 for antibacterial and 






  84 
 Introduction 3.1
 
The discovery and clinical use of antimicrobial agents in the 1950s have 
unquestionably given one of the greatest benefits to humankind (Bérdy, 2012).  
Over the following years, the average lifespan of the population drastically 
increased, some infectious diseases almost disappeared, and several viral diseases 
became controllable. In addition, antibiotics were established to be useful in the 
treatment of bacterial, fungal and protozoan infections and some physiological 
diseases. These agents were also used in veterinary applications, as plant-protecting 
agents and as feed additives. As a result, the misuse and overuse of these compounds 
has led to a global antimicrobial resistance crisis, representing a significant public 
health menace and challenge. There is a current need to develop new antimicrobial 
agents affective against antibiotic-resistant organisms. 
Plants are rich in an extensive diversity of secondary metabolites, such as tannins, 
terpenoids, alkaloids, and flavonoids, which have been revealed to have 
antimicrobial properties in vitro (Cowan, 1999). Indeed, most existing antibiotics are 
derived from natural products, being a rational approach to discover potential novel 
compounds with antimicrobial and resistance-modifying properties (Brown & 
Wright, 2016). 
This chapter describes a mini-screening of unusual sources of natural products 
(‘legal highs’) and the synthetic compound LY2183240 for antibacterial effects. 
It is noteworthy that the data described in this chapter have been developed 
progressively and insofar as the results were obtained. In other words, the decisions 
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 Objectives 3.2
 
Antimicrobial resistance is a worldwide reality and this is a trend that will increase in 
scale rather than decrease. Therefore, development of novel strategies and 
compounds that tackle this issue are important and vital. It is well known that natural 
products from plant sources produce antibacterial metabolites. Many studies from the 
Research Department of Pharmaceutical and Biological Chemistry of UCL School of 
Pharmacy have demonstrated interesting antimicrobial activities from different 
species, including ‘legal highs’. Furthermore, some psychoactive compounds from 
plants exhibit targets that are similar to those present in prokaryotic cells. 
The main objective of this chapter is to investigate the potential antimicrobial 
activity of crude extracts of different species of plants considered as legal highs and 
the synthetic compound LY2183240. 
The specific aims of this section of the study were as follows: 
 To solvent extract the plant materials of Trichocereus peruvianus, 
Trichocereus pachanoi, Mitragyna speciosa, Argyneia nervosa, 
Banisteriopsis caapi, Salvia divinorum, Amanita muscaria, Morning glory 
and Leonotis leonurus with n-hexane, dichloromethane, chloroform and 
methanol in order to obtain standardized extracts to test; 
 To assess the antimicrobial activity by determining the minimum inhibitory 
concentrations (MIC) of the extracts and LY2183240 against a broad range of 
bacteria; 
 To determine the minimum bactericidal concentration (MBC) of compound 
LY2183240 against a broad range of bacteria;  
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 Results and Discussion 3.3
 Crude Extracts and Antimicrobial Activity 3.4
 
The antimicrobial effects of several plants species investigated in this study have 
been well documented over the years with evidence supporting the efficacy of many 
natural products as antibacterial agents (Cowan, 1999). In general, one of the 
approaches to evaluate the antimicrobial activity of natural products is to grade 
activities such that extracts which display an MIC less than 100 µg/mL, are regarded 
as good; from 100 to 500 µg/mL, the activity is considered moderate; from 500 to 
1000 µg/mL the activity is weak; and over 1000 µg/mL the extracts are considered 
inactive. In this study, the antimicrobial potential of several plant species considered 
as ‘legal highs’ were investigated against different bacteria.  
The extraction methods applied in this work yielded twenty-eight extracts from nine 




Figure 3.1. Extract preparations of the main species used in the mini-screening for antimicrobial 
activity. Photo: P. E. De Resende. 
 
The antimicrobial activities of all extracts were assessed by the broth microdilution 
technique against four Gram-positive and four Gram-negative bacteria. None of the 
extracts showed potent antimicrobial activity with MIC values exceeding 1028 
µg/mL for all organisms tested. However, these results do not fully corroborate with 
previous studies; in a screening study using medicinal plants from Northern Peru, the 
antimicrobial activity of Ayahuasca (Banisteriopsis caapi) extract against E. coli 
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gave an MIC of 62.5 µg/ml (Bussmann et al., 2010) . However, consistent with this 
study the extract had no activity against Gram-positive species.  
Regarding Argyreia nervosa, Joshi et al. (2013) demonstrated inhibitory activity 
against various species of Bacillus (MIC 59.7 to 373.2 µg/mL).  Another study 
showed antimicrobial activity for extracts of Salvia, however, they did not include 
the specific species Salvia divinorum used in this study (Khalil et al., 2005). 
Furthermore, it has been reported that extracts from Mitragyna speciosa had some 
antibacterial effect against B. subtillis, however the study reported a high MIC range 
of 3.12 to 6.25 mg/mL, which may well represent weak or no activity (Parthasarathy 
et al., 2009). 
The dissimilar results found in this work when compared with other studies utilizing 
the same species may be due to different extraction methods employed, source of 
plant material, and different bacterial strains used. Since plants were purchased 
online, doubt concerning their authenticity may exist. The possibility of 
contaminants interfering with the purity of the extraction or the action of the 
phytochemicals against the microbes may have contributed to the unexpected 
outcomes.   
Furthermore, the ‘legal high’ plants used in this study have a complex natural 
chemistry and the few studies that have been conducted so far are considered dated 
(Arunotayanun & Gibbons, 2012). In addition, for obvious reasons, most of the 
studies were generally focused on their effects on the central nervous system, rather 
than the antimicrobial activities of these species. 
 Antibiotic Potentiation Activity of Plant Extracts 3.5
 
In order to evaluate the potential antibiotic resistance modifying activity of the 
extracts prepared, the MIC of amoxicillin were determined in the presence or 
absence of the test samples using the broth microdilution technique. All extracts 
were used at the concentration of 512 μg/mL and the standard reference amoxicillin 
at a range of 0 to 128 μg/mL. The main results are summarised in Table 4.  
None of the extracts showed any positive modification in the activity of amoxicillin 
against the microorganisms tested. In fact, some of the extracts of T. pachanoi and S. 
divinorum increased the amoxicillin MIC up to 256-fold, showing a negative 
influence towards the antibiotic activity. 
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Potential inhibitors of drug resistance mechanisms may have great value because 
they could make resistant bacteria sensitive to drugs (Horiuchi et al., 2007). 
Nevertheless, due to these findings, the antimicrobial and resistance-modifying 
activities of the extracts were not studied further and the project focused entirely on 
the properties of LY2183240 regioisomers. 
Table 7. MIC of amoxicillin in the presence and absence of different plant extracts 












0.25 8 4 >128 
 
T. peruvianus HEX 1 16 16 >128 
  
ETA 1 32 16 >128 
  
MET 0.5 8 16 >128 
   
   
 
 
T. pachanoi HEX 4 8 4 >128 
  
ETA 64 8 8 >128 
  
MET 8 8 8 >128 
       
 
M. speciosa HEX 2 16 1 >128 
  
ETA 4 8 4 >128 
  
MET 0.5 8 16 >128 
       
 
A. nervosa HEX 1 16 8 >128 
  
ETA 4 32 8 >128 
  
MET 2 8 4 >128 
       
 
B. caapi HEX 2 32 8 >128 
  
ETA 8 64 16 >128 
  
MET 16 64 16 >128 
       
 
S. divinorum HEX 4 4 4 >128 
  
ETA 64 8 8 >128 
  
MET 8 8 8 >128 
       
 
A. muscaria HEX 1 16 16 >128 
  
ETA 2 32 16 >128 
  
MET 1 4 8 >128 
       
 
L. leonurus HEX 2 16 8 >128 
  
ETA 1 16 8 >128 
    MET 0.5 32 16 >128 
AMX, amoxicillin; HEX, n-hexane; ETA, ethyl acetate; MET, methanol. 
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 Characterisation of LY2183240 3.6
3.6.1 Thin Layer Chromatography 
 
Although there is a tendency towards utilizing HPLC in analyzing chemical 
mixtures, thin-layer chromatography (TLC) is still a very popular and a commonly 
used analytical method in industry and academia (Ferenczi-Fodor et al., 2011) and 
was particularly effective in this case. It is noteworthy that since the sample 
LY2183240 was purchased online, there was a lack of information about the 
ingredients, chemistries, biological activities, pharmacology and toxicology 
provided. Hence, the need to establish whether the ‘compound’ purchased was pure.  
Figure 3.2. A TLC plate of LY2183240 separated with a mobile phase of hexane-ethyl 
acetate 3:7. It is possible to see at least six bands at 240 nm and 1 at 360 nm (UV light). 
 
The isolation of seven different compounds was evident upon TLC analysis, 
indicating that it is a mixture containing potential impurities (Figure 3.2). The 
separated compounds are shown encircled in pencil after viewing at 240 nm. It is 
notable that band “e” was visualized at 360 nm. The sixth band, named “f”, is the 
major compound present in this mixture and may correspond to LY2183240. 
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3.6.2 High Performance Liquid Chromatography (HPLC) 
 
Subsequent to the TLC test, characterisation of LY2183240 was performed by HPLC 
analysis. It was possible to visualize three distinctive peaks at retention times of 6.16, 
6.48 and 6.75 minutes (Figure 3.3). The peaks at 6.48 and 6.75 minutes demonstrated 
to be 50 % and 39 % of the sample, respectively. The first peak, conversely, was 10 
% of the tested sample.  
 
 
Figure 3.3. HPLC chromatogram of LY2183240. 
Based on this analysis, the sample was not pure, consisting of at least 3 different 
compounds, 2 major compounds and one potential impurity. 
3.6.3 Spectroscopic Analyses 
It is generally accepted that a single analytical technique will not provide sufficient 
determination of the compound investigated and therefore multiple analyses from 
different technologies are necessary for a comprehensive view (Summer et al., 2003; 
Young et al., 2004). Nevertheless, it is acceptable to employ a single wide-spectrum 
chemical analytical technique, which is rapid, reproducible, and stable in time. NMR 
and mass spectrometry are techniques that meet those requirements.  
Figure 3.4 depicts the proton one-dimension NMR spectrum of the LY2183240 
mixture. Similar patterns were observed by visual inspections of 
1
H-NMR spectra of 
a 99%-pure sample of LY2183240, purchased from a different source. The signals of 
LY2183240 (
1
H-NMR – 400 MHz, Methanol) 7.6-7.5 (m, 5H), 7.4-7.3 (m, 4H), 4.5 
(s, 1H), 4.4-4.3 (s, 6H) correlated with previous data (Alexander & Cravatt, 2006). 
However, the signals in the lower field spectrum probably correspond to impurities 
or other compounds present in the mixture. Although a more complete analysis of 
NMR and other techniques are needed to comprehend better the LY2183240 
mixture, it was possible to observe the presence of LY2183240 in the sample 
analysed. 




















H NMR spectrum for LY2183240 mixture, recorded in Methanol-d4, 500MHz. The methanol peak is set at 3.31 and 4.87 ppm.
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Figure 3.5. ESI-MS/MS spectrum for LY2183240. 
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The mass spectrometry analysis showed a single peak at 308 m/z, which matches 
with the molecular weight of LY2183240. This finding together with the HPLC and 
NMR analyses confirm the presence of LY2183240 in the sample, although it 
revealed the sample to be not a pure compound, but a mixture of at least two major 
compounds, potentially two regioisomers of LY2183240 since the same molecular 
weight was observed. 
All the biological assessment of this present chapter was performed using this 
sample, nevertheless Chapter 4 will explore more the antimicrobial activity of the 
compounds present, separately. 
 Biological Evaluation 3.7
3.7.1 Antibacterial Activity of the LY2183240 Mixture 
Table 8 shows the antimicrobial activity of LY2183240 mixture against a wide range 
of microorganisms. The mixture showed activity against methicillin-susceptible S. 
aureus, B. subtilis, and to a lesser extent methicillin-resistant S. aureus 13373. 
However, it had no activity against any of the Gram-negative organisms evaluated in 
this study. The results suggested that LY2183240 had specific activity against certain 
Gram-positive bacteria; for example, no effect on E. faecalis growth was observed 
for the concentration range investigated. 







Escherichia coli NCTC 10418  
Klebsiella pneumoniae 17 
Pseudomonas aeruginosa 10663 
Stenotrophomonas ssp. 
Staphyloccocus aureus 12981 
Staphyloccocus aureus 13373 
Enterococcus faecalis 12697 
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Gram-positive bacteria are deficient in many of the complex permeation and export 
pathways found in Gram-negative organisms, making them generally more 
susceptible to antimicrobial therapy (Coleman 2004). However, this class of 
microbes are responsible for a wide range of diseases and Gram-positive bacterial-
related infections impose a major burden on patients and the health system globally 
(Rybak 2001). Additionally, the spread of new multi-drug resistant variants of S. 
aureus in the hospital and community is causing major concern (Daum & Seal, 
2001). The fact that compound LY2183240 demonstrated selective activity against 
Gram-positive bacteria, particularly S. aureus, makes it a subject of further 
exploration, especially in terms of mechanism of action. Moreover, results from the 
MBC assay demonstrated the presence of bacterial growth after 24h-incubation. This 
data suggests that LY2183240 exhibited bacteriostatic activity. 
From the results obtained and in order to understand the specific mode of action of 
LY2183240 against S. aureus and B. subtilis, a range of different experiments and 
assays were conducted. 
 
3.7.2 Bioautographic Agar Overlay Assay  
 
Bioautography is a technique that combines TLC with both biological and chemical 
detection methods. Many studies have been done on the screening of extracts from 
different sources, mostly from plants, for antimicrobial and antifungal activity 
utilizing this method (Horváth et al., 2010; Balouiri et al., 2016). 
In the case of LY2183240, the presence of two main bands were observed on the 
TLC plate and confirmed by HPLC analysis. The main goal of the bioautography 
technique was to verify if both compounds present in the mixture exhibited 
antimicrobial activity. 
Figure 3.6 illustrates the autobiogram of the TLC of LY2183240 mixture against a 
susceptible strain of S. aureus (NCTC 12981). It was observed that the band at the 
top of the TLC plate (see Figure 3.2) gave rise to a zone of inhibition against the 
Gram-positive strain tested. By contrast, the band in the bottom showed no effect at 
all, suggesting that only one compound present in the mixture possess antibacterial 
activity. It is noteworthy that the other bands present in the sample were considered 
impurities and were excluded in this assay. Nonetheless, all the bands were assessed 
in a paper diffusion assay and further discussed in this chapter. 
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The bioautographic method can be a useful tool both for the analytical determination 
of the main compounds within complex mixtures and for characterization of their 
biological properties (Choma & Jesionek, 2015). The discovery of clavulanic acid, 
for instance, was carried out using this technique, revealing its benefit, especially in 
preliminary studies (Reading et al., 1977). In this study, the bioautography was 
successfully applied demonstrating the potential component responsible for the 
antimicrobial activity in the LY2183240 mixture. The next section, hence, moves on 
to explore more this intriguing effect. 
 
 
Figure 3.6. Bioautogram of the two main bands of LY218340 mixture against S. aureus 12981. 
 
3.7.3 Paper Disc Diffusion Assay 
 
Since the discovery of antimicrobials, the issue of drug resistance among pathogens 
became evident. The disk diffusion test, based on radial diffusion of antimicrobial 
agents from paper disks, has been playing a significant role through the years, being 
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well suited for testing pathogens isolated in both clinical and microbiology research 
environments (Kronvall et al., 2011). 
In order to test all compounds present in the mixture, the seven bands present in the 
TLC plate (See Figure 3.2) were extracted from the silica and subjected to the paper 
disc diffusion assay. It was observed that only band “f”, the major compound in the 
mixture, exhibited antibacterial activity against the different strains of S. aureus 
evaluated (Figure 3.7). This finding corroborates the previous bioautogram obtained 
from section 3.7.2 above. This assay showed that LY2183240 has potential 
antibacterial activity against S. aureus 12981 and S. aureus 13373 (MRSA), but 
further research is necessary to confirm this effect. 
 
 
Figure 3.7. Antibacterial activity of the bands found in LY2183240 mixture assessed by paper 
diffusion assay using two different strains of S. aureus: (A) 12981 (MSSA) and (B) 13373 (MRSA). 
 
3.7.4 Potential Anti-Conjugative Activity of LY2183240 
 
Apart from chromosomal DNA, bacteria can carry one or more extra-chromosomal, 
double stranded, circular or linear DNA molecules, called plasmids. Plasmids are 
capable of self-replication and they maintain a substantial diversity of genes, such as 
those that ensure stable inheritance during cell division, as well as genes that confer 
antibiotic resistance and virulence determinants (Bennett, 2008; Aminov, 2009). 
They do not present essential genes for growth or development of the cell; 
nonetheless they transport genetic information that may be valuable to permit 
survival in specific environmental situations, like the presence of a potentially toxic 
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antibiotic. Moreover, they evolve as an important part of the bacterial genome, 
providing resistance genes that can be easily exchanged among bacteria of different 
origin and source by conjugation (Carattoli et al., 2001).  
In conjugation, plasmids are transferred through an external filamentous structure 
called sex pili, especially in Gram-negative bacteria and, less frequently, in gram-
positive bacteria; both donor and recipient end up with a copy of the plasmid. The 
gene for β-lactamase production in resistant Haemophilus strains, for example, is on 
a conjugative plasmid and is believed to have been transferred from this species to 
gonococci, resulting in high-level resistance that is already became a major problem 
worldwide (McManus, 1997; Tenover 2006; Bennett, 2008).  
Although compounds based on anti-plasmid approaches have not yet advanced to 
clinical trials, the well-documented occurrence of plasmids within the most 
problematic drug-resistant bacteria makes the targeting of plasmid-encoded elements 
an intriguing antibacterial option (Williams & Hergenrother, 2008).  
Since plasmid conjugation is vastly relevant for antimicrobial resistance studies and 
considering that it is a topic and research subject within our research group, the 
potential antiplasmid activity of LY2183240 was assessed. 
The inhibitory activity of LY2183240 against bacterial conjugation was evaluated in 
a conjugal transfer of PKM101, TP114, pUB307 and R7K plasmids, using a broth 
mating method. The transfer frequency was calculated as the number of 
transconjugant colonies to the number of the donor colonies, expressed as CFU/mL. 
The results are illustrated in Figure 3.8 as the percentage of transfer frequency 
compared to the activity of the control. 
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Figure 3.8 The percentage of transfer frequency using the plasmids: pKM101 (A), TP114 (B), 
pUB307 (C) and R7K (D). Control (black bar), in the presence of LY2183240 (white bar). 
 
In regards to pKM101 plasmid transfer, LY2183240 showed significant inhibitory 
activity of 61% (p < 0.05) (Figure 3.8 A). Similarly, LY2183240 exhibited a 
moderate inhibitory activity (47.5%) in the transfer of the plasmid pUB307 (Figure 
6.7 C), although not statistically significant (p > 0.05). In contrast, with the plasmids 
TP114 and R7K, LY2183240 showed a marked increase of the conjugal transfer, 
with a transfer frequency percentage of 126 % and 149 %, respectively (Figures 3.8 
B and D).  
Research towards inhibitors of plasmid-mediated resistance is a relatively new and 
unexplored field. Molnár and coworkers (1992) evaluated the antiplasmid activity of 
promethazine and they demonstrated that this synthetic compound cured antibiotic 
resistance and lactose fermentation in E. coli. It was also shown that different 
plasmids of E. coli were eliminated with varying frequency. Moreover, the molecule 
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nodule formation of Rhizobium meliloti. The authors ascribed the antiplasmid 
activity of the promethazine to the increased membrane permeability suggesting and 
inhibition of DNA gyrase and complex formation with the supercoiled form of 
plasmid DNA that leads to the cessation of plasmid replication in the bacterial cells. 
In addition, in vivo plasmid curing was demonstrated at a low frequency (Molnár et 
al., 1992). In a more recent work, Molnár et al. (2003) showed that the plasmid 
elimination efficiency of phenothiazine is markedly enhanced when a second species 
of bacteria is present, indicating that the mechanism of plasmid elimination is 
complex. Regarding natural products, the first report was described by Lakshmi et al. 
(1987), where plumbagin, a plant derived compound, cured R-plasmids in E. coli. In 
a study using Plumbago zeylanica extracts, it was observed an effect on R-plasmid 
harboring E. coli (Beg & Ahmad, 2000). Antiplasmid activity of essential oils was 
studied by Schelz et al. (2006) (Schelz, Molnar et al. 2006) and more recent, Shriram 
et al. (2008) (Shriram, Jahagirdar et al. 2008) have identified 8-epidiosbulbin E 
acetate as a potential plasmid-inhibitor agent from Dioscorea bulbifera L. against 
multi-drug resistant bacteria. 
As far as we know, there have not been any previous studies on the effect of 
LY2183240 on the bacterial conjugation mechanism and this is the first report of 
plasmid transfer inhibition activity by this compound. Nevertheless, further 
investigation must be conducted in order to explain these observations. 
 
3.7.5 LY2183240 May Interact With Cell Division Proteins 
 
The process of cell growth and division involves the formation and assembly of new 
cell wall material along the length of the cell and at the division septum (Hayhurst et 
al., 2008). These processes are regulated by mechanisms controlling the expression 
and localization of the peptidoglycan biosynthetic machinery (Biller et al., 2011). 
Cefotaxime is a third-generation class of cephalosporin and as a β-lactam agent 
inhibits bacterial cell wall synthesis by binding to one or more of the PBPs. A low 
concentration of cefotaxime (0.01 to 1 µg/mL) is known to induce cell elongation of 
Salmonella typhimurium (Gale et al., 1981). Characterisation of PBPs led to the 
conclusion that cefotaxime binds selectively to PBP 2B, (M. Bamberger et al., 2012), 
a high-molecular-weight PBP. Several studies have provided conclusive evidence 
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that this protein is involved in cell division and mutant B. subtilis strains lacking 
sufficient amount of this protein fail to separate and form filamentous structures 
(Daniel et al., 2000). 
In this study, an assessment of the effect of LY2183240 on the morphology of B. 
subtilis cells was used to verify if the compound affected cell wall synthesis or cell 
division and cefotaxime was used as a positive control in these experiments. 
Figure 3.9 shows the results of cefotaxime (0.01 µg/mL) compared to that of 
LY2183240 (1.6 µg/mL) on the morphology of B. subtilis and S. aureus 12981. The 
inserts are representative of the change in cell morphology after 90 minutes of 
exposure to the drug. Both compounds had an effect on the morphology of the 
microorganisms tested. It is evident that the effect of cefotaxime is more prominent 
compared to the effect of LY2183240 on the cells, especially on S. aureus. The 
formation of larger grape like clusters can be seen when S. aureus cells had been 
treated with cefotaxime. In the presence of LY2183240, however, there was no 
obvious difference in the morphology or the arrangements of the spherical cells. The 
morphological response of LY2183240 on the cell shape of B. subtilis is very similar 
to that produced by cefotaxime on the rod shape bacilli. Filamentation and 
elongation of the cells can be seen although a larger proportion of cells seem to have 
been affected by the inhibitory action of cefotaxime than that of LY2183240, 
suggesting that the third generation cephalosporin is a more potent inhibitor of cell 
division.  
Since cells treated with LY21803240 were similar in form to those treated with 
cefotaxime, this could indicate that LY2183240 is also involved in inhibiting 
enzymes responsible for cell separation.  
Little consideration will be given to the morphological effects of S. aureus, since 
evidence of increase in cluster formation was not conclusive. Given that wild type S. 
aureus exists in clusters it seemed that the arrangements detected with the 
microscope were merely the protective formations usually assembled in the microbe 
species to provide the physical form of a biofilm barrier against hostile environments 
(Haaber et al., 2012).  
 
  101 
 
Figure 3.9. Morphological detail recorded with Zen Pro 2012 image software. Elongation of B. 
subtilis rod-shaped cells without any treatment (A), after treatment with cefotaxime (0.01 µg/mL) (B), 
and LY2183240 (1.6 µg/mL) (C). Relative to the S. aureus 12981 control (D), treatment with 
cefotaxime (0.01 µg/mL) (E) shows an increase cluster size and number; however the morphological 
effects of LY2183240 (1.6 µg/ml) on the spherical cells demonstrated no change (F). All six 
microscopic photos were taken after a 90 min-interval of drug exposure. All images were recorded 
under the same magnification (x 100) phase contrast. 
 
3.7.6 Modulation of Penicillin-Induced Cell Lysis  
 
A few years ago, a report that describes LY2183240 as a highly potent small-
molecule inhibitor of anandamide transport has motivated more interest in 
elucidating the protein(s) responsible for this process (Moore et al., 2005). In a more 
recent work, it has been demonstrated that LY2183240 is an extremely potent 
inhibitor of fatty acid amide hydrolase (FAAH), both in vitro and in vivo. This 
compound inactivates FAAH by covalently binding to the enzyme’s serine 
nucleophile (Alexander & Cravatt, 2006). In addition, functional proteomic screens 
recognized numerous additional serine hydrolases that were also inhibited by 
LY2183240, suggesting that this compound has a promiscuous activity against this 
large and diverse enzyme class. However, none of these former studies reported 
inhibition of serine hydrolases present in prokaryotic cells, inspiring interest in 
investigating the action of LY2183240 on bacterial peptidoglycan hydrolases. In this 





























context, the main objective of this assay was to determine whether this compound 
has an effect on inhibiting endogenous M. lysodeikticus (ATCC 4698) cell 
hydrolases, counteracting therefore the action of penicillin G in lysing the cell.  
LY2183240 exhibited a concentration-dependent inhibition of lysis of M. 
lysodeikticus cells. Figure 3.10 illustrates a decrease in the percentage of initial 
absorption according with time and LY2183240 concentration. For instance, at 120 
minutes, a 21 % decrease in absorbance was observed (p < 0.05) in the presence of 
LY2183240 (128 µg/mL). In comparison, within the same timeframe, with the 
compound at 64, 32 and 0.125 µg/mL, a reduction in absorbance of 43, 58 and 69 % 
(p < 0.05) was noted, respectively.  
 
Figure 3.10. The effect of penicillin G in combination with LY2183240 on Micrococcus 
lysodeikticus. The graph illustrates penicillin G (200 µg/mL) in combination with LY2183240 in a 
concentration range of (, 128 µg/mL;  64 µg/mL;  32 µg/mL; × 16 µg/mL;  8 µg/mL;  4 
µg/mL; + 2 µg/mL;  1 µg/mL; = 0.5 µg/mL; – 0.250 µg/mL;  0.125 µg/mL;  0 µg/mL). 
Changes in OD600 were measured at 5-minute intervals for 120 minutes. Data are representative of 
experiments preformed in triplicate. 
β-Lactams are a broad class of antibiotics encompassing cephalosporin and penicillin 
derivatives, both of which were investigated in this study for comparison purposes 
against LY2183240. This class of agents binds covalently to penicillin-binding-
proteins (PBPs) with different affinities dependent upon the individual drug. In 
general, β-lactams target the bacterial cell wall formation, specifically by inhibiting 
the synthesis of the peptidoglycan layer of bacterial cell walls (Kong et al., 2010).  
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Penicillin G, like other β-lactams, acts on actively growing cells to inhibit the 
terminal reaction of cell wall biosynthesis. This reaction is termed transpeptidation 
and involves the formation of a complex with transpeptidase and D-alanyl-D-alanine 
dipeptide. 
Penicillin competes with D-alanyl-D-alanine for the active site of this PBP to form 
an inactive complex. As a result of its action the usually rigid peptidoglycan layer 
loses its integrity and the cell becomes unable to synthesis a typical matrix that can 
withstand the increase in internal osmotic pressure, ultimately leading to cell lysis. 
This would manifest itself as a decrease in turbidity as the number of intact cells 
decrease (Blumberg & Strominger 1974). 
In addition, penicillin also lyses Gram-positive bacteria by activation of autolytic 
enzymes, the activity is triggered by release of an inhibitor from the bacterial cell 
wall (Tomasz, 1974; Fontana et al., 1977; Kiriyama et al., 1987). 
The absorption measurements, obtained in the assay in the presence of penicillin G 
indicated a decrease in cell lysis with increased LY2183240 concentration. This is 
depicted in Figure 3.10 where the percentage decrease in turbidity is significantly 
lower in the presence of LY2183240. The data suggests that LY2183240 inhibits 
enzymes that would otherwise amplify the effect of penicillin G by causing cell lysis. 
This theory points to the inhibition of peptidoglycan hydrolases responsible for 
cleaving the muropeptides from the middle of the division septum to allow for the 
separation of the cells. 
Multiple PBPs are found in microbes, of which some possess synthase activities, and 
other possess hydrolytic activities and would be considered as peptipdoglycan 
hydrolases. Synergistic activity within the PBP family and with other peptidoglycan 
serine hydrolase enzymes, results in the polymerization and subsequent crosslinking 
of the glycan strands forming the murein wall (Sauvage et al., 2008). The selective 
binding therefore of the different β-lactams to the PBP interferes with peptidoglycan 
biosynthesis. The affinity of the different PBPs differs between the β-lactams 
resulting in varied effects on the cell morphology as demonstrated in studies 
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3.7.7 Inhibition of Lysozyme 
 
Bearing in mind the fact that this compound may possess activity against bacterial 
serine hydrolases, this assay aimed to extend the activity of LY2183240 against 
lysozyme. Lysozyme belongs to the hydrolase enzymatic class that catalyzes the 
breakdown of peptidoglycan polymers of bacterial cell wall at the bonds between N-
acetylmuramic acid and N-acetylglucosamine residues, therefore, lysing bacterial 
cells. The lysing activity of lysozyme is essentially focused on Gram-positive 
bacteria, as the target (peptidoglycan) is freely accessible to the enzyme, dissimilar to 
that of Gram-negative microorganisms, which is protected by the lipopolysaccharide 
layer of the outer membrane (Benkerroum, 2008). 
The course of lysis of M. lysodeikficus cells (0.1 %) by lysozyme (400 units/mL) at 
pH 7.2 and the ability of the compound LY2183240 to inhibit the enzymatic activity 
was assessed (Figure 3.11). The results showed that the lysozyme had the ability to 
lyse 44 % of M. lysodeikticus cells in 30 minutes. When LY2183240 was present in 
the solution, at the concentrations of 170 mM, only 22 % of cell lysis was achieved 
in the same period (p < 0.05). Imidazole, used as a positive control, exhibited a total 
inhibition of the cell lysis with time (p < 0.05) (Shinitzky et al., 1966). 
The moderate inhibitory activity of lysozyme by LY2183240 observed in this study 
may be related to the fact that this compound possesses a wide range inhibition effect 
among hydrolases and more assays were carried on to understand this effect. 
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Figure 3.11. The effect of LY2183240 on lysozyme-mediated lysis of Micrococcus lysodeikticus 
cells. The graph illustrates a concentration of 400 units/mL lysozyme (, negative control) in 
combination with LY2183240 (170 mM) () and imidazole (170 mM) (, positive control). 
Turbidity measurements were taken at 1 minute intervals for 30 minutes. The effect on the M. 
lysodeikticus cells was plotted with Microsoft Excel software. Data represents experiments performed 
in triplicate. 
 
3.7.8 Modulation of Triton X-100-Induced Cell Lysis  
 
Autolysins are peptidoglycan (murein) hydrolases able to digest the murein of the 
bacteria that produce them (Korsak et al., 2005). This class of enzymes is 
omnipresent amongst bacteria (Ghuysen et al., 1966; Mani et al., 1993; Shockman & 
Höltje, 1994; Foster et al., 2000; Korsak et al., 2005). Additionally, several important 
roles have been ascribed over the years, including action as a pacemaker for cell wall 
growth, cell separation, assistance in the murein turnover, lysis initiated by cell wall-
active antibiotics, formation of flagella, and bacterial pathogenicity (Goodell, 1985; 
Mani et al., 1993; Höltje, 1995; García et al., 1999; Korsak et al., 2005). 
Some authors claim that the autolytic activity may be stimulated by lysozyme 
(Wecke et al., 1982), cationic peptides (Wecke et al., 1986), proteolytic enzymes 
(Ved et al., 1984), and detergents, including Triton X-100 (Raychaudhuri & 
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activity happens most frequently at the post translational level, comprising specific 
activation of the enzyme by substrate modification, topological restriction of enzyme 
distribution in the cell wall, and control at the site of export (Höltje & Tuomanen, 
1991; Mani et al., 1993). 
In this study, Triton X-100, a nonionic surfactant capable of inducing enzyme-
mediated cell lysis in bacteria, was used in order to verify the effect of LY2183240 
on autolysins.  
Figure 3.12 shows the lysis of the whole cells from different species when they were 
re-suspended in buffer containing Triton X-100 (0.05 %). Notwithstanding, under the 
same conditions and in the presence of LY2183240, a significant reduction of the 
lysis of all cell types tested was observed (p < 0.05). 
A marked inhibition by LY2183240 of the whole cell lysis of S. aureus (Figure 
3.12A) and B. subtilis (Figure 3.12B) was noted; the same organisms that were 
inhibited by the compound. However, LY2183240 did not show antimicrobial 
activity against E. faecalis, but it was capable of slightly limiting the lysis in this 
case (Figure 3.12C). In the same way, LY2183240 did not demonstrate antimicrobial 
activity against Gram-negative bacteria, although despite this, inhibition of the lysing 
activity of E. coli cells induced by Triton X-100 was evident (Figure 3.12D). 
As potentially suicidal enzymes, autolysins must be strictly controlled by the cell. 
Some studies suggest that the mechanisms employed to control autolysin activities 
are ineffective when murein synthesis is affected or inhibited. A classic example is 
the penicillin effect that results in the induction of cell lysis (Höltje, 1995).  
The results obtained in this assay indicate that LY2183240 has a significant impact 
on the cell lysis of at least three different types of bacteria. The mode of action may 
be related with inhibition of cell wall hydrolases, but further studies are needed to 
confirm this.  
It should be stressed that the capacity of LY2183240 to inhibit cell lysis of both 
Gram-positive and Gram-negative bacteria does not correlate with the antimicrobial 
spectrum of LY2183240 activity. 
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Figure 3.12. Autolysis of whole cells re-suspended in 0.05M Tris-HCl (pH 7.2) containing 0.05% 
Triton X-100 and incubated at 37°C. Exponential-phase cultures of Staphylococcus aureus 12981 (A), 
Bacillus subtilis (B), Enterococcus faecalis 12697 (C), and Escherichia coli 10418 (D) with Triton
TM
 
X-100 (control; black diamond) and with LY2183240 mixed with Triton
TM
 X-100 (white square). 
Changes in A600 were measured at 10-minute intervals for 120 minutes. Data represents experiments 
preformed in triplicate. 
 
3.7.9 Detection of Lytic Activity in SDS-PAGE Gels 
 
In order to attempt to identify the specific peptidoglycan hydrolases that were 
inhibited by LY2183240, SDS-PAGE was employed with M. lysodeikticus cells as a 
substrate challenged with an extracellular extract from S. aureus. The total protein 
profile of the extract is shown in Figure 3.13. The protein profile demonstrated 
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Figure 3.13. Protein analysis by SDS-10% PAGE. Extracellular enzyme extract prepared from S. 
aureus 12981 was separated by SDS-10% PAGE and proteins were visualized after staining with 
coomassie blue dye. A protein standard (broad range) was loaded in lane 1, and the extracellular 
extract was loaded in lane 2. 
 
The extract exhibited at least three bacteriolytic enzyme bands (Figure 3.14, lane 2), 
20 kDa, 36 kDa, and marked activity associated with a band around 25 kDa. On the 
other hand, in the lane 3, when LY2183240 was added, a partial inhibition of the 
lysis of M. lysodeikticus cells by the S. aureus extracellular proteins (20, 25 and 36 
kDa) was noted. Comparably, imidazole demonstrated a similar activity with an 
apparent reduction of lysis associated with same proteins (Figure 3.14, lane 4). 
Alexander and Cravatt (2006) worked on the identification and characterization of 
the enzymes inactivated by LY2183240, analyzing tissues from mice with an 
advanced functional proteomic platform referred to as activity-based protein 
profiling (ABPP)-multidimensional protein identification technology. More than 40 
serine hydrolases were identified in the mice brain and they demonstrated that a 
number of these enzymes were partially or completely inhibited by LY2183240 in 
vivo. In this competitive (ABPP) screen, the selectivity of an inhibitor for members 
of the serine hydrolase class is determined by measuring reductions in 
fluorophosphonate-rhodamine labeling intensity for many enzymes in parallel. 
Remarkably, the fluorophosphonate-labeling of several enzymes was blocked in a 
concentration-dependent manner by LY2183240, including FAAH, the 
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uncharacterized hydrolase called KIAA1363, and multiple proteins between the 
molecular masses of 25-35 kDa. 
 
 
Figure 3.14. Zymogram of the extracellular extract from S. aureus 12981 mixed with LY2183240 or 
imidazole, separated by SDS-PAGE with 0.1% SDS. Equivalent amounts of protein were loaded in 
each lane. After electrophoresis, proteins were re-natured by overnight treatment with 25 mM Tris - 
HCl (pH 8.0) containing 1% Triton
TM 
X-100. Lanes: 1, protein standard; 2, extracellular extract 
(control); 3, extracellular extract + LY2183240 (128 µg/mL); 4, extracellular extract + imidazole (128 
µg/mL). The arrows show the lytic enzyme bands of the extracellular extract from S. aureus 12981. 
 
Several bacterial autolysins have been characterized using cell walls from 
Micrococcus spp. as a substrate; such assays are frequently employed due to their 
high level of sensitivity (Ghuysen, 1968; Takahara et al., 1974; Williamson & Ward, 
1979). This tactic, utilizing Micrococcus luteus cells, has been previously 
incorporated into polyacrylamide gels to permit detection of various lytic enzymes 
(Audy et al., 1989). 
There are several reports of identified and well-characterized staphylococcal 
extracellular peptidoglycan hydrolases (Sugai, 1997). Specific to S. aureus, Brunskill 
& Bayles (1996) described an operon consisting of two LytSR-regulated genes. The 
sequence and mutagenesis studies of these genes suggested that lrgB might encode a 
protein having murein hydrolase activity. Further, zymographic analysis of this strain 
revealed the presence of a lytic enzyme band with a size of 25.1 kDa. In another 
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report, Mani et al. (1993) demonstrated the presence of a 36-kDa bacteriolytic 
protein in S. aureus. Zymographic analyses of a bacteriolytic-compromised mutant 
revealed the lack of all bacteriolytic bands except the 36-kDa-band when compared 
with wild type strains. The authors suggested that it probably regulates the 
expression or processing of autolysins in S. aureus and this single lytic enzyme band 
present in the mutants may be essential for cell morphogenesis. 
The bacteriolytic proteins observed in Figure 3.14, may be similar to the murein 
hydrolases described in these former reports (Mani et al., 1993; Bruskell and Bayles, 
1996) and furthermore, compound LY2183240 may inhibit them. However, whether 
these bacteriolytic proteins identified in this study correspond to lytic enzymes, 
described in previous studies still awaits definitive determination. 
 
3.7.10 Effect of LY218320 Mixture on AmpC β-Lactamases from E. coli G69 
and C. freundii 382010 
 
β-lactamases are a major cause of bacterial resistance to penicillins and 
cephalosporins. There are several studies, especially conducted in the 1990’s that 
suggest a close link between β-lactamase induction and the recycling of released 
muropeptides from the bacterial peptidoglycan (Höltje et al., 1994; Jacobs et al., 
1994; Korsak et al., 2005). β-lactam-mediated inhibition of peptidoglycan synthesis 
stimulates cell wall hydrolases to release muropeptides, particularly anhydro-
muropeptides, from the cell wall. AmpG is a transporter responsible for the uptake 
into the cell of these released muropeptides, and consequently a mutant unable to 
express AmpG is therefore incapable of recycling the cell wall components and 
concurrently β-lactamase expression is not inducible by a β-lactam. The cytosolic 
AmpD amidase degrades the above muropeptides and derivative muropeptides, 
releasing the tripeptide from cytosolic muropeptides brought into the cell via AmpG 
(Höltje & Tuomanen, 1991). Mutants inept to produce AmpD are blocked in a 
cytosolic step for cell wall recycling and accumulate extensive amounts of cytosolic 
murein-tripeptide. It is considered that cytosolic muropeptides can act as ligands for 
the β-lactamase regulator AmpR to activate expression of β-lactamase. AmpD 
mutants, therefore, essentially overproduce the chromosomal β-lactamase and are β-
lactam resistant. In wild-type strains, β-lactams that result in an increased cell wall 
cessation will trigger a rise in the cytosol of muropeptides and give rise to β-
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lactamase induction. Mutants affected in the ampD gene can be selected during third-
generation cephalosporin-mediated treatment, which are non-inducible, but 
overexpress β-lactamase in large quantities (Normark, 1995; Stapleton et al., 1995; 
Stapleton et al., 1999). Once these mutants are deficient in a functional cell wall 
recycling system they may be at a competitive disadvantage compared to wild-type 
strains in the absence of selection. Nevertheless, since muropeptides may act as 
cytotoxins, especially for respiratory epithelial cells, AmpD mutants due to their 
large accumulation of murein-tripeptide may be altered in their pathogenic properties 
when compared to wild-type cells possessing a normal cell wall recycling system 
(Normark, 1995). 
Many Gram-negative bacteria, including C. freundii 382010, express a 
chromosomally encoded AmpC β-lactamase, which is inducible by many β-lactams, 
for instance meropenem (Sykes & Matthew, 1976). Since β-lactam induction is 
dependent upon cell wall hydrolase activity, if LY2183240 blocks β-lactamase 
induction in the presence of an inducer such as meropenem, this could be further 
evidence that LY2183240 inhibits cell wall hydrolase activity. 
 
Figure 3.15. β-Lactamase induction assay using Citrobacter freundii in the presence of meropenem, 
DMSO and LY2183240. β-Lactamase activity is indicated by a red color after 1 - 3 minute reaction 
after the addition of nitrocefin. Photo: P. E. de Resende. 
β-Lactamase activity can be detected utilizing nitrocefin. Nitrocefin is a chromogenic 
cephalosporin that changes from yellow to red on hydrolysis, providing a sensitive 
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It was observed that the antibacterial agent meropenem was capable of inducing 
significant β-lactamase production in Citrobacter freundii cells in comparison to the 
control in the absence of this drug (Figure 3.16). Conversely, when LY2183240 was 
incubated with C. freundii and meropenem for a 1-hour period, a reduction of the β-
lactamase production was noted (p < 0.05) (Figure 3.16). 
Since β-lactamase is released from cells as they die during stationary phase, 
supernatant (growth media with cells removed) from an overnight culture can be 
used as a source of the enzyme. An assay was performed using the supernatant of the 
C. freundii culture in order to understand the mechanism of action of the potential 
inhibitory activity of LY2183240. Figure 3.16 illustrates that β-lactamase can be 
detected within C. freundii supernatant after induction with meropenem. As in the 
previous assay, meropenem showed evident induction of β-lactamase production.  
 
 
Figure 3.16. -lactamase in C. freundii 382010. -lactamase activity was determined using a 
nitrocefin-based assay on supernatant of C. freundii cultures that had been incubated with meropenem 
alone (), LY2183240 mixture 420 μM (), 200 μM (), 100 μM (), 50 μM (), 25 μM (), 15 
μM (), 6.5 μM (), and 3 μM (), and () shows -lactamase activity in a control not incubated 
with meropenem.  
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Furthermore, LY2183240 apparently inhibited β-lactamase production (p < 0.05). 
Notwithstanding, in this particular case, since no cells were present in the solution, 
LY2183240 could potentially be acting as a β-lactamase inhibitor rather than 
preventing β-lactamase induction per se. 
As described in the literature, β-lactamase inhibitors present different strategies to 
combat resistance mediated by these enzymes. One of the most efficacious 
approaches is the use of agents able to bind at the active site, which have previously 
been β-lactam-based (Drawz & Bonomo, 2010). This can be achieved by reversible 
or irreversible substrates that bind the enzyme with high affinity with unfavourable 
steric interactions as an acyl-enzyme or as mechanism-based “suicide inhibitors” that 
can permanently inactivate the β-lactamase through secondary chemical reactions 
within the enzyme active site. Some examples of mechanism-based inhibitors are 
clavulanic acid, sulbactam, and tazobactam, which are recognized as a substrate by 
the β-lactamase, bonding them covalently to produce chemical modifications that 
cause irreversible attachment to the enzyme (Pérez-Llarena & Bou, 2009). The fact 
that LY2183240 reduced the β-lactamase activity in the supernatant of C. freundii 
may suggest a direct interaction with the enzyme like mechanism-based inhibitors. 
 
Figure 3.17. The effect of AmpC β-lactamase from E. coli G69 (, control) and in presence of 420 
μM LY2183240 mixture (). DSMO was used as a control (). 
 
Figure 3.17 illustrates the influence of LY2183240 towards AmpC from E. coli G69, 
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a multi-drug resistant isolate that expresses the plasmid encoded class C β-lactamase, 
which is non-inducible. The supernatant of the E. coli G69 was collected and 
processed similarly to C. freundii, although without induction. Similar to C. freundii, 
β-lactamase activity was detectable with a relevant rise in the percentage of initial 
absorbance of nitrocefin at 486 nm, but in presence of LY2183240 at 420 μM, a 
significant reduction in the enzyme activity was observed (Figure 3.17). 
Again, the solvent used to dissolve the samples, DMSO, showed no effect on enzyme 
activity. 
It is generally agreed that cell wall metabolism and β-lactamase induction have a 
complex biochemistry and the signaling pathways for the induction of these enzymes 
offer a broad array of promising targets for the discovery of novel antibacterial drugs 
as well as the understanding of the biochemical processes. According with the 
previous results presented in this study, LY2183240 exhibited a potential influence 
in the activity of bacterial hydrolases. Although the specific mechanism of action is 
still unknown, the activities found here are intriguing and deserve more exploration. 
To further understand the mode of action of LY2183240 towards β-lactamases and 
others bacterial hydrolases additional biochemical and molecular studies are 
necessary and will be discussed in the next chapter. 
Although this part of the study has successfully demonstrated that LY2183240 
reduced AmpC β-lactamases activity from Gram-negative bacteria, it has certain 
limitations in terms of enzyme standardization and sample purity. At this stage of the 
project LY2183240 was being used as a mixture due to difficulties in isolating both 
regioisomers. Nevertheless, at this point these results can be considered preliminary 
and encouraging, leading this study to pursue this intriguing activity of the 
compound towards bacterial serine hydrolases.  
In order to verify to what extent this compound affects other β-lactamases, the next 
section moves on to examine the potential activity towards class A penicillinases.  
 
3.7.11 Inhibition of Class A β-Lactamase (TEM-1) 
 
Class A β-lactamases are, in general, susceptible to commercially available β-
lactamase inhibitors such as clavulanic acid, and tazobactam. Nonetheless, there is an 
increasing number of this class of β-lactamases in E. coli and K. pneumoniae, as well 
as the occurrence of these enzymes in other significant pathogens, that are refractory 
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to inhibitors, leading to the development of extended-spectrum cephalosporins, 
carbapenems, and monobactams (Drawz et al., 2010). 
Subsequent to the finding of the inhibitory activity of LY2183240 against AmpC β-
lactamases from E. coli and C. freundii, the potential activity of this compound 
towards class A β-lactamase was assessed. The TEM-1 β-lactamase was selected for 
two main reasons. The first is because TEM-1 is a standard reference for class A and 
commercially available and easily accessible. The second is because the enzyme is 
one of the most frequently encountered plasmid-mediated β-lactamases identified in 
clinical isolates of E. coli (Cooksey et al., 1990). LY21832440 mixture was 
evaluated against TEM-1, and clavulanic acid was used as a reference inhibitor 
(Figure 3.18).  
It was observed that in presence of the chromogenic substrate nitrocefin, TEM-1 
showed a gradual activity increase in a time-dependent fashion. In addition, DMSO 
(sample dissolution solvent) had no significant effect on enzyme activity. 
 
 
Figure 3.18. The activity of TEM-1 β-lactamase (2.5 μM) using nitrocefin (100 μM) as a substrate 
(, control) and in the presence of 420 μM LY2183240 mixture () or 10 μM of clavulanic acid 
(). DSMO was used as a solvent control (). 
 
Unpredictably, the LY2183240 exhibited considerably less potency towards TEM-1 
when compared to AmpC β-lactamases. At the highest concentration of 420 μM, 
LY2183240 demonstrated a minor reduction in the class A enzyme activity (Figure 
3.18). Conversely, at the concentration of 10 μM, clavulanic acid dramatically 
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reduced the β-lactamase activity. This result is in line with former findings, where 
clavulanic acid revealed a potent activity against TEM-1. Many studies demonstrated 
that the inhibition constant (Ki) of clavulanic acid is 0.1 μM towards TEM-1 (Chaibi 
et al., 1998; Imtiaz et al., 1994; Naumovski et al., 1992). Moreover, according to 
Bush (1988) it is necessary for only 160 clavulanate molecules to completely 
inactivate TEM-1, indicating a significant potency against this β-lactamase. 
The fact that LY2183240 mixture presented a stronger effect against class C than 
class A suggests that this compound has a considerable selectivity towards β-
lactamases. As revealed by Alexander and Cravatt (2006), LY2183240 possess a 
promiscuous activity against several serine hydrolases detected through a functional 
proteomic screen. Nevertheless, Ortar and coworkers (2008) agreed only in part with 
the conclusions drawn by these authors. They found that out of the 17 tetrazoles 
synthesized and screened, four compounds presented potent activity for FAAH 
selectively over all other targets tested, corroborating with the selectiveness 
presented in this study. 
Admittedly, a major source of unreliability in this part of the study is the fact that 
LY2183240 is a mixture potentially containing the regioisomers 1,5-LY (~50 %) and 
2,5-LY (~39 %) as aforementioned in the chemical characterisation. Hence, the 
proportion and content of the mixture may influence directly the inhibitory activity 
against β-lactamases.  
Therefore, Chapter 4 of this thesis is mainly dedicated to addressing the biological 
and chemical evaluation of LY2183240 regioisomers 1,5 and 2,5 independently as 
well as pursuing the potential modes of action of the activities indicated in this 
chapter. 
 
3.7.12 Antimicrobial Potentiation Activity of LY2183240  
 
The major aim of this assay is to evaluate the potential resistance-modifying and 
synergy effects of LY2183240 with amoxicillin and cefoxitin against antimicrobial 
resistant Gram-negative organisms.  
Although the end-points were not determined, LY2183240 showed no significant 
antibiotic potentiation effect against the strains tested (Table 9). The MIC values for 
the standard antimicrobial agents used were the same with or without LY2183240. 
There are some possible explanations for these results. Firstly, the presence of efflux 
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pumps system strongly limit the intracellular concentration of antimicrobial agents 
(Poole, 2005; L. J. V. Piddock, 2006; Poole, 2007; Li & Nikaido, 2009). The genes 
and proteins of this system can be present in both antibiotic-susceptible and 
antibiotic-resistant bacteria. There are at least two mechanisms for a resistant strain: 
(1) expression of the efflux pump protein is augmented; and (2) the protein contains 
an amino acid substitution(s) that makes the protein more effective at drug export. 
Whichever the case, the intracellular concentration of the substrate antimicrobial is 
reduced and the organism becomes less susceptible to that particular agent (L. J. V. 
Piddock, 2006).  
The multi-drug resistant clinical isolate E. coli used in this study has not been 
completely characterised although the organism is likely to have several efflux 
pumps. In addition, this strain carries plasmids that encodes class A and C β-
lactamases, also contributing towards the antimicrobial resistance phenotype 
(Stapleton et al 1999). Likewise, the C. freundii strain employed intrinsically 
produced class C β-lactamases. The potential activity of LY2183240 against β-
lactamases will be investigated more extensively in Chapter 4.  
 
Table 9 Antimicrobial potentiation activity of LY2183240 towards Gram-negative 
bacteria. 
Bacteria E. coli G69 C. freundii 382010 
Antibiotic/compound AMX AMX+2,5-LY CEF CEF+2,5-LY 
MIC (μg/mL)  > 512 > 512 > 256 > 256 
AMX, amoxicillin; CEF, cefoxitin. 
 
Another possible reason is that Gram-negatives are intrinsically resistant to certain 
compounds due to the presence of the outer membrane. This membrane plays a 
fundamental role of providing an extra layer of protection to the Gram-negative 
organisms (Delcour, 2009). The outer membrane consists of an inner leaflet 
comprising phospholipids and an outer leaflet containing the lipid A moiety of 
lipopolysaccharides (Kumar & Schweizer, 2005). This composition gives 
impermeability to many substrates and transportation across the outer membrane is 
achieved by porin proteins that form water-filled channels.  
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The possibility of LY2183240 being prevented of entering in Gram-negative bacteria 
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 Conclusions 3.8
 
The data in this chapter demonstrate that none of the plants extracts evaluated had 
useful direct antimicrobial activity. The discrepancies in the MIC values when 
compared with previous studies may be due to differences in the methods used to 
extract and determine the MICs, or to differences in the characteristics of the plants, 
such as their origins. The lack of antimicrobial activities with any of the extracts 
suggests that they may not be useful as leads for new antibiotics. Nonetheless, more 
studies are necessary to confirm whether they have any other useful properties such 
as resistance modulatory activities. 
With regards to LY2183240, collectively the results show potent growth inhibitory 
activity against certain Gram-positive bacteria, including S. aureus 12981 (MSSA), 
S. aureus 13373 (MRSA) and B. subtilis. Additionally, chemical characterisation 
reveals that the sample evaluated consisted of a mixture of two major compounds, 
conceivably being regioisomers of LY2183240, as formerly reported in the literature 
(Ortar et al., 2007; Ortar et al., 2008; Asada et al., 2015). 
One of the purposes of this study was to extend early observations of the inhibition 
of serine hydrolases in eukaryotes and to provide a basis for the potential 
antimicrobial effectiveness of the compound. 
The inhibition of cell lysis stimulated by either the activity of lysozyme, Triton
TM
 X-
100 or penicillin G, by LY2183240 suggests the compound inhibits autolysins 
associated with the bacterial peptidoglycan. Autolysins are peptidoglycan hydrolases 
that lyse the cell in such a way that the integrity of the murein wall is damaged. This 
class of enzymes is involved in several bacterial processes such as cell division and 
separation, inhibition of their action would therefore affect the pathogenicity and 
virulence of the microbe (Smith, Blackman et al. 2000). The presence of multiple 
autolysins as well as their functional redundancy complicates attempts to identify 
which enzyme is specifically targeted by LY2183240, if that is indeed the case. In 
this context, partial inhibition of bacterial hydrolases from S. aureus by LY2183240 
was shown, with effects on at least three proteins with molecular masses between 25 
- 35 kDa. Moreover, LY2183240 was able to significantly inhibit β-lactamases 
induced by meropenem in C. freundii cells, exhibiting a possible link between 
murein hydrolases and β-lactamases, formerly reported in literature (Höltje et al., 
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1994; Jacobs et al., 1994; Korsak et al., 2005). However, the activity against cell wall 
hydrolases does not correlate with the antimicrobial spectrum of activities per se. 
One of the limitations of this first part of the study was the difficulty to obtain a pure 
compound from a reliable source. Nevertheless, these findings successfully 
demonstrated some antimicrobial and resistance-modifying effects of LY2183240. 
Therefore, in Chapter 4 the potential specific targets of the regioisomers of 
LY2183240 will be explored to gain a better understanding of the antimicrobial 
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 Introduction 4.1
 
The pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species are the 
leading cause of nosocomial infections throughout the world (Santajit & Indrawattana, 
2016). Most of them are multidrug resistant isolates, which is one of the greatest 
challenges in clinical practice. The emergence of methicillin-resistant S. aureus 
(MRSA), for instance, is a source of concern with millions diagnosed with MRSA 
infections each year. Another significant mechanism of antibiotic resistance presented 
by some of these pathogens is the production of enzymes that irreversibly modify and 
inactivate the antibiotics, such as β-lactamases (Drawz et al., 2010). 
As a consequence, research has focused on combatting these mechanisms that bacteria 
have developed to resist antibacterial agents. 
Chapter 3 revealed significant and promising antimicrobial-related activities of 
LY2183240. Firstly, this simple molecule showed potent direct antimicrobial activity 
against certain Gram-positive bacteria, especially S. aureus including MRSA. Secondly, 
the compound inhibited class C β-lactamases. 
This chapter will explore in detail these different aspects; in this case using pure 
preparations of LY2183240 regioisomers independently in order to assess the impact 
changes in the structure of these molecules have towards prokaryotic systems. Former 
reports in the literature showed that the simple position change of the carbamoyl group 
from -1,5 to -2,5 in the tetrazole influenced considerably the potency of the activities 
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 Objectives 4.2
 
The main objective of this chapter is to evaluate the direct antimicrobial and resistance-
modifying properties of each of the two LY2183240 regioisomers.  
 
The specific aims of the study are as follows: 
 
- To determine the minimum inhibitory concentrations (MICs) of both 
LY2183240 regioisomers. 
- To determine the potential target or targets of the antimicrobial activity of 
LY2183240 regioisomers using different methods and approaches. 
- To assess the β-lactamase inhibitory properties via an extensive enzyme kinetic 
study. 
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 Results and Discussion 4.3
4.3.1 Characterisation of LY2183240 Regioisomers 
 
In order to establish the purity of the compounds, as stated by the suppliers, 
characterisation of both LY2183240 regioisomers was performed by HPLC, NMR 
and mass spectrometry.  
4.3.1.1 HPLC Analysis 
 
The HPLC analysis was implemented as stated on Chapter 2, section 2.3.2.1.2. In 
addition the LY2183240 mixture was used for comparison purposes. 
 
Figure 4.1: HPLC chromatograms of LY2183240. (A) LY2183240 mixture; (B) 1,5-regioisomer; (C) 
2,5-regioisomer. 
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It was possible to confirm the presence of the 1,5-regioisomer in the sample. The 
chromatogram revealed a single peak with the retention time of 6.46 minutes and an 
area under the curve of 100 %, suggesting a highly pure sample as stated by the 
provider Santa Cruz Biotechnology (Figure 4.1B). Comparably, the 2,5-regioisomer 
exhibited only one peak, with retention time of 6.73 minutes and 100% of area under 
the curve, indicating a pure sample as well (Figure 4.1C). In addition, when 
compared with the LY2183240 preparation used in the first part of this project, it 
was observed that both regioisomers were present in this mixture, having similar 
retention times to the pure samples (Figure 4.1A). The analysis revealed a content of 
50 % and 39 % for 1,5-isomer and 2,5-isomer, respectively. Moreover, an extra 
minor peak was noted (10 %) with a retention time of 6.16 minutes that could be 
another potential isomer of LY2183240 or an impurity of the synthesis process. 
This complete analysis employing all LY2183240 samples used in this study 
reiterates the hypothesis of the 2,5-isomer being responsible for the anti-
staphylococcal activity found in Chapter 3 and confirmed in the section 4.3.2.1 
below.  
4.3.1.2 NMR Analysis 
 




C, DEPT, COSY, HMQC, HMBC and NOESY 
experiments with both LY2183240 regioisomers in methanol-d4 were performed.  
The results of the 
1
H NMR spectrum for 1,5-LY2183240 were as follows: d 2.70 (6 
H, s), 3.07 (2H, s), 4.46 (1H, t), 7.34 (2H, d), 7.42 (2H, t), 7.60 (4H, d). 
The results of the 
1
H NMR spectrum for 2,5-LY2183240 were as follows: 
1
H NMR 
(400 MHz, methanol-d4): d 3.05 (6 H, s), 3.23 (2H, s), 4.37 (1H, t), 7.32 (2H, d), 





C NMR data of these compounds were in agreement with published 





C NMR resonances of both regioisomers was performed. HMQC, 
HMBC, COSY and NOESY data confirmed the structures. All the spectra of both 
LY2183240 regioisomers can be found within Appendix section 8.1. 
The 
1
H-NMR resonances of the N,N-dimethyl (CH3)2 group were clearly visible 
within the space correlations between the protons from the two methyl groups in the 
NOESY analysis (Appendix 8.1). HMBC correlations were observed for both 
regioisomers from the methylene protons (H2-1") to C-3" and 4" and within the 
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biphenyl rings, for example from H-3" to C-1", as well as from H-2" to C-4". COSY 
correlations from H-5" to H-6" and from H-2" to H-3", which in turn coupled to H-4" 
together with the NOESY coupling between H-1" and H-3", were also noticed and 
assisted the confirmation of the proton resonances. The essential resonances to 
differentiate and authenticate these compounds were the 
13
C resonances of the 




J correlations from the 
dimethyl protons to the carbonyl carbons and from methylene protons (H-1") to 
tetrazole carbons (C-5) observed in HMBC spectra of both regioisomers permitted 
the complete assignment of the 
13
C resonances. The carbonyl carbons of 1,5-
LY2183240 and 2,5-LY2183240, which were both attached to nitrogen atoms of the 
tetrazole ring revealed 
13
C resonances at a comparable chemical shift, δC 149.3 and 
δC 149.6, respectively (see Figures 8.1A and 8.4A). Furthermore, the CN4 
13
C 
resonance of the 1,5-regioisomer was noticed at a higher field (δC 157.3) when 
compared to the 2,5-regioisomer (δC 166.7) suggesting that the tetrazole carbon of 
1,5- was more shielded. In summary, the extensive NMR analysis confirms both 
regioisomer structures as declared by the chemical suppliers.  
 
4.3.1.3 Mass Spectroscopy Analysis 
 
The mass spectra of both LY2183240 regioisomers showed a peak at m/z 306.4 and 
m/z 306.7 for 1,5- and 2,5-, respectively, which corresponded to the chemical 
formula of C17H17N5O. The other peaks present in the analyses represent the 
fragmentation pattern formed by the ionization process (Figures 4.3 and 4.5). 
 
 




















H NMR spectrum for 1,5-LY2183240, recorded in methanol-d4, 400MHz. 
 

















Figure 4.3. ESI-MS/MS spectrum for the isomer 1,5-LY2183240. 





















H NMR spectrum for 2,5-LY2183240, recorded in methanol-d4, 400MHz. 


















Figure 4.5. ESI-MS/MS spectrum for 2,5-LY2183240. 
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4.3.2 Biological Evaluation 
4.3.2.1 Minimum Inhibitory Concentration 
 
The antimicrobial activities of both regioisomers of LY2183240 were evaluated 
through the determination of minimum inhibitory concentrations by the broth 
microdilution method; the results are summarized in Table 10. 
Remarkably, only the 2,5-isomer exhibited a potent antimicrobial effect against 
certain Gram-positive bacteria. Moreover, this compound revealed potent activity 
towards staphylococcal isolates, including MRSA, with drug MIC values as low as 
0.5 μg/mL against a methicillin-resistant clinical isolate. 2,5-LY2183240 had no 
effect against the Gram-negatives or other Gram-positives tested such as E. faecalis 
strains. The 1,5-regioisomer showed no significant activity against all 
microorganisms tested, with MIC values higher than 128 μg/mL. 
These results strongly suggest that the position of the carbamoyl in the tetrazole 
plays an essential role in the direct antimicrobial activity observed. As seen in 
Chapter 3, the LY2183240 mixture, containing both regioisomers, gave rise to 
bacteriostatic effects against Gram-positives, including Staphylococcus aureus. 
Nevertheless, when the isomers were assessed separately, only the 2,5-isomer 
showed activity, implying that the 2,5-isomer is responsible for the antimicrobial 
activity found in the mixture.  
As stated before, both LY2183240 isomers present a tetrazole group in the structure 
(See Figure 1.17). Tetrazole is a class of synthetic organic heterocyclic compounds 
consisting of a five-member ring of four nitrogen atoms and one carbon atom. In 
general, substantial evidence has gathered during the past decades demonstrating the 
countless pharmacological effects of tetrazoles and their derivatives (Mohite PB & 
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Table 10. Minimum inhibitory concentrations of LY2183240 regioisomers 







S. aureus 12981 0.125
a
 >128 1 − 2 
S. aureus 13373 4
a
 >128 4 − 8 
B. subtilis 15 0.125
a
 >128 8 − 16 
MRSA 80415G* >128
a
 128 1 − 2 
MRSA 80415R* >128
a
 128 4 − 8 
MRSA 80415S* >128
a
 >128 0.5 − 1 
MRSA 80415K* >128
a
 >128 2− 4 
EMRSA 15 Not determined >128 2 − 4 
RN4220 1
b
 >128 2 − 4 
XU212 16
b
 >128 0.5 − 1 
S. aureus 1199b 32
b
 >128 8 − 16 
S. epidermidis 0.125
a
 >128 2 − 4 
E. faecalis 12967 0.5
a
 >128 >128 
E. faecalis 13379 4
a
 >128 >128 
Stenotrophomonas sp. 1
a
 >128 >128 
E. coli NCTC 10418 0.125
b
 >128 >128 
E. coli G69* >128
c
 >128 >128 
K. pneumoniae 17 32
c
 >128 >128 
Streptococcus pneumoniae 0.125
a
 >128 >128 
P. aeruginosa 10662 1
b












  133 
These activities include antibacterial (Bekhit et al., 2004; Salahuddin et al., 2009; 
Mohamed et al., 2009; Rostom et al., 2009; Varadaraji et al., 2010; Arulmurugan et 
al., 2011; Shan et al., 2014; Dai et al., 2015), antifungal (Matysiak et al., 2003; 
Upadhayaya et al., 2004; Mohite et al., 2011), anti-tuberculosis (Karabanovich et al., 
2015; Němeček et al., 2017), antiviral (Miles et al., 1978; Hutchinson & Naylor, 
1985), analgesic (Rajasekaran & Thampi, 2004), anti-inflammatory (Pande et al., 
1987; Ikeda et al., 1992), anticancer (Bhaskar & Mohite, 2010; Kumar et al., 2011; 
El-Sayed et al., 2012), hypoglycemic (Momose et al., 2002), and antihypertensive 
(Sharma et al., 2010), amongst others. 
Further, a number of studies have examined the influence of the position of a 
substituent group in the tetrazole on different types of activities. For example, 
consistent with the current study, reports depicted the antitubercular potency, 
selectivity and toxicity of tetrazole derivatives containing different substituents 
(Karabanovich et al., 2014; Karabanovich et al., 2015; Karabanovich et al., 2016). In 
these works, the authors clearly determined the influence of the position of 
substituent groups in the tetrazole upon antimycobacterial activity. For instance, 
amongst all the compounds produced, 1,5- and 2,5-regioisomer tetrazole derivatives 
revealed the highest antimycobacterial effect, with minimal inhibitory concentration 
values of approximately 1 μM (0.37 – 0.46 μg/mL) against a Mycobacterium 
tuberculosis strain (Karabanovich et al., 2015). Furthermore, the 2,5-regioisomers 
exhibited reproducibly higher antimycobacterial activity compared to the 1,5-
isomers. In addition, selectivity and toxicity were evidently affected by the positions 
in the tetrazole group. More recently, the same research group revealed that the 
introduction of a tetrazole-5-thioalkyl moiety at position 2 of the tetrazole increased 
even more the antimycobacterial activity, presenting a stronger in vitro activity 
against M. tuberculosis as well as a significant activity against non-tuberculous 
mycobacterial strains (Němeček et al., 2017). 
As mentioned in other sections, Ortar and coworkers (2007) synthesized a series of 
18, 1,5- and 2,5-disubstituted carbamoyl tetrazoles, including both LY2183240 
regioisomers, and revealed that on inhibition of anandamide cellular uptake, most 
1,5-isomers are considerably more potent than the corresponding 2,5-isomers. Still, 
structurally less flexible substituents in the 5-position appear to yield better inhibitors 
than more flexible ones. On the other hand, 2,5-isomers can also be more potent 
against FAAH when compared with their 1,5-equivalent. 
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On the whole, the position of substituent groups in the tetrazole seems to be a crucial 
factor for the potency of the molecule. The anti-staphylococcal effect of 2,5-
LY2183240 presented in this study is unprecedented in the literature. Many reports 
showed the activity of these compounds against eukaryotic serine hydrolases, 
including FAAH and MAGL, related to the putative anandamide membrane 
transporter (Alexander & Cravatt, 2006; Ortar et al., 2007; Ortar et al., 2008; Maione 
et al., 2009). However, there are no reports of the activities of these regioisomers 
towards bacteria.  
In this context, the observation that the 2,5-regioisomer has potent anti-
staphylococcal activity, warrants further investigation of this isomer as a novel 
scaffold for the development of treatments of MRSA infections.  
Further studies were carried out to establish the mode of action of this specific effect. 
 
4.3.2.2 Effect of Cell Membrane Permeabiliser, PEI, on the Anti-Gram-Negative 
Activity of 2,5-LY2183240 
 
Gram-negative bacteria possess an outer membrane that acts as a permeability barrier 
capable of excluding macromolecules or hydrophilic substances, hence the structure 
is essential for the intrinsic resistance of these microorganisms to antimicrobial 
agents (Denyer & Maillard, 2002; Nikaido, 2001; Alakomi et al., 2006).  
The presence of lipopolysaccharide molecules in the external part of the membrane 
contributes towards the barrier function of the outer membrane and hence resistance, 
along with porin type and the presence of multidrug efflux pumps (Nikaido, 2003). 
Novobiocin, an inhibitor of DNA replication and active against Gram-positive 
organisms, is ineffective against Gram-negative bacteria like E. coli due to the 
barrier function of the outer membrane. 
Despite the fact that the outer membrane guards the cells of Gram-negative bacteria 
from various external agents, it is possible to modulate this property using different 
types of agents, commonly known as permeabilizers, which either disrupt the 
lipopolysaccharide or lipid bilayers or both, increasing the permeability of the outer 
membrane (Alakomi et al., 2006). For example, polyethyleneimine (PEI), a cationic 
polymer, has been acknowledged as a permeabilizer that operates by interpolating 
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into the outer membrane rather than releasing lipopolysaccharides (Helander et al. 
1997).  
 
Table 11: Effect of PEI on the susceptibility of E. coli 10418 to novobiocin and 2,5-
















> 256 256 0.5 > 512 ~ 64 
a
MIC of novobiocin in the presence of a fixed concentration of PEI (256 g/mL). 
b
MIC of 2,5-LY2183240 in the presence of a fixed concentration of PEI (256 g/mL). 
 
PEI successfully led to the permeation of both novobiocin and 2,5-regioisomer, but 
to different extents against E. coli 10418 (Table 11). Novobiocin had a MIC value of 
256 μg/mL, however, in the presence of PEI the MIC reduced more than 500-fold to 
0.5 g/mL. With 2,5-LY2183240, an MIC greater than 512 μg/mL was noted, but in 
the presence of PEI, despite two-fold variations in the data, a decrease to 64 μg/mL 
was noted (modal value of five determinations).  
These findings mirror those of the previous studies that have examined the effect of 
PEI and novobiocin towards a Salmonella typhimurium strain (Helander et al., 1997; 
Helander et al., 1998). The authors demonstrated that at concentrations from 20 
μg/mL, PEI increased the bacterial uptake of a hydrophobic compound whose 
activity would be significantly decreased by the outer membrane. Furthermore, 
through an agar diffusion method, PEI induced susceptibility to novobiocin and other 
antibiotics towards different Gram-negatives, including E. coli. Yet, the 
antimicrobial agents were not effective in the absence of PEI. Moreover, it is 
noteworthy that PEI did not inhibit the growth of E. coli to any significant extent.  
These data indicate that the antimicrobial activity of 2,5-LY2183240 revealed in the 
previous chapter was selective to Gram-positives potentially due to the presence of 
the outer membrane and consequently is the basis of intrinsic resistance within 
Gram-negatives (at least E. coli). However, the fact that the 2,5-isomer was effective 
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against S. aureus and not E. faecalis, for instance, is still open for discussion and 
need further studies to enlighten this intriguing effect.  
 
4.3.2.3 In Vitro Protein Synthesis Inhibition 
 
Protein synthesis is one of the major targets in the cell for antimicrobial agents 
(Wilson, 2009). Bacterial ribosomes diverge in structure from their counterparts in 
eukaryotic cells. Antibacterial agents take advantage of these differences to 
selectively inhibit bacterial growth (Tenover, 2006). The bacterial ribosome is a 
cytoplasmic nucleoprotein particle whose main function is to serve as the site of 
mRNA translation and protein synthesis. The ribosome has a mass of about 2.5 MDa, 
with RNA accounting for 2/3 of the mass. It consists of two subunits denoted 30S 
(small subunit) and 50S (large) (Laursen et al., 2005). When joined, the ribosome has 
a sedimentation coefficient of 70S as opposed to 80S due to tertiary structure. The 
different subunits are the sites of inhibition for different classes of antimicrobial 
agents, for example, aminoglycosides, and tetracyclines bind to the 30S subunit of 
the ribosome, whilst chloramphenicol binds to the 50S subunit (Spector et al., 2002). 
During protein synthesis a ribosome moves along on mRNA molecule, reading the 
codons and adding the correct amino acid (from the corresponding aminoacyl tRNA) 
to the growing protein. When a stop codon is reached, translation ceases, and the 
mRNA and protein are released (Weaver, 2012). 
In this current study, all the findings so far gathered about the mode of action of the 
anti-staphylococcal activity of the LY2183240 regioisomers, including the 
bacteriostatic effect, may suggest potential protein synthesis inhibition.  
The in vitro protein synthesis experiments were performed using the commercially 
available cell-free transcription-translation system composed of purified components 
(PURExpress). The main goal of this assay was to verify if LY2183240 regioisomers 
could interact or inhibit protein synthesis, especially via ribosomal subunits.  
Figure 4.6 shows the SDS-PAGE gel of dihydrofolate reductase (DHFR) protein 
expression. It was observed that when the DNA was not present in the reaction 
solution, no DHFR was synthesized (lane 2). Conversely, once the DNA was added 
to the reaction, the enzyme DHFR, which possesses a size of approximately 20 kDa, 
was produced (lane 3). Moreover, when LY2183240 regioisomers were 
supplemented, the presence of the enzyme was noted, indicating no significant 
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alteration to DHFR synthesis (lanes 4 and 5). As a positive control, chloramphenicol, 
a standard protein synthesis inhibitor was used; total inhibition of the DHFR 
synthesis was observed (lane 6). 
Protein synthesis is a complex, multi-step process involving many enzymes as well 
as conformational alignment. The aminoacyl tRNA synthetases that activate each 
amino acid required for peptide synthesis may by targeted by antibiotics such as 
mupirocin, which specifically inhibits isoleucine tRNA synthetases in Gram-positive 
bacteria (e.g. staphylococci and streptococci). However, the majority of antibacterial 
agents that stop bacterial protein synthesis interfere with the processes involving the 
30S or 50S subunits of the 70S bacterial ribosome (Maguire, 2009). The primary 
steps in the process that are attacked are (i) the formation of the 30S initiation 
complex, (ii) the formation of the 70S ribosome by the 30S initiation complex and 
the 50S ribosome, and (iii) the elongation process of assembling amino acids into a 
polypeptide. 
Chloramphenicol is a bacteriostatic agent that prevents protein chain elongation by 
inhibiting the peptidyl transferase activity of the bacterial ribosome (Brock & Brock, 
1959; Jardetzky, 1963). It specifically binds to A2451 and A2452 residues in the 23S 
rRNA of the 50S ribosomal subunit, preventing peptide bond formation (Schifano et 
al., 2013).  
This simple in vitro assay could demonstrate the inhibitory activity of 
chloramphenicol towards the DHFR synthesis, validating the applied method. 
Overall, these findings indicate that neither regioisomers have any relevant effect on 
the synthesis of dihydrofolate reductase.  
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Figure 4.6. Protein expression using the PURExpress™ in vitro protein synthesis kit in presence of 
LY2183240 regioisomers and the standard chloramphenicol (CHL). Around 25 µL reactions 
containing 250 ng template DNA of DHFR was incubated at 37°C for 2 hours. 2.5 µL of each reaction 
was analyzed by SDS-PAGE using a 10% Tris-glycine gel. The red arrow indicates the protein of 
interest, dihydrofolate reductase. 
 
4.3.2.4 Wall Teichoic Acid and Lipoteichoic Acid Biosynthesis Inhibition 
 
Wall teichoic acids are a major component of the Gram-positive bacteria cell wall. 
They consist of anionic and carbohydrate-based polymers that are covalently 
attached to the peptidoglycan matrix (Ward 1981; Shockman & Barren 1983; 
Neuhaus & Baddiley 2003; Meredith et al. 2008). Some of the main functions of the 
these acids are involved in the determination of cell shape in S. aureus, assisting 
relevant roles in host colonization, virulence, coordination of peptidoglycan 
synthesis and resistance to β-lactam antibiotics (Sewell & Brown, 2014). More 
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recently, due to these characteristics, wall teichoic acid biosynthesis has appeared as 
an authentic new antimicrobial target against S. aureus.  
The SDS-PAGE analysis of wall teichoic acids isolated from S. aureus 12981 grown 
in increasing but sub-inhibitory concentrations of tunicamycin, a standard inhibitor, 
shows a dose-dependent reduction in wall teichoic acid biosynthesis (Figure 4.7A).  
By contrast, when 2,5-LY2183240 was present, under the same conditions, no 
significant effect was observed (Figure 4.7B). 
These results observed are similar to those of the previous study that have assessed 
the effect of tunicamycin against wall teichoic acid isolated from S. aureus RN4220 
(Swoboda et al., 2009). The authors revealed a similar profile for this compound, 
showing a concentration-dependent decrease in the wall teichoic acid biogenesis. 
Nevertheless, in this current study a higher concentration of tunicamycin, still below 
the MIC was used. Many studies have reported the minimum inhibitory 
concentration of tunicamycin to be around 0.4 μg/mL (Hancock et al., 1976; Pooley 
& Karamata, 2000; Campbell et al., 2011). In addition, at this concentration, 
tunicamycin inhibits WTA expression (Atilano et al., 2010; Campbell et al., 2011). 
On the first attempt, the same concentration range as described in the literature was 
used (0 – 0.08 μg/mL) (Swoboda et al., 2009). However, no inhibition was detected. 
After some modifications and endeavours, a significant decrease in the WTA 
assembly was noticed with tunicamycin (0.16 μg/mL), but not 2,5-LY2183240. 
According to the literature, tunicamycin is a selective TarO inhibitor at low 
concentrations. TarO belongs to a group of essential enzymes that contribute to the 
synthesis of the wall teichoic acid adding polymers like poly(ribitol-phosphate) and 
sugars such as N-acetylglucosamine (Brown et al., 2013). Hence, it can be used to 
block WTA expression at concentrations that have no effect on bacterial growth.  
The 2,5-regioisomer, albeit using concentrations up to the MIC, had no inhibitory 
effect, suggesting that the target of the antimicrobial activity was not associated with 
the WTA biosynthesis pathway. However, further studies are necessary to confirm 
this possibility. 
Besides WTA, another important teichoic acid present in S. aureus is lipoteichoic 
acid (LTA). LTAs are anchored in the bacterial membrane via a glycolipid, whereas 
WTAs are covalently attached to peptidoglycan (Ward, 1981; Neuhaus & Baddiley, 
2003). Lipoteichoic acid can be found in the cell membrane of virtually all Gram-
positive bacteria and is liberated into the circulation after antimicrobial treatment. 
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Moreover, in vivo, LTA has been revealed to contribute greatly to the onset of sepsis 
and septic shock (Alkan & Beachey, 1978; Fischer et al., 1990; Kengatharan et al., 
1998; Ginsburg, 2002; Hattar et al., 2006).  
Furthermore, this type of teichoic acid synthesis involves the polymerization of 
polyglycerol-phosphate and its transfer to glucosyl-diacylglycerol (Glc2-DAG) 
(Koch et al., 1984).  
 
Figure 4.7. PAGE analysis of WTA isolated from S. aureus 12981 grown in increasing 
concentrations (µg/mL) of (A) tunicamycin, a TarO inhibitor, and (B) 2,5-LY2183240.
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Figure 4.8 illustrates the agar-well diffusion test using both LY2183240 regioisomers 
against the susceptible S. aureus 12981. The main objective of this test was to verify 
the influence of the presence of LTA upon the activity of 2,5-LY2183240. 
2,5-LY2183240 caused a significant zone of inhibition (Figure 4.8). The presence of 
LTA in the agar-well had no effect on regioisomer activity since the same zone of 
inhibition was observed, which suggested that the mode of action of 2,5-LY may not 
be related to the interaction of the molecule with lipoteichoic acid. 
 
 
Figure 4.8.Agar-well diffusion test with LY2183240 regioisomers in presence of LTA against S. 
aureus 12981. 
In order to explore the potential target or targets of the anti-staphylococcal activity 
additional studies were performed and discussed in further sections. 
 
4.3.3 Inhibition of Bacterial Fatty Acid Synthesis 
 
Fatty acids play a crucial role in bacterial membrane formation as well as cellular 
structures and functions (Rock & Jackowski, 2002). Bacteria synthesize fatty acids 
by utilizing a highly conserved group of enzymes within the type II fatty acid 
synthase system. Therefore, this system is an attractive target for antibacterial drug 
discovery (Campbell & Cronan, 2001; Zhang et al., 2003; Heath & Rock, 2004; Yao 
& Rock, 2016).  
Until this point, the data in this study indicate that the potential target or targets of 
the 2,5-regioisomer could be associated with the membrane of certain Gram-positive 
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bacteria. A bacteriostatic effect against S. aureus was observed, as well as significant 
effects on the autolysins associated with the peptidoglycan, and a possible link 
between the murein hydrolases and β-lactamases inhibitory activities. More striking 
is the spectrum of activity of the 2,5-regioisomer, which mirrors the selectivity 
observed for fatty acid synthesis inhibitors such as triclosan. 
There is a report showing that the inhibition of phospholipid synthesis, accomplished 
by inhibiting fatty acid synthesis with cerulenin, a FabF and FabB inhibitor, resulted 
in the simultaneous inhibition of peptidoglycan synthesis (Rodionov & Lshiguro, 
1996). Moreover, studies with triclosan, demonstrated that this compound acts as a 
bacteriostatic agent associated with an inhibition of membrane biogenesis (Gomez 
Escalada et al., 2005). 
Therefore, the main purpose of this section was to assess whether fatty acid synthesis 
was a potential target or targets of the 2,5-regioisomer thus contributing to the 
inhibitory activity of the molecule towards S. aureus. 
A simple assay to test this hypothesis is to supplement the growth media with 
exogenous fatty acids using for example, Tween 80 or human serum, which are 
abundant sources of fatty acids. Under these conditions, bacteria would incorporate 
extracellular fatty acids, circumventing the inhibition of de novo fatty acid synthesis 
and increasing the MIC value of the assessed drug (Brinster et al., 2009; Parsons & 
Rock, 2011). 
In this study triclosan exhibited a potent antimicrobial effect with MIC values of 0.05 
μg/mL and 0.5 μg/mL against S. aureus and B. subtilis, respectively (Table 12). By 
contrast, in the presence of Tween 80, a significant increase of 80-fold in the MIC 
towards S. aureus, and to a lesser degree, 64-fold against B. subtilis was noted. In a 
similar way, the 2,5-isomer of LY2183240 revealed a potent inhibitory activity 
against S. aureus and to a lesser extent, B. subtilis. Nevertheless, in the presence of 
Tween 80 a dramatic increase in the MIC (greater than 150-fold) towards S. aureus 
was observed. The same increase happened with B. subtilis, although in a smaller in 
magnitude (Table 12). It is worth mentioning that Tween 80 was assessed alone 
against both organisms and no inhibition of bacterial growth was found. 
These findings are consistent with former studies on triclosan. A recent work 
reported concentration-dependent antimicrobial activity of triclosan against S. aureus 
and Streptococcus agalactiae, showing reductions in activities with increasing 
concentrations of Tween 80 (Krsta et al., 2014). The same study showed a very 
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similar effect using platensimycin against S. agalactiae, but the reverse effect against 
S. aureus. Platensimycin is a selective inhibitor of FabF, an important enzyme in the 
type II fatty acid synthesis pathway of Gram-positive bacteria (Das et al., 2016).  
 
Table 12. Inhibitory activity of 2,5-LY2183240 in the presence and absence of 
Tween 80. 
                               MIC (μg mL-1) of 
 Triclosan 2,5-LY2183240 
Organism 




No Tween 80 
+ Tween 80 
(0.1% v/v) 
S. aureus 12981 0.05 4 2 - 4 > 512 
B. subtilis 13 0.5 32 16 64 
 
Bacterial fatty acid biosynthesis is a potentially significant target for antimicrobial 
treatment, but is not without controversy. As mentioned above, recent reports have 
suggested that the addition of exogenous fatty acids to growth media may bypass the 
inhibition of this pathway both in vitro and in vivo (Brinster et al., 2009). Hence, 
agents targeting fatty acids synthesis could have restricted in vivo relevance for 
human therapy because fatty acids are highly abundant within the body. However, 
Balemans et al. (2010) have suggested that the observations of Brinster and co-
workers (2009) do not hold true for S. aureus. They revealed that human serum had 
no influence on fab gene expression in S. aureus, although downregulation of fab 
genes expression for S. agalactiae was observed. In a reply to Balemans and 
coworkers, Brinster concluded that FASII-directed antimicrobials can indeed reach 
their targets when exogenous fatty acids are present, to inhibit fatty-acid synthesis in 
S. aureus. Nonetheless, FASII inhibition is compensated by the exogenous fatty 
acids, and allows bacterial growth. Another report also demonstrated that the activity 
of triclosan in vitro is severely compromised by the addition of oleic acid and Tween 
80 (Prosen et al., 2011). 
Using animal models, other studies on Staphylococcus and Neisseria species, have 
shown that exogenous fatty acids are not able to circumvent FabI inhibition in these 
specific microorganisms (Parsons & Rock, 2011; Yao & Rock, 2015).  
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Despite this controversy, major pharmaceutical companies are still investigating the 
potential use of FAS inhibitors as antimicrobial agents, such as platensimycin and 
platencin (inhibitor of FabF/H). Each has activity against several Gram-positive 
pathogens, including MRSAs.  
The fatty acids present in Tween 80, as shown in this study, are able to compromise 
the activities of triclosan and 2,5-LY2183240 suggesting a target of 2,5-LY2183240 
may lie within the type II fatty acid synthase system.  
 
4.3.3.1 Characterization of 2,5-LY2183240-Resistant Mutants  
 
One of the last steps in the fatty acid synthesis pathway is executed by the enzyme 
enoyl-acyl carrier protein (ACP) reductase (FabI) (Heath & Rock, 1995). Preceding 
genomics studies, FabI was assumed to be the only enoyl-ACP reductase in bacteria. 
Nevertheless, investigation of key bacterial genomes demonstrated that FabI is not 
present in some micro-organisms, and an alternative enoyl-ACP reductase, FabK, is 
found instead (Rock & Heath, 2000; Payne et al., 2002). In some cases, both FabI 
and FabK may occur in the same organism; for instance, FabK is the only enoyl-
ACP reductase in S. pneumoniae and both FabI and FabK have been discovered in 
pathogens such as E. faecalis and P. aeruginosa. Therefore, FabI represents a 
selective antibacterial target for those pathogens such as S. aureus, where FabI is the 
only enoyl-ACP reductase. Conversely, a compound that possesses inhibitory 
potency against both FabK and FabI would be expected to possess a far broader 
spectrum of antibacterial activity. In this context, it is believed that a target of 2,5-
LY2183240 could potentially be FabI. Moreover, besides S. aureus strains, 2,5-
LY2183240 had antimicrobial activity against B. subtilis  (Table 10). It is recognized 
that the closest homologies with the FabI structure of S. aureus are from the Gram-
positive bacteria Bacillus anthracis and B. subtilis, suggesting that FabI might be a 
potential target of 2,5-LY2183240 for these organisms too. 
A vital part in the discovery and development of antibacterial drugs is a precise 
evaluation of the mode of action (Cunningham et al., 2013). A major bottleneck in 
the drug discovery process is the target identification (Silver, 2011).  
In general, no systematic target-identification procedures of broad efficacy currently 
exist. Undeniably, target identification has been described as the ‘missing link’ in 
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chemical genetics, a technical impediment that restricts the immense potential of the 
method (Burdine & Kodadek, 2004; Galloway et al., 2009). 
There are different strategies described in the literature to identify the potential 
targets of novel antimicrobial agents. One of the classic approaches is the use of 
resistant mutants to determine the mechanism of action (O’Neill & Chopra, 2004). 
The selection of triclosan- and 2,5-LY2183240-resistant bacterial mutants is 
illustrated in Figure 4.9. Colonies that have grown in the zone of inhibition were 
selected and subcultured on agar plates and the MIC of 2,5-LY2183240 determined 
by a microbroth dilution procedure to quantify the change in susceptibility (if any). 
 
 
Figure 4.9 Generation of drug-resistant mutants of S. aureus 12981.  
 
Antibiotic resistance can be achieved by different modes, such as horizontal 
acquisition of resistance genes, recombination of foreign DNA into the chromosome, 
or by mutations in different chromosomal loci (Davies, 1997). Mutation rate is often 
defined as the in vitro frequency at which detectable mutants appear in a bacterial 
population in the presence of a specific antimicrobial agent concentration. It is 
noteworthy that in this particular case it is the number of mutant cells that are 
recorded and not the number of mutation events (Martinez & Baquero, 2000). 
Consequently, it is only taking into account selectively favorable mutations that led 
to a visible antibiotic resistance phenotype.  
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Generally, the determination of the spontaneous mutation frequency at a particular 
drug concentration is achieved by counting the confirmed resistant-colonies growing 
on drug-containing plates and dividing by the total inoculum size across all of the 
plates at that concentration. Although this determination is widely considered an 
important assignment, at this stage of the project, the mutation frequency was not 
determined due the availability and price of 2,5-LY2183240; it would be necessary 
to use significant quantities of the drug in order to determine the mutation frequency. 
Examination of the isolates that grew in the inhibition zone, yielded only one isolate 
(D) that exhibited a significant increase of around 8 to 16-fold in the MIC of 2,5-
LY2183240 for the mutant compared to the susceptible wild type parental strain (A) 
(Table 13). Amongst the isolates selected, no resistance to triclosan was noticed. 
Curiously, no concomitant reduction in susceptibility to triclosan was observed for 
isolate D.  
 
Table 13. Minimum inhibitory concentrations of triclosan and 2,5-LY2183240 




S. aureus 12981 (A) 0.03 4 
S. aureus B 0.03 8 
S. aureus C 0.03 4 
S. aureus D 0.03 32 – 64 
S. aureus E 0.03 4 
 
In order to determine the nature of the reduced susceptibility to the drug, the fabI 
genes and flanking regions from spontaneous 2,5-LY2183240-resistant S. aureus 
isolate (D) and the parental strain (S. aureus MSSA 12981; A) were sequenced. 
Analysis showed that the sequence of the fabI gene and flanking regions, which 
includes the promoter, were identical (Figure 4.10). Consequently, alterations to the 











Figure 4.10. Examples of two of the DNA sequencing traces of fabI from S. aureus (wild type) and 
2,5-LY2183240-resistant mutant. Sequence was generated from the reverse-stand primer. 
 
There are several possible explanations for these results; the mutation giving rise to 
resistance could affect accumulation of the drug in the cell, a metabolic bypass 
pathway or process could be activated, FabI expression could be affected by an 
alternative mechanism or FabI is not the main target responsible for antimicrobial 
activity. Firstly, as mentioned before, a common mechanism of drug resistance is the 
active extrusion of the antimicrobial agents by efflux pumps (Webber & Piddock, 
2003). These pumps may be specific for one substrate or may transport a range of 
structurally dissimilar compounds. In this case, it could be specific for 2,5-
LY2183240 and not triclosan, since isolate D was susceptible to triclosan. It is well 
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documented in the literature that efflux pumps play an important role in 
antimicrobial resistance. Mutations in the local repressor gene, or in a global 
regulatory gene, and also in the promoter region of the transporter gene are some of 
the mechanisms that lead to increased expression of efflux pumps in clinical isolates 
(Piddock 2006; Piddock 2006; Li & Nikaido 2004; Sun et al. 2014).  
Another possibility might be that the fabI mutation is unstable and susceptible to 
reversion with subsequent loss of the antimicrobial resistance. Hence subculture on 
drug-free media may have promoted reversion prior to fabI PCR amplification and 
sequence analysis. Resistance mutations may be expected to give rise to a fitness cost 
since they target important biological functions in the cell. Resistance to antibiotics 
frequently reduces the fitness of bacteria in the absence of antibiotics, and this is 
frequently referred to as the “cost” of resistance (Spratt, 1996; Sander et al., 2002). 
In other words, the acquisition of drug resistance may impose a cost on bacteria 
affecting such processes as growth rate, generation time and virulence, especially 
with the first mutation (Johnson et al., 2004; Pope et al., 2010). This cost plays a 
crucial role in the dynamics of resistance by generating selection against resistance 
when bacteria encounter an antibiotic-free environment (Vogwill & Maclean, 2015). 
As modest increases in the level of FabI protein expression have been correlated with 
a reduction in sensitivity to FabI inhibitors, and FabI expression can be affected by 
events independent of promoter modifications, FabI expression for the parental strain 
and 2,5-LY2183240-resistant mutant were determined by western blotting and anti-
FabI antibody (Fan et al., 2002) (Figure 4.11). 
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Figure 4.11. Western blot of S. aureus 12981 (wild-type) (A), and 2,5-LY2183240-resistant mutant 
(B) FabI expression. M stands for protein marker. 
A band around 30 kDa, that corresponds to FabI protein as previously described in 
literature was observed in both samples (Ji et al., 2004; Yao et al., 2016). There was 
no significant increase in FabI expression in the 2,5-LY2183240-resistant isolate 
when compared to wild-type strain (Figure 4.11B). Actually, the band in sample B 
seems slightly less concentrated. A lack of over-expression of FabI is consistent with 
the triclosan susceptibility observed for mutant D; a strain of S. aureus 
overexpressing FabI has been shown by others to give rise to an increase in triclosan 
MIC, whilst susceptibilities to a range of unrelated antimicrobial agents are 
unaffected (Slater-Radosti et al., 2001). 
Further inspection of the western blot reveals an additional band of 50 to 60 kDa in 
the profile of the wild-type parental strain. This higher molecular weight band could 
be due to technical artifacts, for example, the target protein may form multimers, or 
different quantities of proteins may have been loaded on the gel despite 
standardisation. To investigate this, an SDS-PAGE gel of both protein extracts was 
run in parallel with the samples to be blotted and stained with coomassie blue (Figure 
4.12). Surprisingly, whilst similar total quantities of proteins appear to have been 
loaded on to the gel, several differences were noted in the protein profiles between 
the mutant and parental strain. This is unusual for a single-step mutant and could 
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indicate variations in protein extraction between samples or a mutation that has 
affected protein expression globally within the cell. 
 
Figure 4.12. SDS-PAGE gel of the protein extracts from S. aureus 12981 (wild-type) (A) and 2,5-
LY2183240-resistant mutant (B). M stands for protein marker. The gel was stained with coomassie 
blue. Arrows indicate putative FabI protein bands. 
 
In summary, the antimicrobial spectrum of activity and the capacity of Tween 80 to 
reduce the potency of 2,5-LY2183240 suggested that the fatty synthesis pathway, 
particularly the step mediated by FabI was a probable target responsible for the 
antimicrobial activity of the compound. However, analysis of a 2,5-LY2183240-
resistant mutant revealed no significant difference in sequence of the fabI gene or in 
FabI expression. Multiple changes to the protein profile were found for the mutant 
although the significance has yet to be determined. Whilst no changes to FabI were 
noted, this enzyme cannot be rule it out at this stage nor can fatty acid synthesis as 
the putative target. Studies are ongoing to determine the antimicrobial mechanism of 
action of the 2,5-LY2183240 regioisomer.  
 
4.3.4 Effect of LY2183240 Regioisomers Against β-Lactamases 
 
Chapter 3 presented initial findings of the activities of LY2183240 against class C β-
lactamases. Albeit not a pure compound, the LY2183240 mixture had a potent effect 
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towards AmpC β-lactamases from E. coli and C. freundii, but lacked significant 
activity against the class A β-lactamase TEM-1. 
In this section the hypothesis that both LY2183240 regioisomers exhibit selective 
activity towards β-lactamases was assessed with enzymes from class A (TEM-1), 
class B (metallo-β-lactamase NDM-1), and in order to confirm the activity towards 
class C β-lactamases, a purified cephalosporinase from Enterobacter cloacae sp. was 
investigated. 
 
4.3.4.1 Class A β-Lactamase TEM-1 
 
Subsequent to the finding that the inhibitory activity of LY2183240, as a mixture, 
had no significant effect towards class A β-lactamase, both LY2183240 regioisomers 
were tested independently against TEM-1 with nitrocefin as a substrate. 
A significant and progressive increase in the absorbance at 486 nm was observed 
when 100 μM of nitrocefin was added to the solution containing the enzyme TEM-1 
(Figure 4.13). The solvent used to dissolve the samples (DMSO) showed no relevant 
effect on enzyme activity. However, in the presence of the 2,5-regioisomer (at 420 
μM) a significant reduction in enzyme activity was noted (Figure 4.13). After 3 
minutes of incubation, the isomer gave rise to a decrease of almost 50 % when 
compared to the absorbance in the absence of the inhibitor. Likewise, albeit to a 
lesser extent, the 1,5-isomer led to reduced TEM-1 activity of about 25 % compared 
to the control. For comparison and method validation determinations, clavulanic acid 
was used at a concentration of 10 μM and, as anticipated, revealed a strong decrease 
in the class A β-lactamase action, displaying a 75 % loss in TEM-1 activity after 180 
seconds of incubation.  
These findings suggest that the position of the carbamoyl in the tetrazole of 
LY2183240 has a direct impact on inhibitory activity, an effect seen before in this 
study.  
Previously in section 3.7.11, the LY2183240 mixture of both isomers plus other 
impurities, showed no significant activity against TEM-1. When assessed separately, 
the 1,5-regioisomer revealed a higher effect towards the same enzyme suggesting 
that the quantity and concentration of this isomer was crucial for the inhibitory 
activity.  
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Figure 4.13. The activity of class A β-lactamase TEM-1 (penicillinase) using nitrocefin as a substrate 
(, control) and in presence of 10 μM of clavulanic acid (), 420 μM 1,5-LY2183240 () or 420 
μM 2,5-LY2183240 (). DSMO was used as a solvent control (). 
 
This more potent effect of 1,5-isomer seems to be in agreement with earlier findings 
of LY2183240 activities (Moore et al., 2005; Alexander & Cravatt, 2006; Ortar et al., 
2007). These studies revealed that 1,5-LY2183240 demonstrated higher 
pharmacological potency towards serine hydrolases from eukaryotic cells than 2,5-
LY2183240.  
Throughout this thesis it was possible to observe that the two regioisomers presented 
different potencies and activities depending on the type of enzyme investigated. 
It should be stressed that although an inhibitory effect against the class A 
penicillinases TEM-1 was observed, a larger quantity of the drug was used (420 µM) 
when compared to clavulanic acid (10 µM). Furthermore, this inhibitory activity is 
substantially lower when compared with the activities of the regioisomers against 
class C enzymes. This aspect will be explored and discussed in detail within section 
4.3.4.7 of this Chapter.  
4.3.4.2 Class B β-Lactamase (Metallo-β-Lactamase) 
 
The New Delhi metallo-β-lactamase 1 (NDM-1) was first acknowledged in 2008 
within Klebsiella pneumoniae isolated from a Swedish patient relocated from India. 
This β-lactamase is described as a carbapenemase that hydrolyzes all β-lactams 
excluding monobactams, being sensitive to EDTA but not to clavulanic acid 
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(Nordmann et al., 2011; Arpin et al., 2012). This enzyme is encoded by the gene 
blaNDM-1 and it is generally carried by conjugative plasmids that possess multiple 
additional determinants, contributing towards the multidrug resistance phenotype 
(Göttig et al., 2010). 
 
Figure 4.14. Progressive curves with different concentrations of the LY2183240 regioisomers; 1,5-
LY2183240 at 420 μM (), 42 μM () and 2,5-LY2183240 at 420 μM (), 42 μM (), against 
supernatant from Klebsiella pneumoniae containing the class B -lactamase NDM-1 (, control) and 
the substrate nitrocefin (100 μM). For some points, the error bars would be shorter than the height of 
the symbol. In these cases, the software GraphPad Prism does not draw the error bars. 
 
In this current study, for comparison purposes, the supernatant of Klebsiella 
pneumoniae NCTC 13443 containing the metallo-β-lactamase NDM-1 was used. The 
results revealed a significant increase of around 220 % of the initial absorbance at 
486 nm when incubated with the substrate nitrocefin (Figure 4.14), indicating the 
presence of the metallo--lactamase. In the presence of LY2183240 regioisomers, a 
gradual and concentration-dependent reduction in the enzyme activity was observed. 
Surprisingly, the 2,5-isomer revealed to be more potent than 1,5-LY2183240 
showing a significant decrease at both concentrations tested. At a concentration of 
420 μM for instance, the 2,5-isomer exhibited a decrease of about 35 % after 3 
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minutes incubation. At the same concentration, the isomer 1,5 showed a similar 
inhibitory effect, although to a lesser extent, giving rise to a 20 % reduction in the 
NDM-1 activity. Again, the results suggest that the position of carbamoyl in the 
tetrazole of the molecule influenced directly the inhibitory activity against NDM-1.  
From a chemical point of view these findings seem to be in agreement with previous 
studies about the position of the substituent group in the tetrazole. Compounds with a 
similar structure to LY2183240, i.e., possessing biphenyl tetrazoles, demonstrate 
significant activity towards metallo-β-lactamases (Toney et al., 1998; Toney et al., 
1999). Toney and co-workers screened a Merck chemical collection of biphenyl 
tetrazoles linked to various heterocyclic aromatic rings. The study revealed a potent 
and competitive inhibitory effect against a metallo-β-lactamase from Bacteroides 
fragilis as well as good activity when used in combination with imipenem. 
Intriguingly, it was demonstrated that the position relative to the biphenyl ring 
system in the tetrazole group influenced the activity. For instance, the ortho position 
was discovered to be essential for enzyme inhibition; movement of the tetrazole 
group to the meta or para positions resulted in IC50 values of 10 to 20 mM (Toney et 
al., 1998). In addition, replacement of carboxamide for the tetrazole group at the 
ortho position also led to a reduction of the inhibitory effect. Comparably, movement 
of the carboxamide group to the meta or para positions also led to a loss of activity 
with IC50 values between 2.5 and 1.0 mM, respectively.  
Since its identification, this class B β-lactamase has become a challenging menace to 
public health, encouraging the World Health Organization to issue a global warning 
(Feng et al., 2014). Moreover, as mentioned in Chapter 1, the hydrolytic mode of 
metallo-β-lactamases are in general considerably distinctive comparing to the other 
classes, requiring one or two atoms of zinc (Palzkill, 2013; Drawz et al., 2014). The 
substrate profile comprises all known β-lactams and β-lactamase inhibitors, except 
monobactams such as aztreonam, illustrating a highly extensive substrate profile.  
In this regard, this class of β-lactamases represents a particular challenge for 
clinicians and researchers of the field. However, to illustrate some of the 
achievements, a series of mercaptoacetic acid thiol ester derivatives have been 
identified as potent metallo-β-lactamase inhibitors and initiated further investigation 
of thiols as potential lead compounds (Payne et al., 1997). L-Captopril, for instance, 
used to treat hypertension by angiotensin-converting enzyme inhibition, has been 
reported to inhibit metallo-β-lactamase by chelating to the catalytic site zinc ions 
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through its thiolate (Li et al., 2014; Brem et al., 2015). The authors revealed 
correlations between the binding modes and inhibition potency using high-resolution 
crystal structures of three metallo-β-lactamases (IMP-1, BcII and VIM-2) in complex 
with both L- and D-captopril stereoisomers. Consecutively, other compounds 
containing the sulfur atom, such as thiol carboxylates (Concha et al., 2000), as well 
as thiols (Siemann et al., 2003; Liénard et al., 2008) and thiomandelic acid (Mollard 
et al., 2001) were assessed and revealed significant effect (Faridoon et al., 2012; 
Yang et al., 2015; Feng et al., 2014; Zhang et al., 2014). More recently, 
triazolylthioacetamides compounds demonstrated specific inhibitory effect against β-
lactamase NDM-1 with an IC50 down to 1.90 μM, however, no activity against other 
metallo-β-lactamases was noted (Zhai et al., 2016). 
Although interesting activity was demonstrated, none of the promising inhibitors 
mentioned have significant prospect against class B enzymes (Drawz et al., 2014). 
In this study evaluation of the MIC values of LY2183240 regioisomers towards K. 
pneumoniae expressing NDM-1 as well as K. pneumoniae 17 expressing a CTX-M-
type β-lactamase revealed no activities against these particular microorganisms 
(Table 14). Similarly, as demonstrated in the previous section, this result suggests 
that both isomers exhibit a specific activity against the serine hydrolase (-
lactamase), but not the microorganism per se. Still, it was possible to verify the 
resistance of the K. pneumoniae NDM-1-producing strain with meropenem as a 
reference. Meropenem is a broad-spectrum antibacterial agent of the carbapenem 
family, suggested as empirical therapy preceding to the identification of causative 
microorganisms, or for a disease caused by single or multiple susceptible bacteria in 
patients with a broad range of serious infections (Baldwin et al., 2008). In previous 
reports, this antimicrobial agent revealed good in vitro activity against clinically 
relevant Enterobacteriaceae, including C. freundii, E. cloaceae, E. coli and K. 
pneumoniae. In this current study, meropenem exhibited MIC values of 8 to 16 
μg/mL against K. pneumoniae 17 and higher than 128 μg/mL for the NDM-1-
producing strain. These results substantiate previous findings in the literature. 
Worthington et al. (2012) demonstrated a similar MIC value of meropenem against 
the NDM-1-producing strain (256 μg/mL). In regards to K. pneumoniae 17, 
meropenem showed a potent effect, however with a MIC value higher than presented 
in literature for a susceptible organism (Baldwin et al., 2008). 
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Table 14. MICs of LY2183240 regioisomers and meropenem against K. 
pneumoniae. 
MIC (µg/mL) 
Organism Meropenem 1,5-LY2183240 2,5-LY2183240 
K. pneumoniae 
NDM-1 
> 128 > 128 > 128 
K. pneumoniae 
17 
8 − 16 > 128 > 128 
 
It is worth mentioning that, as seen in the Chapter 3, the LY2183240 mixture 
presented a significant effect against class C β-lactamases from E. coli G69 and C. 
freundii 382010, and no significant activity towards the class A enzyme TEM-1. In 
this sense, the main motivation to test LY2183240 isomers against metallo-β-
lactamases is to verify the specificity of these compounds towards different classes 
of β-lactamases. The activity of both regioisomers found in this section against 
NDM-1 albeit intriguing, is much less potent when compared to AmpC β-lactamases. 
Hence, the following sections of Chapter 4 focus on the activity towards class C of 
these enzymes. 
 
4.3.4.3 Purification of the Class C β-Lactamase from Enterobacter cloacae 
 
Innumerable proteins have been purified in active forms based on features such as 
size, solubility, charge, or specific binding affinity. Commonly, protein extracts or 
mixtures are subjected to a sequence of separations, which are based on the 
differentiating properties of the target with an to aim to obtain a pure protein (Berg et 
al., 2002). 
The literature describes a diversity of methods used to purify cephalosporinases from 
Enterobacter cloacae (Minami et al., 1980; Charlier et al., 1983; Cartwright et al., 
1984; Graham & Mantle, 1989). With respect to class C β-lactamases, it is well 
recognized that boric and boronic acids act as reversible competitive inhibitors of 
this enzyme type (Beesley et al., 1983; Crompton et al., 1988). Thereby, many β-
lactamases from class C have been purified by affinity chromatography utilising 
boronic acid-containing gels. The process is selective, efficient and fast, allowing 
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one-step purification of large quantities of enzyme from crude protein extracts 
(Cartwright et al., 1984).  
Figure 4.15 is an example of SDS-PAGE analysis of the β-lactamase from 
Enterobacter cloacae in a sample with a composition of around 60 % protein (0.2-
0.6 units/mg protein) purchased from Sigma-Aldrich, UK. 
 
Figure 4.15. SDS-PAGE (10 % gel) of sample (100 µg) containing the β-lactamase from 
Enterobacter cloacae. M, molecular weight marker, E, extract of β-lactamase from Enterobacter 
cloacae. The red arrow shows the position of class C enzyme in the gel. 
 
Analysis of the sample revealed the presence of several bands from 11 to 245 kDa, 
including a ~39 kDa band that corresponds to the AmpC β-lactamase.  
A 100 mg-sample of this protein mixture was subjected to purification by affinity 
chromatography on phenylboronic acid-agarose according to the method developed 
by Cartright and Waley (1984). After the dialysis phase, the crude protein was eluted 
with 0.5 M-borate/0.5 M-NaCl (pH 7) and fractions of approximately 5 mL each 
were collected throughout the procedure. β-Lactam hydrolytic activities of the 
fractions were monitored during the purification process with nitrocefin as the 
chromogenic substrate in order to verify the presence of the β-lactamase in the 
fractions.  
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Figure 4.16. SDS-PAGE (10% gel) of fraction obtained during the purification process utilising a 
boronic acid column. M, molecular weight marker; E, extract of β-lactamase from Enterobacter 
cloacae P99; lane 1, Fraction 1; lane 2, Fraction 2; lane 3, Fraction 3; lane 4, Fraction 4; lane 5, 
Fraction 5; lane 6, Fraction 6; lane 7, Fraction 7; lane 8, Fraction 8; The red arrow shows position of 
P99 enzyme in the gel. 
 
As judged by SDS–PAGE (Figure 4.16), the AmpC β-lactamase started to elute in 
quantity from fraction 3 to fraction 8, yielding a single band of around 39 kDa. The 
collected fractions containing AmpC β-lactamase were then combined and 
concentrated by means of a spin-filter with 10 kDa molecular weight cutoff (Figure 
4.17).  
The results were consistent with those of other researchers who have purified β-
lactamases with the same technique (Cartwright et al., 1984; Marchou et al., 1987; 
Stachyra et al., 2010). Although a significant degree of purification had been 
achieved by the single step of purification process using boronic affinity 
chromatography, contaminating proteins were still present. Consequently, it was 
necessary to subject the sample to a further round of purification this time employing 
Fast Protein Liquid Chromatography utilizing a HiLoad 16/60 Superdex 75 column 
(GE Health) and β-lactamase elution with KH2PO4 (pH 5.5). 
 
  159 
 
Figure 4.17. SDS-PAGE (10 % gel) of the β-lactamase from Enterobacter cloacae after purification 
and desalting. M, molecular weight marker, P, purified extract of β-lactamase from Enterobacter 
cloacae sp. The red arrow shows the position of the β-lactamase in the gel. 
 
Figure 4.18 shows the SDS-PAGE result of the purification process with FPLC. As 
expected, after the procedure, the purified soluble β-lactamase was present with a 
high degree of purity, illustrated by a single and clear band with a molecular mass 
approximately of 39 kDa in all the fractions collected. 
The fractions containing the β-lactamase (fractions 4 to 10) were combined and 
concentrated as previously described. The other fractions containing contaminants or 
other proteins were discarded (data not shown).  
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Figure 4.18. SDS-PAGE (10 % gel) of the β-lactamase from Enterobacter cloacae after FPLC 
utilizing a Superdex 75 column. M, molecular size marker; the number represent the fractions 
collected in the order obtained. 
 
The purified enzyme was then quantified by the Bradford method (Figure 4.19). 
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Figure 4.19. BSA calibration curve using the Bradford reagent. The BSA standard curve with a 
concentration range of 2 – 15 µg/mL is shown. The measurements were performed in triplicate. For 
some points, the error bars would be shorter than the height of the symbol and consequently these are 




The results show that boronic acid agarose gels together with FPLC using a 
Superdex 75 column provided a reasonable and effective method for purifying 
AmpC β-lactamase from the protein mixture. The purified cephalosporinase was then 
used in different types of experiments, including a steady-state kinetic assay.  
 
4.3.4.4 Effect of URB597 against class C β-lactamase  
 
URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester), previously 
know as KDS-4103, is a crystalline white solid with a molecular weight of 338.4 
(Piomelli et al., 2006). The compound has two hydrogen bond donors and five 
hydrogen bond acceptors (Figure 4.20). 
Several studies have defined URB597 as a strong FAAH inhibitor in vitro and in vivo 
(Kathuria et al., 2002; McKinney & Cravatt, 2005; Alexander & Cravatt, 2006; 
Dickason-Chesterfield et al., 2006; Petrosino et al., 2009; Powers et al., 2010; Mileni 
et al., 2010). This compound is reported to bind in the hydrophobic site and catalytic 
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pocket of FAAH that connects the active site residues to the membrane surface of 
FAAH (Mor et al., 2004). 
LY2183240, like the FAAH inhibitor URB597, potently inhibits FAAH activity by 
carbamylation of the enzyme's serine nucleophile. Nevertheless, unlike URB597, 
LY2183240 is not selective for FAAH as multiple other serine hydrolases are 
inactivated by LY2183240, according to several studies (Alexander & Cravatt, 2006; 
Ortar et al., 2007; Ortar et al., 2008). 
The compound URB597 was assessed in order to verify if there is a relation between 
FAAH inhibitory effect and the activity against β-lactamases. 
 
Figure 4.20. Chemical structure of URB597, also known as KDS-4103. 
 
The FAAH inhibitor showed no significant effect against cephalosporinase from E. 
cloacae sp. (Fig. 4.21). The graph displays a slight decrease in the AmpC enzyme 
activity, especially at concentrations 0.5 mM and 1 mM of URB597. It is necessary 
to mention that the concentrations used for URB597 were in the milimolar range, 
e.g., x1000 more concentrated than those used to assess the LY2183240 
regioisomers.  
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Figure 4.21. The effect of URB597 against a purified class C β-lactamase from Enterobacter cloacae. 
The mixture contained 2.5 nM of cephalosporinase with 0 mM (), 0.25 mM (), 0.5 mM () 1 
mM () of URB597. 
FAAH is an unusual serine hydrolase due to the catalysis of the hydrolysis of both 
amide and ester substrates at comparable rates, with an acylation rate limiting step 
(Mileni et al., 2010). Despite this, some classes of FAAH inhibitors also inhibit non-
homologous serine hydrolases, suggesting the enzymes share some degree of 
mechanistic similarity. Nonetheless, in this study, the compound URB597 exhibited 
no relevant effect against class C β-lactamase from E. cloacae. 
These findings suggest that although both URB597 and LY2183240 are FAAH 
inhibitors, only LY2183240 revealed activity against class C β-lactamase from E. 
cloacae sp. These data reinforce the idea that both LY2183240 regioisomers have 
promiscuous activities towards serine hydrolases, although to different extents.  
 
4.3.4.5 IC50s of Inhibitors 
 
Half maximal inhibitory concentrations, IC50 values, for LY2183240 regioisomers 
were determined and compared with clavulanic acid, tazobactam and avibactam for 
both TEM-1 and AmpC β-lactamases (Table 15 and Figure 4.22). For both enzyme 
classes, avibactam presented the lowest IC50 values, 0.01 and 0.11 µM for class A 
and C, respectively. For the class A enzyme TEM-1, clavulanic acid gave an IC50 
value of 0.37 µM. Tazobactam had IC50 values of 0.03 and 0.57 µM, for TEM-1 and 
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AmpC, respectively. Both regioisomers gave rise to similar IC50 values; the 1,5-
isomer showed a slight higher activity than the 2,5-isomer towards TEM-1 with 
values of 244 and 290 µM, respectively. These high IC50 values exhibited by both 
regioisomers towards the class A β-lactamase corroborates with previous 
experiments on TEM-1 (Section 4.3.4.1).  
Regarding the enzyme AmpC, tazobactam and avibactam, revealed higher IC50 
values when compared to the class A TEM-1 β -lactamase. On the other hand, both 
LY2183240 regioisomers showed significantly lower IC50 values for this class of 
enzyme, exhibiting 20- to 30-fold higher activity when compared with the class A β-
lactamase, illustrating a high specific activity for class C β-lactamases. 
 
Table 15: Half maximal inhibitory concentration values (µM) for LY2183240 
regioisomers and other β-lactamase inhibitors determined after 10 minutes of 
incubation with TEM-1 or AmpC. 
 
IC50 (µM)* 
                                          
Enzyme 
Class Source Clav. 
acid 
Tazobactam Avibactam 1,5- 2,5- 
TEM-1 A E. coli 0.37 0.03 0.01 244 290 
AmpC C E. 
cloacae 
N.D. 0.57 0.11 6.78 13.83 
* Performed in triplicate. 
N.D. – Not determined.  
 
An extensive search in the literature, including ChEMBL, one of the major databases 
of public bioactivities for small molecules, revealed substantial variations in the IC50 
values from several different studies, employing the same reference compounds and 
similar β-lactamases used in this study (Bento et al., 2014).  
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Figure 4.22. Determination of IC50 values for LY2183240 regioisomers against Ampc β-lactamase 
from E. cloacae; 1,5-isomer (); 2,5-isomer (). The point of inflection of this curve corresponds to 
the logarithm of the inhibitor concentration that decreases enzyme velocity (V) by 50 %. 
 
For instance, with the enzyme TEM-1, Payne et al. (1994) reported an IC50 for 
tazobactam of 0.04 µM, similar to that found in this study (0.03 µM). Conversely, 
wide-ranging IC50 values, from 0.01 to 0.1 µM, were also reported in the literature 
(Bush et al., 1993; Bret et al., 1997; Chaibi et al., 1998). 
In a comparable way, some variations seem to occur with the inhibitor clavulanic 
acid as well. Many studies reported different IC50 values in a range of 0.02 to 0.12 
µM (Payne et al., 1994; Bret et al., 1997; Caniça et al., 1998; Jamieson et al., 2003). 
With regard to the AmpC enzyme, similar variations were reported, presenting 
divergences in the half maximal inhibitory concentrations to all standard compounds 
used. In the case of tazobactam, for example, there are reports showing IC50 values 
fluctuating from 0.0085 to 25 µM (Bush et al., 1993; Doi et al., 2004). 
These variances can be attributed to several factors, including the method used and 
enzyme employed. However, one of the main aspects is the fact that IC50 data is very 
assay specific and comparable only under certain conditions (Kalliokoski et al., 
2013). 
In this context, in order to establish robust data regarding β-lactamase inhibitory 
activities, an extensive kinetic study using the same compounds and enzymes, was 
performed. Moreover, the relation between IC50 and Ki (Constant of Inhibition) was 
evaluated and further discussed in the following sections. 
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4.3.4.6 Inactivation of the AmpC β-lactamase from E. cloacae by LY2183240 
Regioisomers 
 
The main goal of this experiment was to verify the potential inhibitory activity of 
both LY2183240 isomers using the purified AmpC β-lactamase. For validation and 
comparison purposes, tazobactam and avibactam were used as reference standards. 
Progressive and time-dependence inhibition of the class C β-lactamase 
(cephalosporinase) from Enterobacter cloacae by tazobactam is depicted in Figure 
4.23. At the start, first-order of inhibition was observed up until 20 minutes of 
incubation, thereafter tazobactam inactivated almost completely the enzyme at two 
different inhibitor/enzyme (I/E) ratios, 33 and 165. Conversely, I/E ratios of 7 and 
14, only led to a drop in enzyme activity of 60 % after approximately 2 hours of 
incubation. However, a further 18 hours of incubation resulted in a significant 
reduction in the enzyme activity to less than 20 %. There was no indication of a 
reversion of enzyme inhibition after 18 hours incubation for any of the 
concentrations tested.  
These results are partially in accordance with a previous report using tazobactam and 
the class C β-lactamase from Enterobacter cloacae P99 (Bush et al., 1993). Bush and 
co-workers demonstrated a similar profile of enzyme inactivation by tazobactam, 
however, at an I/E ratio of 7:1 after 10 min of incubation 60 % of P99 enzyme 
activity was inhibited rather than 84 % found in this study. In addition, they revealed 
that the enzyme activity gradually recovered during incubation with different 
tazobactam concentrations, except at the highest concentration evaluated. 
Throughout the 18 hours of incubation, the enzyme showed no significant loss in 
activity in the absence of the inhibitor in this study. 
The lack of recovery from inhibition of the cephalosporinase after extended 
incubation (18h) observed in this study was not consistent with other studies that 
report partial recuperation of activity of E. cloacae β-lactamases with tazobactam 
(Akova et al., 1990; Bush et al., 1993). Notwithstanding, Akova et al. (1990) showed 
that the inactivated complexes were very stable in the recovery activity of the 
enzyme from E. cloacae inactivated by tazobactam. The authors suggested that the 
recovery kinetics fit with the accumulation of a single inactivated species that breaks 
down to free the active enzyme. 
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Figure 4.23. Inactivation of the class C β-lactamase from Enterobacter cloacae by tazobactam. The 
mixture contained β-lactamase (2.5 nM) with 18 (), 35 (), 83 (), and 413 (), nM tazobactam 
and a control () without the inhibitor present. I/E is the inhibitor-enzyme ratio. 
 
In other words, the cephalosporinase can entirely be recovered only if the free 
inhibitor is removed; suggesting that the recovery occurred in these experiments only 
once the free tazobactam was separated by gel filtration. In this current work, 
inhibitor removal was not performed, representing a possible source of variance 
between the studies. 
Although the recovery activity of the cephalosporinase used in this current work was 
entirely consistent, these minor differences observed may be related to the method 
employed or different enzymes studied. 
In a similar fashion, avibactam demonstrated time- and concentration-dependent 
inhibitory activity of the cephalosporinase (Figure 4.24). After 5 minutes of 
incubation, the non-β-lactam inhibitor caused more than a 60% reduction in enzyme 
activity, and complete enzyme inactivation after 20 minutes of incubation at an 
inhibitor/ enzyme ratio of 60:1 (150 nM). 
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Figure 4.24. Inactivation of the class C β-lactamase from Enterobacter cloacae by avibactam. The 
mixture contained β-lactamase (2.5 nM) with 12 (), 25 (), 75 (), and 150 (), nM avibactam 
and a control without the inhibitor present (). I/E is the inhibitor-enzyme ratio. 
 
A gradual decrease in enzyme activity with 25 and 75 nM of avibactam was 
observed, with almost complete inactivation within 120 minutes of incubation.  
It is worth mentioning that according to the literature, avibactam is a highly potent β-
lactamase inhibitor. In this respect, lower concentrations and inhibitor/enzyme ratios 
were adopted in order to be able to compare the results with the others compounds 
evaluated. 
Once again, no sign of enzyme reversibility was noted at all concentrations of 
avibactam tested. These results are somewhat similar to former reports; Stachyra et 
al. (2010) demonstrated a complete inactivation of the cephalosporinase P99 at a 1:1 
I/E ratio after 5 and 30 minutes of incubation. Regarding enzyme recovery of 
activity, the same authors observed a recovery of less than 10 % activity after 10 to 
15 minutes using 4-µM avibactam and the enzyme P99. However no further 
significant recovery of activity was observed within 24 hours.  
The inhibitory activity of the LY2183240 regioisomers against AmpC β-lactamase 
was gradual showing time and concentration dependence. The rate of inhibition rose 
progressively as more inhibitor was provided (Figure 4.25). Isomer 1,5 showed 
complete inactivation of the enzyme after 60 minutes of incubation at a molar ratio 
of 165:1 (Figure 4.25A). Comparatively, the 2,5 isomer exhibited a similar profile, 
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but to a lesser extent, with almost 80% of enzyme inactivation within the same time 
interval (Figure 4.25B). Furthermore, both isomers revealed no signs of reversibility 
throughout the incubation period assessed.  
Once again, the influence of the position of the carbamoyl on the tetrazole is evident, 
illustrating that it may play an important role in β-lactamase inhibitory activity as 
well (Alexander & Cravatt, 2006; Ortar et al., 2007; Ortar et al., 2008; Moore et al., 
2005). Although the inhibitor-enzyme molar ratios of 7 and 14 showed no significant 
signs of inhibition within the first 120 minutes, after 18 hours of incubation both 
concentrations did result in more than 50% of reduction of enzyme activity. 
Ortar et al. (2008) demonstrated that several of the carbamoyl tetrazoles synthesized, 
including LY2183240 regioisomers, strongly inhibited the hydrolysis of 2-
arachidonoyglycerol by a serine hydrolase (monoacylglycerol lipase-like) present in 
the cytosol of a fibroblast-like cell lines (COS cells). Moreover, the authors agreed 
only in part with the conclusions drawn by Alexander and Cravatt (2006) about the 
promiscuity of LY2183240, since their findings showed that out of the 17 tetrazoles 
screened, four compounds exhibited potent activity for FAAH and selectively over 
all other targets tested in the study. 
From a chemical point of view, there are other reports in the literature highlighting 
the significance of covalent carbamoylation of the enzyme’s serine nucleophile in the 
inhibitory activity of these compounds within mammalian cells (Adibekian et al., 
2012; Ebdrup et al., 2004). 
With regard to prokaryotic systems, avibactam, stands out as a novel and potent 
inhibitor of both class A and C β-lactamases (Stachyra et al., 2009). As mentioned 
above, avibactam is considered a non-β-lactam, and its chemical structure is 
composed of a bicyclic structure containing a strained cyclic urea, which includes a 
carbamoyl group (carboxamide) (See Figure 1.8D) (Choi et al., 2016). 
Recently, several studies have outlined the potential mode of action of this 
compound towards β-lactamases (Stachyra et al., 2009; Ehmann et al., 2012; Lahiri 
et al., 2013; Lahiri et al., 2014; King et al., 2015). One of the defining features of the 
mechanism proposed is the stable acyl enzyme formed by the carbamoyl link 
between the inhibitor and the enzyme active-site serine residue (Lahiri et al., 2014). 
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Figure 4.25. Inactivation of the class C β-lactamase from Enterobacter cloacae by LY2183240 
regioisomers. (A) The mixture contained β-lactamase (2.5 nM) with 18 (), 35 (), 83 (), and 
413 (), nM 1,5-LY2183240 and a negative control lacking the inhibitor (). (B) The mixture 
contained β-lactamase (2.5 nM) with 18 (), 35 (), 83 (), and 413 (), nM 2,5-LY2183240 and 
a negative control in the absence of the inhibitor (). I/E is the inhibitor-enzyme ratio. 
 
Furthermore, according to Lahiri and co-workers (2014), the carboxamide of 




 in the binding pocket of 
AmpC. Also, the inhibition of avibactam is believed to be reversible and the active 
inhibitor is regenerated via deacylation and recyclization of the 5-membered urea 
ring (Ehmann et al., 2012). 
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Clearly, the carbamoyl group can play an important role in the inhibitory activities of 
compounds towards serine hydrolases. Notwithstanding, further experimental 
investigations are needed to verify if the carbamoyl group present within LY2183240 
regioisomers is involved in the inhibition of AmpC β-lactamases and this will be 
discussed in the following sections. 
Although the study has successfully demonstrated the inhibitory effect of the 
compounds tested, it has certain limitations in terms of reversibility of the 
cephalosporinase. Unfortunately, it was not possible to detect any sign of enzyme 
reversibility with all the ligands assessed in this study. This may represent a critical 
restriction of this study, since this parameter helps in understanding the mode of 
action of the inhibitors. This factor will be investigated further and discussed in 
following sections. 
An extensive research using several databases revealed that there are very few 
studies concerning LY2183240 in the literature. To the best of my knowledge, this is 
the first work reporting the activities of LY2183240 regioisomers against prokaryotic 
systems. The results presented in this section indicated that LY2183240 regioisomers 
possess strong inhibitory activities against class C β-lactamases. In the next section, 
the study will move on to discuss the potential mechanism of action of both 
LY2183240 regioisomers and explore the kinetic characteristics of this activity in 
more detail. 
 
4.3.4.7 Kinetic Analysis of the Inhibition of Class C β-Lactamase from E. cloacae 
by LY2183240 Regioisomers 
 
The purpose of a mechanism of action study is to characterize the interaction of a 
compound with its target to understand how natural substrates at physiologic 
concentrations will modulate this activity (Strelow et al., 2004).  
Enzyme kinetic assays are widely used to estimate the substrate affinity and enzyme 
activity in general, including β-lactamases. The main purpose of this kinetic study is 
to verify the potency of LY2183240 regioisomers toward a purified class C β–
lactamase and establish the modality of inhibition. In order to standardize and 
validate the method used in this project, three different standard β-lactamase 
inhibitors, clavulanic acid, tazobactam, and avibactam were used against two 
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different enzymes (TEM-1 and a purified AmpC from Enterobacter cloacae). In 
addition, in order to verify the range of LY2183240 regioisomer activities towards β-
lactamases the metallo-β-lactamase NDM-1 was also tested. 
To achieve this an appropriate experimental design for enzyme kinetic evaluation is 
essential for a correct interpretation of the data obtained. Estimating an inhibition 
constant (Ki) for a competitive inhibition model for instance, requires observations at 
low substrate concentrations, mainly because a competitive inhibitor is most 
effective at low substrate concentrations (Cornish-Bowden, 2014). From this 
standpoint, knowing from the literature the behavior of the standard β-lactamase 
inhibitors utilized in this work, low concentrations of the substrate nitrocefin (0 to 40 
µM) were adopted. It is noteworthy that the enzyme concentrations employed were 
lower than the amount of substrate present in the solution, always having an excess 
of nitrocefin.  
Figure 4.26 illustrates a plot of reaction velocity (V) as a function of substrate 
concentration [S] for the TEM-1 β-lactamase that follows Michaelis-Menten kinetics 
(Equation 3). In both reactions, the rate of catalysis was observed to gradually 
elevate as nitrocefin concentration increases. As expected, clavulanic acid gave rise 
to a significant reduction in the enzyme hydrolysis velocity in a concentration-
dependent fashion (Figure 4.26A). In addition, tazobactam demonstrated a similar 
profile, although with a higher inhibitory potency, showing a reduction of a quarter 
of the TEM-1 hydrolytic activity, at the higher inhibitor concentration tested (Figure 
4.26C). 
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Figure 4.26. Determination of the inhibition mode of class A TEM-1 (0.25 µM) by clavulanic acid (A 
and B) and tazobactam (C and D). (A) Direct non-linear plot using the Michaelis-Menten equation. 
(B) Double reciprocal, Lineweaver-Burk plot. Final concentrations of clavulanic acid were 0 µM (), 
0.05 µM (), 0.1 µM (). (C) Direct non-linear plot using the Michaelis-Menten equation. (D) 
Double reciprocal, Lineweaver-Burk plot. Final concentrations of tazobactam were 0 µM (), 0.03 
µM (), 0.06 µM (). 
 
To determine the mode of inhibition of TEM-1 by clavulanic acid and tazobactam, 
double reciprocal plots following the Lineweaver-Burk equation (Equation 4) in 
conjunction with the alpha (α) parameter derived from a mixed-model inhibition and 
statistical comparison by GraphPad Prism software were used (Minond et al., 2010). 
The results depicted in Figures 4.26 (B) and (D) suggest that both compounds are 
competitive inhibitors of β-lactamase class A TEM-1, e.g., the inhibitor acts as 
though it competes with the substrate, in this case nitrocefin, for binding to the 
enzyme (Copeland, 2000). Lineweaver-Burk plots are particularly valuable in 
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differentiating between competitive and noncompetitive inhibitors. In competitive 
inhibition, the intercept on the y-axis is the same in the presence or absence of 
inhibitor, although the slope is increased (Figure 4.26B & D) (Berg et al., 2002). The 
findings of the current study are consistent with former reports that studied 
clavulanate inhibition of class A β-lactamases (Labia & Peduzzi, 1978; Bret et al., 
1997; Luhavaya & Grigorenko, 2010; Sulton et al., 2005; Drawz et al., 2010). 
All the other relevant enzyme kinetic parameters for TEM-1 are summarized in 
Table 16.  An increase in the Michaelis constant (apparent Km) as a result of the 
presence of the inhibitors, clavulanic acid (170 ± 36.17) and tazobactam (299.3 ± 
67.28), was observed (Table 16). In contrast, all the Vmax values are similar, 
reinforcing again a competitive inhibition effect. This is in accordance with 
previously published determinations demonstrating the effect of a competitive 
inhibitor; a raised concentration of substrate is required to achieve a certain velocity, 
nonetheless the Vmax is unaffected by a competitive inhibitor (Copeland, 2000). 
Another important parameter calculated in this study was the alpha (α) value. The 
constant α defines the level to which inhibitor binding influences the affinity of the 
enzyme for the substrate. The α-value for both standard inhibitors were greater than 
1 (Table 16). According to Copeland (2000), this constant determines the mode of 
action, e.g., when α = 1 the inhibitor does not alter binding of substrate to the 
enzyme, being identical to noncompetitive inhibition. If α is very large (α > 1), 
binding of the inhibitor prevents the binding of the substrate, which is equivalent to 
competitive inhibition. When α is very small (but greater than zero), binding of the 
inhibitor enhances substrate binding to the enzyme, fitting nearly to the 
uncompetitive model. In the same way, statistical analyses of the comparison of fits 
(p < 0.05) indicate that the preferred model for both standard compounds is 
competitive inhibition. 
Clavulanic acid and tazobactam revealed constants of inhibition (Ki) of 0.1113 ± 
0.0145 µM and 0.0261 ± 0.0032 µM, respectively (Table 16). Similar results were 
reported for clavulanic acid towards TEM-1 with a Ki around 0.1 µM (Bret et al., 
1997; Chaibi et al., 1998; Drawz et al., 2010; Imtiaz et al., 1994; Naumovski et al., 
1992). Likewise, previous studies revealed a Ki between 0.01 to 0.02 µM for 
tazobactam (Bonomo et al., 1997; Chaibi et al., 1998; Drawz et al., 2010). The 
similarity of the constant of inhibition values from this study with former works 
reveals that the method employed is adequate and robust. 
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Table 16. Kinetic parameters of TEM-1 in presence of standard inhibitors. 
TEM-1 
  No inhibitor Clavulanic acid Tazobactam 
Km (µM) 122.5 ± 82.9 170 ± 36.17 299.3 ± 67.28 
Vmax (µM S
-1
) 0.7087 ± 
0.3816 
0.674  ± 0.1204 0.7167 ± 0.2319 
Kcat (S
-1
)  2.83  ± 1.049 - - 
Ki (µM) - 0.1113  ± 0.0145 0.0261 ± 0.0032 
Alpha (α) - 1.82  ± 4.89 18.63 ± 334.4 
R
2
 0.985 0.9903 0.9883 
Preferred 
Model 
- Competitive  
(p < 0.05) 
Competitive  
(p < 0.05) 
 
A similar kinetic study with equivalent parameters was conducted utilizing the 
purified class C β-lactamase from Enterobacter cloacae with tazobactam and 
avibactam as reference compounds. In general, under the same conditions mentioned 
above, tazobactam showed an effective reduction in the enzyme hydrolysis velocity, 
however to a lesser extent when compared to the class A β-lactamase TEM-1 (Figure 
4.27). This inhibitor revealed a similar comportment, consistent with a competitive 
inhibition model with Ki of 0.372 ± 0.064 µM (Table 17). Table 17 illustrates some 
of the main enzyme kinetic parameters for the cephalosporinase. Once again, as a 
competitive inhibitor, an increase in the Km was observed. In comparison, tazobactam 
showed higher activity against TEM-1 than class C β-lactamase.  
There are several lines of evidence that suggest that inhibitors of class A enzymes 
such as tazobactam have much less effect on AmpC β-lactamases (Jacoby, 2009). 
For that reason, few studies focus on tazobactam inhibition of class C β-lactamases. 
Nevertheless, data available reporting the constant of inhibition of tazobactam 
against AmpC β-lactamases is variable. In a report concerning the in vitro inhibition 
of CMY-type β-lactamases by tazobactam a Ki of 50 ± 9.5 µM was reported 
(Endimiani et al., 2010). In another study, Bush and co-workers (1993) demonstrated 
an IC50 of 8.5 nM towards a class C β-lactamase from Enterobacter cloacae P99. 
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Figure 4.27. Competitive inhibition by standard β-lactamase inhibitors towards the class C enzyme 
from Enterobacter cloacae. (A) Direct non-linear plot of tazobactam using the Michaelis-Menten 
equation. (B) Double reciprocal, Lineweaver-Burk plot of tazobactam. Final concentrations of 
tazobactam were 0 µM (), 0.2 µM (), 0.5 µM (). (C) Direct non-linear plot of avibactam using 
the Michaelis-Menten equation. (D) Double reciprocal, Lineweaver-Burk plot of avibactam. Final 
concentrations of avibactam were 0 nM (), 1 nM (), 5 nM (). 
 
Admittedly, although IC50 and Ki are not equivalent and challenging to compare, 
some of these differences still could be explained by certain factors. Firstly, although 
these enzymes belong to the same class, there are differences in physical and 
enzymatic properties, structures and essential active sites, among others that could 
affect directly inhibitor performance (Jacoby, 2009).  
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Table 17. Kinetic parameters of AmpC from Enterobacter cloacae in the presence of standard inhibitors and LY2183240 regioisomers. 
Cephalosporinase from Enterobacter cloacae 
  No inhibitor Tazobactam Avibactam 1,5-LY2183240 2,5-LY2183240 
Km (µM) 25.39 ± 1.506 49.09 ± 35.34 42.75 ± 16 31.1 ± 12.25 28.8 ± 0.9653 
Vmax (µM S
-1
) 0.1855 ± 0.008 0.129 ± 0.018 0.135 ± 0.018 0.227 ± 0.06 0.175 ± 0.004 
Kcat (S
-1
)  742  ± 22.82 - - - - 
Ki (µM) - 0.372 ± 0.064 0.0041 ± 0.002 1.8 ± 0.245 2.45 ± 0.301 
Alpha (α) - 1.054 ± 1.264 2.2 ± 4.9 6.42 ± 22.77 2.21 ± 1.9 
R
2
 0.9997 0.9888 0.9839 0.9897 0.9998 










 p < 0.05 
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Another important aspect is that the determination of Ki may not be uniform from 
laboratory to laboratory, including the method used. As a point of fact, there is an 
intriguing debate about how to characterize enzyme inhibition activity in terms of 
inhibition constants, such as IC50 and Ki (Cha, 1975). The aforementioned, 50 % 
inhibitory concentration (IC50) measures the amount of inhibitor required to decrease 
enzyme activity to 50 % of its non-inhibited velocity and is often used in 
pharmacological studies to characterize inhibitors. While an IC50 can reflect an 
inhibitor's affinity, this parameter is not constantly consistent; for instance, an 
inhibitor can have a very poor affinity and acylate the enzyme slowly but still yield a 
low IC50 because of very low deacylation rates (Drawz et al., 2010). In addition, 
while Ki is a constant value for a given compound with an enzyme, an IC50 is a 
relative value, whose significance alters upon the concentration of substrate used in 
the assay. A particular compound will display several different IC50 values for the 
same enzyme if assays are performed employing different substrate concentrations 
(Burlingham & Widlanski, 2003). In this sense, the constant of inhibition Ki was 
selected as the main value in this study to estimate the potency of the compounds 
tested in all kinetic experiments to generate consistent and reliable data. 
In a similar mode, albeit evidently more potent, avibactam exhibited a highly 
efficient decrease in the cephalosporinase hydrolysis velocity (Fig. 4.27C). 
Moreover, as predicted, the Lineweaver-Burk plot (Figure 4.27D) together with α 
value and statistical analysis revealed that avibactam acted as a competitive inhibitor 
with a low constant of inhibition of 4.1 ± 2 nM (Table 17). 
The present findings regarding avibactam seem to be partially consistent with other 
research. In the last decade, an abundance of studies have been conducted with 
avibactam, formerly known as AVE1330A and NXL104 (Bonnefoy et al., 2004; 
Livermore et al., 2008; Stachyra et al., 2009; Mushtaq et al., 2010; Coleman, 2011; 
Ehmann et al., 2012; Ehmann et al., 2013; Lahiri et al., 2013; Lahiri et al., 2014; 
Endimiani et al., 2009). Several of these reports reveal the strong inhibitory activity 
of this non-β-lactam inhibitor towards relevant class A, C and D β-lactamases, 
especially when compared to other standard inhibitors such as clavulanic acid, 
tazobactam and sulbactam. Avibactam has lower IC50s, in a range of 3 to 170 nM, 
and reduced reactivation rates, including cephalosporinases from E. cloacae and P. 
aeruginosa (Bonnefoy et al., 2004; Livermore et al., 2008; Stachyra et al., 2010; 
Lahiri et al., 2014). Furthermore, a mechanistic study of the inactivation of the class 
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C cephalosporinase P99 by avibactam revealed a constant of inhibition of 7.7 µM 
(Stachyra et al., 2010). This value is considerably higher compared with the value 
determined in this study (0.0041 µM). This discrepancy could be attributed to the 
methods used in both studies. Although similar, the Ki value was achieved by 
competition with nitrocefin during a very short incubation of 5 seconds. This brief 
incubation may have affected the potential activity of avibactam.  
Avibactam and tazobactam were used in this study for the sole purpose of 
comparison and validation of the method, and the attainment of meticulous kinetic 
data for these standard compounds is out of the scope of this project. However the 
mode of action of avibactam will be discussed more in the following sections. 
 
 
Figure 4.28. Competitive inhibition by LY2183240 regioisomers of the class C β-lactamase from 
Enterobacter cloacae. (A) 1,5-LY2183240 direct non-linear plot using the Michaelis-Menten 
equation. (B) 1,5-LY2183240 double reciprocal, Lineweaver-Burk plot. (C) 2,5-LY2183240 direct 
non-linear plot using the Michaelis-Menten equation. (D) 2,5-LY2183240 double reciprocal, 
Lineweaver-Burk plot. Final concentrations of both LY2183240 regioisomers were 0 µM (), 0.5 µM 
(), 0.8 µM (). 
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The kinetics analyses of both LY2183240 regioisomers using the Michaelis-Menten 
equation followed by the Lineweaver-Burk equation suggested that both isomers act 
as competitive inhibitors (Figure 4.28). Interestingly, both LY2183240 isomers gave 
rise to a significant reduction in the class C β-lactamase hydrolysis velocity. Also, an 
increase in Km in the presence of the inhibitors, tazobactam (49.09 ± 35.34), 
avibactam (42.75 ± 16), 1,5-LY2183240 (31.1 ± 12.25) and 2,5-LY2183240 (28.8 ± 
0.9653) was observed (Table 17) comparable to that observed for TEM-1 and 
cephalosporinase with the standard inhibitors. Nevertheless, contrary to expectations, 
a variation in some of the Vmax values was detected. Both reference standards, 
tazobactam and avibactam, showed a significant decrease from 0.241 ± 0.0081 to 
0.129 ± 0.0177 and 0.135 ± 0.018 in the Vmax values, respectively. However, the 1,5-
isomer had an increased Vmax, whereas 2,5-LY exhibited a similar value when 
compared to control (no inhibitor). As mentioned above, in a competitive inhibition, 
the Vmax value is unaffected. Despite the fact that the Vmax values were not consistent, 
additional analysis of the inhibition model confirmed by the alpha parameter and the 
comparison of the fits (p < 0.05) suggested that the preferred model is competitive 
inhibition (Table 17). 
Surprisingly, LY2183240 isomers demonstrated highly potent inhibitory activities 
against AmpC β-lactamase from Enterobacter cloacae with Ki values of 1.8 and 2.45 
µM for 1,5- and 2,5-isomers, respectively. These values reveal these compounds to 
be less potent than tazobactam and avibactam assessed in this study, 
notwithstanding, LY2183240 was not developed to bind these types of enzymes, 
especially from a bacterial source. Furthermore, the primary modification of the 
LY2183240 regioisomers is the position of the carbonyl (1’5 to 2’5) on the tetrazole 
heterocyclic group (See Figure 1.17). Again, these data indicate that the change of 
position of this group increases the constant of inhibition Ki, suggesting an important 
role in the inhibitory effect towards the class C β-lactamase. As described previously, 
the 2,5-LY2183240 isomer displays a lower pharmacological potency as well as 
activity towards eukaryote serine hydrolases when compared to the 1,5-isomer 
(Moore et al., 2005; Alexander & Cravatt, 2006; Ortar et al., 2007; Ortar et al., 2008; 
Maione et al., 2009; Asada et al., 2015). Importantly, the mechanism of action of 
LY2183240 towards FAAH proposed by Alexander et al. (2006) involves the 
carbamylation of the enzyme’s serine nucleophile (Ser241), corroborating the 
significance of this group in inhibition of serine hydrolases. 
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Another parameter calculated in this kinetic study for both enzymes was Kcat. As 
mentioned above, this parameter is a constant that describes the turnover rate of an 
enzyme-substrate complex to product and enzyme. It is also the rate of catalysis with 
a particular substrate. 
The class A β-lactamase TEM-1 exhibited a low Kcat value of 2.83  ± 1.049 s
-1
. This 
finding is significantly different from previous results reported in the literature. The 
Kcat measurement for TEM-1 using nitrocefin as substrate reported by Legendre et al. 
(2002) was surprisingly 100 fold higher (300 s
-1
), although determined under 
different experimental conditions and by different methods. One important factor 
that is not disclosed in Legendre’s study is the enzyme concentration used, which 
would directly affect the constant Kcat. Another study conducted by Raquet and co-
workers (1994) revealed an even higher Kcat value (930 s
-1
) when compared to this 
current study. Possible explanations for the discrepancies in the catalytic properties 
of TEM-1 among these works mentioned are the different methodologies selected, as 
well as the enzyme source and concentrations. It is noteworthy that several studies do 
not indicate the amount of enzyme used in the assay, making it difficult to reproduce 
the method applied. Again, the concentration of enzyme reflects directly in the Kcat 
value (Equation 5), hence making it challenging to compare data of the same enzyme 
and inhibitors with previous studies. 
On the other hand, AmpC β-lactamase from Enterobacter cloacae showed a high 
rate reaction of 742  ± 22.82 s
-1
 corroborating former studies performed on class C β-
lactamases (Galleni et al., 1988; Siemers et al., 1996; Zindel et al., 2016). In a survey 
of the kinetic parameters of class C β-lactamases, two enzymes from Enterobacter 
cloacae (P99 and 908R) presented a Kcat of around 780 s
-1
 (Galleni et al., 1988). 
Moreover, in the same study, the enzymes showed a Michaelis constant (Km) of 
around 25 µM, which support favorably the Km value found in this current study. As 
expected, these data suggest a strong correlation between the constants Km and Kcat. 
Variations in Kcat, can be achieved by modifications in the enzyme, including 
modification of specific amino acid residues, or comparison of enzymes in different 
solution conditions like pH, ionic strength, and temperature, amongst others 
(Copeland, 2000; Segel, 1975). In addition, several enzyme kinetic studies 
commonly use the catalytic efficiency of an enzyme (Kcat/Km) to compare the 
utilization of different substrates for a particular enzyme. This ratio has units of a 
second-order rate constant and is generally used to compare the efficiencies of 
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different enzymes to one another (Copeland, 2000; Segel, 1975; Cornish-Bowden, 
2012). Intriguingly, there is a curious debate among enzyme kinetic researchers 
about the application and usefulness of the ratio Kcat/Km. Eisenthal and co-workers 
(2007) showed that a particular enzyme even having a higher Kcat/Km value (catalytic 
efficiency) is capable of catalyzing an equal reaction at lower rates than one 
possessing a lower catalytic efficiency, at specific substrate concentrations. This 
suggests that the ratio of the two reaction rates is not a constant, but depends on the 
value of [S]/Km. Consequently, using catalytic efficiency value as an index for 
comparing the catalytic effectiveness of enzymes is not only incorrect, but can also 
be misleading (Eisenthal et al., 2007). However, the main purpose of this study is not 
the comparison of enzymatic efficiencies, but to verify the potency and modality of 
action of LY2183240 regioisomers towards β-lactamases. In this sense, it was 
decided not to use this parameter in this study because it was considered beyond the 
scope of this project. 
To summarize, the kinetic study provided relevant and robust data in regards of the 
mode of action and potency of LY2183240 regioisomers towards class C β-
lactamases. Although some divergences with other studies were noted, it was 
possible to confirm that both isomers act as competitive inhibitors and other 
important kinetic parameters were determined in a validated procedure. With the 
purpose of further studying this intriguing activity, an in silico study applying 
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 Conclusions 4.4
 
In this chapter, the 2,5-LY2183240 regioisomer has been shown to possess potent 
antimicrobial activity. This activity is selective towards certain Gram-positive 
bacteria, which includes Staphylococcus aureus (MSSA and MRSA) and Bacillus 
subtilis, but not E. faecalis or S. pnuemoniae. Conversely, the 1,5-LY2183240 
isomer had no anti-bacterial activity strongly implicating the position of the 
carbamoyl on the tetrazole in the structure-activity relationship of the molecule. 
Studies with the membrane permeabilizing agent polyethyleneimine revealed that 
2,5-LY2183240 had potential activity against E. coli, indicating that the selective 
activity of this compound may be related with the presence of the outer membrane in 
Gram-negative bacteria. 
Further studies on the mechanism of antimicrobial activity suggest that while 2,5-
LY2183240 had bacteriostatic activity this was probably not due to inhibition of 
protein synthesis, a target commonly associated with a cessation of growth rather 
than cell death.  Despite specificity towards staphylococci, inhibition of teichoic acid 
synthesis (both cell wall and lipo-teichoic acids) was also unlikely to be responsible 
for the observed antimicrobial activity. Nevertheless, this activity may be related to 
the inhibition of bacterial fatty acid synthesis. Supporting this hypothesis, addition of 
exogenous fatty acids within Tween 80 was able to compromise 2-5-LY2183240 
anti-staphylococcal activity. Due to redundancy, selective antimicrobial activity 
towards particular organisms is a feature of agents such as triclosan that target single 
enzymes involved in fatty acid synthesis. Based on the spectrum of activity and 
known redundancies at each of the steps in the fatty acid synthesis pathway, the most 
likely target was deduced to be FabI. However, characterization of a 2,5-
LY2183240-resistant mutant revealed no alteration to the amino acid sequence of 
FabI or relevant changes to FabI protein expression, an observation confirmed by 
analysis of the fabI promoter region and western blot studies. Since resistance to 2,5-
LY2183240 could be mediated through non-target related factors such as drug efflux 
or drug entry into the cell, FabI could not be ruled out as a potential target. In 
addition, whole cell protein profiling revealed the 2,5-LY2183240 mutant to have 
differences in the expressions of several proteins, suggesting resistance may occur 
through a more global effect. Due to the promiscuous nature of LY2183240, the 
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possibility of having multiple targets in S. aureus that collectively exhibit a 




















































5 CHAPTER 5 
In Silico and Crystallographic Studies of LY218340 
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 Introduction 5.1
 
The completion of the human genome project has resulted in an increasing number 
of new therapeutic targets for drug discovery. Furthermore, sequencing of bacterial 
genome sequences is now a standard procedure, and the information from tens of 
thousands of bacterial genomes has had a major impact on the view of the bacterial 
world, including potential novel antimicrobial targets (Land et al., 2015). At the 
same time, high-throughput protein purification, X-ray crystallography and mass 
spectroscopy techniques have been developed and contributed to many structural 
details of proteins and protein–ligand complexes (Walters et al., 1998; Langer & 
Hoffmann, 2001; Bajorath, 2002; Kitchen et al., 2004; Jorgensen, 2004). These 
advances allow the computational strategies to permeate all aspects of drug 
discovery today, such as the virtual screening techniques for hit identification and 
methods for lead optimization (Gohlke & Klebe, 2002; Meng et al., 2011). 
Compared with traditional experimental high-throughput screening in silico studies 
may be a more direct and rational drug discovery approach and has the advantage of 
low cost and effective screening (Moitessier et al., 2009). Moreover, molecular 
docking approach can be used to model the interaction between a small molecule and 
a protein at the atomic level, which allows characterisation of the behavior of small 
molecules in the binding site of target proteins as well as the elucidation of 
fundamental biochemical processes (McConkey et al., 2002). 
This chapter will further investigate the mechanism of action of the inhibitory 
activity of LY2183240 regioisomers towards AmpC β-lactamases using molecular 









  187 
 Objectives 5.2
 
The main objective of this chapter is to evaluate the interactions of the two 
LY2183240 regioisomers with the AmpC β-lactamase of E. cloacae using molecular 
modeling and crystallography.  
 
The specific aims of the study are as follows: 
 
- To evaluate the potential mechanism of action of the β-lactamase inhibitory 
activity of LY2183240 regioisomers via an in silico study. 
- To assess the interactions of LY2183240 regioisomers with the AmpC β-
lactamase are of a covalent or non-covalent type using mass spectrometry. 
- To determine the potential binding interactions of LY2183240 regioisomers 
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 Results and Discussion 5.3
5.3.1 In silico Study 
 
Molecular docking is now considered a conventional approach in virtual screening or 
lead optimization for drug screening and design. This technique permits the study of 
the main interactions between different molecules using several software packages 
accessible for this kind of study (Grinter & Zou, 2014). The comprehension of the 
molecular system plays an important role in determining what software to apply in 
the study. On the whole, software packages can be categorized based on the 
molecular system that they are normally employed to analyses and may implement 
either rigid or flexible docking. In the case of iGEMDOCK, flexible docking is 
engaged, which means that the conformation of part or entire molecules change 
during the best-fit investigation (Hsu et al., 2011). Typically, molecular docking 
concerns two connected steps: sampling of possible conformational states of the 
protein-ligand complex as well as calculation of the free energy of such complexes, 
or producing a score that correlates with biological activity or other function, also 
known as scoring (Novikov & Chilov, 2009). In sampling, there is a generation of a 
variety of different conformations and poses of a ligand, including orientations 
regarding to the binding surface of the protein target. At the same time, the scoring 
function delineates the potential energy surface and ranks the predicted poses 
according to a mathematical algorithm. It is worth mentioning that the scoring 
function is where most software packages differ and where the most research has 
progressed (Jain, 2006; Huang et al., 2010; Yuriev et al., 2015; Barata et al., 2016). 
Frequently, docking software packages are assessed according to the accuracy of the 
free energy calculations and the pose predictions between protein and ligand. In 
general, the scoring functions can be grouped into three basic types according to how 
they are derived: force field-based, empirical, and knowledge-based (Wang et al., 
2003; Huang et al., 2010). To begin with, force field-based scoring methods attempt 
to essentially calculate the atomic interaction energies in the system, for instance, 
van der Waals, bond terms (length, angles and torsions), and electrostatics derived 
from force-field parameters. Secondly, empirical scoring functions access parameter 
coefficients by fitting to many crystal complexes with identified binding affinities 
(Huang et al., 2010; Barata et al., 2016). These functions process the free energy 
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between protein and ligand into a sum of the weighted free binding energies for each 
component such as electrostatics and hydrogen bond, that contribute to the 
interaction (Wang et al., 2002). Lastly, knowledge-based functions are derived from 
a statistical analysis of the interaction distances among different pairs of atom types 
in co-crystallized protein-ligand structures. Subsequently, statistical analyses are 
employed to originate pairwise potentials acquired directly from experimental data. 
This approach derives the energy potentials for the atomic interactions of all residue 
pairs as a function of the distance between the involved atoms and consequently 
estimates the energies of all conformations (Sippl, 1990). 
To further investigate the binding of LY2183240 regioisomers to the AmpC β-
lactamase from Enterobacter cloacae, molecular docking of LY2183240 isomers 
was performed using the cephalosporinase P99 (PDB ID: 1xx2) which is a standard 
representative of the class C β-lactamase from E. cloacae.  
Figure 5.1 illustrates the structure of a class C cephalosporinase from E. cloacae P99 
utilized in this study. The crystal structure was selected through an investigation of 
the Protein Data Bank website. According to the deposition authors the crystal 
structure was obtained via vapor diffusion method using PEG 8,000, sodium 
cacodylate (C2H7AsO2), MgCl2, NaN3, pH 6.5 - 8.5 (Charlier et al., 1983; Lobkovsky 
et al., 1993; Lobkovsky et al., 1994). Moreover, the method employed was X-ray 
diffraction with a resolution of 1.88 Å. 
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Figure 5.1. 3D Schematic representations of β-lactamase P99 structure (PBD 1xx2). (A) Ribbon 
diagram (in light blue for barrels and red for helices). This kind of visualization evidently shows the 
secondary and tertiary structure of the protein but completely hides atoms and in particular the side 
chain ones. (B) Molecular surface of the cephalosporinase showing the catalytic site in red. 
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The positioning of functional binding pockets on protein molecules is the basis of 
structural genomics and targeted drug discovery (Goldsmith-Fischman & Honig, 
2003; Mirkovic et al., 2006; Weigelt et al., 2008; Van Voorhis et al., 2009; Hetényi 
& Van Der Spoel, 2011). Protein-ligand docking is not frequently applied to the 
whole protein surface to predict the binding site of a particular ligand. Therefore, 
most of the software demands some information about the binding site for accurate 
results. Albeit some packages permit for extension of the protein’s area, typically by 
enlarging a grid or box, but this may result in loss of definition. For instance, with a 
larger area, reduced points inside the grid will be contemplated, consequently 
compromising the results (Barata et al., 2016). As an alternative, independent 
approaches or biological information about the protein target can be used to 
determine the principal binding site, and the following docking is confined to this 
specific site of interest. There are some linked methods in which the binding site 
search and docking procedure are performed concomitantly, also known as blind 
docking (Het Enyi & Van Der Spoel 2011; Grinter & Zou 2014). During this 
procedure the entire surface of the protein target is scanned for hypothetical binding 
pockets of the ligand, and an atomic resolution complex structure is developed 
(Hetényi & Van Der Spoel, 2011). Nevertheless, this method presents some 
limitations, for example, the requirement of using explicit water molecules to explore 
the binding site, as previously reported by Minke et al. (1999). Another disadvantage 
of blind docking is that the target molecule is not flexible, and the accuracy of the 
force field parameters is limited. In other words, the possibility of precisely docking 
a ligand to a protein target depends crucially on the quality of the target structure 
(Hetényi & van der Spoel, 2002).  
In this sense, it is fundamental in this study to employ a software package without 
requiring information on the binding site, given that the mechanism of action of the 
LY2183240 regioisomers is still uncertain. Although the kinetic interactions studies 
with AmpC β-lactamase from Enterobacter cloacae and all the ligands indicate a 
competitive inhibition model, e.g., competing with the substrate for the same binding 
site, for this part of the work the iGEMDOCK software package was employed since 
the whole protein surface would be considered, hence the molecular docking would 
be entirely objective. Furthermore, molecular docking could have biased results if 
the ligand is restricted to interactions only within the active site. 
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Figure 5.2 illustrates all the poses predicted by the molecular docking for the five 
ligands used in this study. It was noticed that each ligand exhibited a range of 
different conformations and orientations in respect to the binding surface of β-
lactamase P99. Overall, despite the fact that this method is targeting the entire 
protein surface, it was observed that most of the predicted conformations for all the 
ligands concentrated in the active site of P99. 
As anticipated, nitrocefin, in yellow (Figure 5.2A), showed its poses restricted to the 
catalytic site. Similarly, avibactam, in orange (Figure 5.2B), exhibited all the 
conformations in the catalytic pocket. With regards to tazobactam (dark pink; Figure 
5.2C), and both regioisomers (1,5-, cyan; 2,5-, green) (Figures 5.2D & E), it was 
noticed that iGEMDOCK identified hotspots mainly in the active site, but also on 
other parts of the protein surface. Although LY2183240 regioisomers exhibited 
poses outside of the catalytic site, the lowest energy conformations were interacting 
inside of the active site, as further discussed below. 
Following onto the second stage of the docking procedure, these poses were scored 
and ranked according to a mathematical algorithm used to predict the binding 
affinities, in which the best candidates are those with the lowest energies or having 
individually high binding affinities. Due to some limitations in the ranking process of 
the package used, a re-scoring procedure was performed using VEGA ZZ software in 
order to circumvent the issue. 
Table 18 depicts the energy rank of the all ligands used in the study. Additionally, 
the force-field scoring function of iGEMDOCK separated ligand binding energy into 
individual interaction terms such as van der Waals, hydrogen bond and electrostatic 
energy. The lowest energy solution, i.e., the maximum interaction, was found to be 
with the substrate nitrocefin. In addition, all the best poses with lowest energies of 
the five ligands were found to be in the active site of the protein, with similar 
residues interactions (Figures 5.3 to 5.7). 
Among the inhibitors tested, the maximum interaction was observed for avibactam 
with a score of –114.34. By contrast, tazobactam showed the least interaction and, 
remarkably, both isomers of LY2183240 presented good interactions (Table 18). 
The regioisomer 1,5-LY2183240 revealed a small lower energy solution of -109.09 
kcal/mol when compared to the 2,5-isomer, -104,88 kcal/mol. Moreover, this 
difference can be related with the van der Walls interactions, since 1,5- and 2,5-
isomers exhibited -95.08 and -81.83 kcal/mol, respectively. The present findings 
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seem to be consistent with the previous kinetic study data (Section 4.3.4.7) and 
inactivation curve (Section 4.3.4.6), showing that the potency of the 1,5-isomer is 
slightly higher towards AmpC β-lactamases.  
 
Table 18. Docking scores for AmpC β-lactamase P99 (PDB 1xx2) rescored using 
VEGA ZZ. 
The units for all energy interactions are in kcal/mol. 
 
Both LY2183240 regioisomers are larger compounds than tazobactam and 
consequently flexible molecules that bind more effectively within the enzyme active 
site resulting in higher binding energy. It is worth mentioning that the package 
iGEMDOCK provides algorithms for a flexible docking approach; which would 
show a larger decrease in total energy compared to the molecules in this study as 
these are smaller in structure and possess less flexibility. However, this seems not to 
be the case with the standard reference avibactam. The binding energies of the 
regioisomers are lower than tazobactam, but the kinetic analysis reveals that the 
compounds exhibited comparable inhibition (1,5-isomer Ki = 1.8 µM; 2,5-isomer Ki 
= 2.45 µM) to this reference inhibitor (Ki = 0.372 µM). 
Fig 5.3 shows the interaction of the substrate nitrocefin and the P99 enzyme. As 
estimated, the predicted binding mode suggests that nitrocefin was more stable in the 
active site of this particular enzyme. The best pose calculated shows interaction 
between the oxygen of the β-lactam ring of nitrocefin with Ser64 (2.53 Å and 2.96 Å) 
via a carbon hydrogen bond. Furthermore, the other oxygen atoms of the carboxy 
group of nitrocefin strongly interact with the residues Tyr
150
 (2.31 Å), Thr
316
 (1.60 
Compound Energy van der Waals HBond 
Electrostatistic 
energy 
Nitrocefin -123.75 -84.33 -39.95 0.54 
Avibactam -114.34 -82.26 -32.08 0 
1,5-LY2183240 -109.09 -95.08 -14.01 0 
2,5-LY2183240 -104.88 -81.83 -23.05 0 
Tazobactam -93.17 -56.07 -35.97 -1.13 
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Å), Lys
315
 (2.11 Å) and His
314
 (1.71 Å) by conventional hydrogen bonds. Finally, it 
was also noticed that a π-cation interaction between the 2-thienylacetyl-amino ring 
and the residue Arg
349
 (3.92 Å), and an alkil/π-alkil interactions with residues Leu293 
(4.56 Å) and Ala
292
 (4.22 Å) were predicted. 
All the ligand-protein interactions distances of the ligands tested are summarized in 
Table 19. 
 
Figure 5.2. All binding modes predicted by molecular docking using iGEMDOCK package software 
targeting the whole β-lactamase P99 surface (20 solutions). (A) Nitrocefin (substrate), (B) Avibactam, 
(C) Tazobactam, (D) 1,5-LY2183240, (E) 2,5-LY2183240. 
  195 
Figure 5.4 depicts one of the predicted conformations of avibactam interacting with the 
cephalosporinase P99. The carboxamide group interacted with the residues Ser
64
 (2.56 
Å and 2.16 Å) and Gly
317
 (2.61 Å and 2.79 Å) by van der Waals forces, Ser
318
 (2.81 Å 
and 2.38 Å) by conventional hydrogen bond and Leu
119
 (5.43 Å) by alkil/π-alkil 
interactions (Fig. 5.4A). 
The sulfate moiety was positioned by a salt bridge and a π-anion interaction with the 
residue Thr
316
 (2.83 Å and 2.30 Å), together with Tyr
150
 (2.55 Å), Lys
315
 (2.86 Å and 
2.69 Å) and Asn
346
 (2.46 Å) by a conventional hydrogen bond. In addition, Lys
315
 
(2.49 Å) also presented a strong π-anion interaction with the oxygen of the sulfate 
group. It is worth mentioning that the lowest energy conformation of avibactam 
predicted by iGEMDOCK was not the best-docked pose, indicating some limitations 
of the software used. Nevertheless, after re-scoring process using Vega ZZ software, 
the lowest-energy conformation became the most favorable pose. 
Figure 5.5 illustrates the main interactions of tazobactam and the β-lactamase P99. It 
was observed the triazole group strongly interacts with the residues Ser
64
 (2.67 Å) by 
π-lone pair interaction and Lys67 (4.32 Å) by a π-cation bond. The oxygen of the β-
lactam ring interacted with Lys
315
 (2.63 Å) by hydrogen bond, and the residues Asn
346
 
(3.26 Å) and Thr
316
 (2.32 Å) interacted with the oxygen of the carboxylic acid by 
hydrogen bond and van der Waals forces, respectively. Moreover, the molecular 
docking calculations suggested a conventional hydrogen bond between Tyr
150
 (3.35 Å) 
and the oxygen of the 4-thia-1-azabicyclo group of tazobactam. Also, a carbon 
interaction with Ser
318
 (3.25 Å) was noted.  
The best pose predicted for the 1,5-isomer of LY2183240 by iGEMDOCK software 
and main interactions with the cephalosporinase P99 is represented in Figure 5.6. The 





 (3.10 Å and 3.74 Å) and Ala
292
 (4.81 Å), showing a π-stacking (T-shaped), 
π-cation and π-sigma interactions, respectively. Also, the carbamoyl group interacted 
with the residue Thr
316
 (3.74 Å) by van der Waals forces. Moreover, interactions 
between the benzenes present in 1,5-LY2183240 and the residues Gly
286
 (2.78 Å), 
Met
265
 (4.38 Å), and Leu
274
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Table 19. Heteroatom-heteroatom distances A – Z (Å) between the amino acids of β-
lactamase P99 and all the ligands for the best conformations calculated. 
Residue Nitrocefin Avibactam Tazobactam 1,5- 2,5- 
Ala
292
 3.95 3.41 – 4.06 5.25 
Ala
292
 4.21 3.11 – 4.81 – 
Ala
292
 [O] – – – – 3.43 
Ala
292










H] – 2.70 – – – 
Arg
349















































H]  – – – 2.77 – 
His
314





H]  1.71 – – – – 
Leu
274
 – – – 4.56 5.47 
Leu
293
 4.56 – – – – 
Leu
293
 – 4.28 – – – 
Lys
315

























N] – – 4.32 – – 
Met
265
 – – – 4.37 – 
Met
265
 – – – – 5.27 
Met
265
 – – – – 3.85 
Ser
318
 [H] – 2.64 – – – 
Ser
318

























O] – – 2.66 – – 
 Thr
316
 [O] – – – 3.73 – 
Thr
316
 [H] 1.60 – – – – 
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Table 19. (Continuation) Heteroatom-heteroatom distances A – Z (Å) between the 
amino acids of β-lactamase P99 and all the ligands for the best conformations 
calculated. 
 
In Figure 5.7, the enzyme-substrate interactions between E. cloacae P99 protein and 
the 2,5-isomer of LY2183240 are indicated, as computed by molecular modelling. It 
was noticed that the 2,5-regioisomer revealed similar interactions when compared to 
1,5-isomer. Essentially, the carbamoyl group interacted with Ala
292
 (3.43 Å and 3.68 
Å) by carbon hydrogen bond, Lys
315
 (2.08 Å) by conventional hydrogen bond and 
Tyr
150
 (3.45 Å) by π-sigma interaction. In addition, the residues Glu272, His314, Thr316 
and Lys
315
 interacted with the tetrazole group of 2,5-LY2183240 by π-anion, π-
sigma, carbon hydrogen, and conventional hydrogen bonds, respectively. Still, both 


















 [H]  – – – – 2.97 
Thr
316















O] – – – – 2.92 
Tyr
150





H] 2.31 2.56 2.48 – – 
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Figure 5.3. Nitrocefin interactions with β-lactamase P99. (A) Docking in the active site, nitrocefin 
appears in yellow; (B) 2D interactions. 
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Figure 5.4. Avibactam interactions with β-lactamase P99. Different perspectives (A) and (B) of 
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Figure 5.5. Tazobactam interactions with β-lactamase P99. (A) Docking in the active site, in magenta; 
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Figure 5.6. 1,5-LY2183240 interactions with β-lactamase P99. (A) Docking in the active site, in 
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Figure 5.7. 2,5-LY2183240 interactions with β-lactamase P99. (A) Docking in the active site, in 
green; (B) 2D interactions. 
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For AmpC β-lactamases, several significant catalytic residues have been addressed. 













 dramatically decrease enzyme activity up to 
10
5
-fold compared to the wild type (Tsukamoto et al., 1990; D Monnaie et al., 1994; 
Didier Monnaie et al., 1994; Dubus et al., 1994; Dubus et al., 1996; Lamotte-
Brasseur et al., 2000; Beadle & Shoichet, 2002; Powers & Shoichet, 2002; Chen et 
al., 2006; Chen et al., 2009; Endimiani et al., 2010). 
The current in silico study could demonstrate significant interactions with some of 
these major catalytic amino acids of AmpC β-lactamase P99.  
Consistent with the literature, the substrate nitrocefin interacted with some of the 
major catalytic residues, including Ser
64
 (Figure 5.3). Moreover this substrate 
showed the lowest-energy pose among all the ligands tested. These findings 
substantiate former studies that described the characterisation of several key residues 
of cephalosporinases, like for example, the attack of residue Ser
64
 to the β-lactam 
ring (Oefner et al., 1990; Galleni et al., 1995; Knox et al., 1996; Curley & Pratt, 
1997; Beadle & Shoichet, 2002; Chen et al., 2006). According with these studies, 
this reaction gradually advances initially by a pre-covalent first-encounter complex, 
secondly, two high-energy intermediates followed by a moderately low-energy 
covalent intermediate, and finally a product complex. 







. These residues present in the pocket sites of cephalosporinases play crucial 
roles as previously reported by many researchers (Oefner et al., 1990; D Monnaie et 
al., 1994; Dubus et al., 1994; Dubus et al., 1996; Tripathi & Nair, 2016; Beadle & 
Shoichet, 2002; Chen et al., 2006). Essentially, the residue Tyr
150
 seems to be the 
catalytic base for the deacylation process, receiving a proton from the deacylating 
water whilst it attacks the acyl-enzyme intermediate. More recent calculations have 







 decreased activities considerably for both the acylation and 
deacylation steps, suggesting this residue is somehow involved in advancing the 
nucleophilic substitutions throughout this reaction pathway. In addition, the residue 
Thr
316




appears to perform an essential function in the 
substrate recognition, through their interactions with one of the oxygens of the β-
lactam carboxyl group (Fenollar-Ferrer et al., 2003). 
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 was observed. As a cephalosporin, nitrocefin possess a β-lactam ring required 
for the penicillin binding protein (PBP) reactivity, a 2-carboxyl group, an X-
substituent and 3 and 7-substituents (See Figure 2.3). In a study conducted with 
cephalothin, a first-generation cephalosporin, and a class C β-lactamase, a general 
mechanism for the formation of an acyl−enzyme complex was proposed (Tripathi & 
Nair, 2013). The authors revealed the individual functions of the active site residues 
and the substrate, suggesting the important role of the Lys
67
 in the acylation step, 
while Tyr
150
 assists the protonation of the β-lactam nitrogen via either the substrate 
carboxylate group or a water molecule.  
Other reports have shown that mutation of the conserved Asn
152
 can have a 
substantial effect on substrate selectivity of the enzyme AmpC (Lefurgy et al., 2007; 
Ruble et al., 2012; Skalweit et al., 2013). 
As previously described throughout this thesis, recently, many works proposed the 
mechanism of action of avibactam at a molecular level, using different approaches, 
including crystallographic studies (Lahiri et al., 2014; King et al., 2015; Choi et al., 
2016).  
Particular to class C β-lactamases, these authors indicated that avibactam binds 
covalently with Ser
64
 in the active site of the enzyme. This molecule possesses a 
curious mode of action, acting as a covalent inhibitor via ring opening, however in 
contrast to other currently used β-lactamase inhibitors, this effect is reversible. 
Lahiri and coworkers (2014) revealed that at least eight residues presented 
significant contributions to the binding interactions with avibactam. Particularly, the 















 were placed to 




In comparison, the molecular docking data of avibactam provided in this current 
study is partially in agreement with these former reports. For instance, the sulfate 
group exhibited similar interactions with the same residues (Figure 5.4, Table 18). 
Conversely, in this particular case, crystallization and molecular docking are 
challenging to compare especially due to the fact that avibactam changed its structure 
and conformation after binding covalently to the residue Ser
64
. Still, the best pose 
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predicted for avibactam by docking showed an approximate conformation in the 
active site reported by crystallization (Lahiri et al., 2014; King et al., 2015). 
Not surprisingly, tazobactam, having a β-lactam ring, showed interactions with the 
main catalytic residues of the cephalosporinase P99. However, the interactions are 
not totally in agreement with the literature. The residue Ser
64
 showed a strong 
interaction with the triazole group of tazobactam. As mentioned above, many reports 
demonstrated that Ser
64
 directly attacks the β-lactam ring of the ligand (Chen et al., 
2006). In this regard, the best-predicted pose of tazobactam seems to be inaccurate. 






 appear to be 
in accordance with previous reports (Fenollar-Ferrer et al., 2002; Fenollar-Ferrer et 
al., 2005; Chen et al., 2006) 
Whilst some research has been carried out on LY2183240, no in silico study has 
investigated the activity of LY2183240 regioisomers against β-lactamases. The little 
research done with these compounds and other serine hydrolases as well as 
structurally similar molecules towards cephalosporinases may assist interpretation of 
the results obtained. 
Contrary to expectations, the best poses of both LY2183240 regioisomers showed no 
significant interactions with Ser
64
 (Figures 5.6 and 5.7). None of the 20 solutions 
generated showed any interaction with this residue. These regioisomers are 
recognized for having promiscuous activities against several serine hydrolases and 
particularly to FAAH, exhibit a covalent bond with Ser
241
 (Alexander & Cravatt, 
2006; Ortar et al., 2007). Therefore, the interaction with the amino acid Ser
64
 in the 
β-lactamase would be expected.  
In comparison, the molecular docking performed with both LY2183240 regioisomers 
showed no significant differences between them, in the interactions toward β-
lactamase P99. Both regioisomers presented comparable interactions with similar 
residues present in the active site of the enzyme (Table 18). However, it was 
observed that only the 2,5-isomer showed an interaction with the residue His
314
. 
Notwithstanding, as previously demonstrated by Dubus and coworkers (1996) the 
His
314
 residue is insignificant and not required for catalysis.  







a substantial role in class C β-lactamases (Dubus et al., 1996; D Monnaie et al., 
1994). According to Dubus et al. (1996), residue Glu
272
 showed no essential function 
in the enzyme acylation process, however the amino acid was involved, to a minor 
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extent, in the deacylation. Notably, as cited before, the residue Tyr
150
 is suggested to 
be essential for catalysis, at least using different β-lactams as substrates. The authors 
proposed that the phenolate anion of Tyr
150
 together with the alkyl ammonium of 
Lys
315
, acts as the general base responsible for the activation of the active site Ser
64
 
during the acylation stage and, following activation of a water molecule, in the 
deacylation activity. Additionally, critical deficiency in hydrolytic capacity was 





 were replaced by cysteine, suggesting the considerable contribution of these 
two residues in the catalytic reaction (Tsang & Leung, 2007). 
In order to comprehend better the influence of the ligands in the catalytic site, Figure 
5.8 shows the best binding modes predicted of LY2183240 regioisomers together 
with the substrate nitrocefin. Clearly, both isomers shared interactions with the same 







. This could indicate that these interactions may have a significant role in the 
competitive inhibitory effect of the regioisomers towards Class C β-lactamases. 
Moreover, it was observed that upon overlaying the conformations, the carbamoyl 
group of 1,5-LY2183240 was occupying the same space as the carboxy group of 
nitrocefin, interacting especially with Thr
316
. This factor may be responsible for the 
higher inhibitory activity of 1,5-LY2183240 when compared to the 2,5-isomer 
(Figure 5.8B). Nevertheless, this hypothesis needs to be further confirmed with more 
studies.  
Inevitably, there were some inaccuracies possibly due to the molecular docking and 
scoring function selected. The software iGEMDOCK, as with any other software 
package, has disadvantages and limitations that reflect in the final outcome. There 
are recurrent complications throughout in silico studies such as an inaccuracy in the 
binding site of the target, the docking pose selection, binding affinity, lack of clarity 
over whether the compound is an inhibitor or agonist, as well as the docking results 
being inconsistent with bioassays (Chen, 2015). 
Genuinely, one of the main sources of error in the molecular docking applied in this 
study is the deletion of the water molecules prior to docking. As already mentioned, 
water molecules can promote many problems, for example, the process of finding 
poses and orientations or calculating binding affinity and due to these reasons it was 
decided to exclude them before the docking procedure. Nevertheless, as expected, 
water molecules can play important roles in the catalytic site of cephalosporinases. It 
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has been described that there are at least four water molecules in the active-binding 
site of AmpC enzymes (Yamaguchi et al., 2009). Powers and Shoichet (2002) 
suggested that one of the water molecules seems to be the deacylating water, which 
hydrogen bonds to the residue Thr
316
 along with a different water molecule. 
Furthermore, there is another water molecule that seems to have a hydrogen bond to 
the main-chain carbonyl of Ala
318





 (Yamaguchi et al., 2009).  
Another limitation found in this study was the energy score ranking. The software 
iGEMDOCK gave an inaccurate ranking of the ligands (data not shown). 
Nevertheless, after rescoring a more precise energy ranking was presented. The 
reasons for this particular inaccuracy are still unknown, but other studies have 
reported similar divergences. For instance, free energy rescoring was more accurate 
compared with the selected package AutoDock4, indicating that free energy 
rescoring could be a beneficial tactic to reduce false positive calculations in 
molecular docking experiments (Malmstrom & Watowich, 2011). Moreover, the 
level at which the empirical energy function describes the observed free energy of 
binding impacts the accuracy of the relative energy difference between bound 
potential ligands, and consequently the correct identification of molecules that bind 
to the protein target. 
An additional problem encountered in this molecular docking study was that the 
calculated avibactam best pose, i.e., showing the lowest energy (Table 18), did not 
corresponded with the best orientation previously found in the literature. However, 
among the 20 solutions predicted, one of them showed similar orientation with 
previous reports (Ehmann et al., 2013; Lahiri et al., 2014). Although avibactam is a 
covalent and reversible inhibitor as well described by several studies, in this current 
in silico study the software used only considered non-covalent bonding, neglecting 
potential covalent binding and therefore hindering the correlation with other reports. 
The final limitation of this docking study is that it is restricted to non-covalent 
molecular docking. Recently, covalent molecular docking has been used successively 
by many researchers (London et al., 2014; London et al., 2015; Bianco et al., 2016). 
Notwithstanding, the larger part of the development research on docking methods is 
focused on the efficient prediction of the binding modes of non-covalent inhibitors 
(Kumalo et al., 2015). The ligands that bind covalently to the receptor are complex 
and problematic; a key problem of covalent inhibitors is their off-target reactivity 
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because of the presence of electrophilic reactive groups. In addition, covalent 
docking possesses similar problems to noncovalent docking, including poor scoring 
functions, with entropy, speed and accuracy (Kumalo et al., 2015). In this respect, 
the decision of what type of docking program is the best for a specific target protein 
is challenging and intricate (Chen, 2015). 
The primary goal of this in silico study was to verify the potential mechanism of 
action of both LY2183240 regioisomers towards cephalosporinases as well as 
confirm the inhibitory activity model found in the kinetic assay. Therefore, a deep 
and extensive analysis of the molecular docking study is beyond of the scope of this 
thesis. 
In this context, apart from the limitations presented and some discordances with 
literature, these findings do support the earlier findings in this study. Molecular 
modelling studies corroborate the hypothesis that LY2183240 regioisomers bind 
within the active site of class C β-lactamases, interacting with some of the same 
residues used by the substrate nitrocefin and standard β-lactamase inhibitors. In 
addition, these results support the competitive inhibition model previously observed 
in the kinetic study. 
With this in mind, assessment of a potential covalent complex of LY2183240 
regioisomers and AmpC β-lactamase is essential to confirm the proposed binding 
mode. Hence, in the next section assessment of the potential production of a covalent 
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Figure 5.8. Best poses of molecular docking of (A) LY2183240 regioisomers 1,5 (cyan) and 2,5 
(green), (B) LY2183240 regioisomers 1,5 (cyan) and 2,5 (green) with nitrocefin (yellow), and (C) all 
ligands used in this study; LY2183240 regioisomers 1,5 (cyan) and 2,5 (green) with nitrocefin 
(yellow), avibactam (orange) and tazobactam (dark pink).
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5.3.2 LY2183240 Regioisomers Revealed a Non-Covalent Interaction with 
AmpC β-Lactamase 
 
The use of mass spectrometry in proteomics is divided into three main fields. It is the 
preferred method for characterization and quality control of recombinant proteins 
and other macromolecules, a relevant assignment in the area of biotechnology. Mass 
spectrometry is also frequently used for protein identification, including large-scale 
proteomic projects. Lastly, due to the fact that mass spectrometry measures the 
molecular weight of a protein, it is the technique of choice for the detection and 
characterization of posttranslational modifications and can identify any covalent 
modification that alters the mass of a protein (Mann et al., 2001; Yanes et al., 2004). 
In this respect, mass spectrometry is an appealing substitute to other procedures for 
the analysis of interactions occurring between enzymes and their ligands, both 
covalent and non-covalent binding (Benkestock et al., 2004). For example, mass 
spectrometry can be used as an alternative to traditional spectrophotometric methods 
for kinetic and mechanistic characterisation of enzymes, both by monitoring 
substrate consumption and product formation, but also by monitoring enzyme-
substrate interactions (Sundqvist et al., 2007). 
After the purification of AmpC β-lactamase from E. cloacae and the characterisation 
of the interactions with LY2183240 regioisomers, mass spectrometry experiments 
employing MALDI-TOF were performed in order to assess potential complex 
formation between the enzyme and regioisomers. Avibactam was used for 
comparison and validation purposes. 
The mass spectra of the peaks of the cephalosporinase are depicted in Figure 5.9. The 
molecular masses of the AmpC β-lactamase and enzyme plus avibactam measured 
by MALDI-TOF were 39,134 and 39,399 Da, respectively. This represents a mass 
increase of 265 Da, which corresponds with the molecular mass of avibactam, 
suggesting that this inhibitor was covalently attached in a complex.  
These findings are in good agreement with Stachyra and coworkers  (2010). The 
authors demonstrated a similar mass spectrum after the production of a covalent 
complex between avibactam and two different β-lactamases. On this occasion, they 
used the AmpC β-lactamase from E. cloacae P99, exhibiting molecular masses of 
39,237 and 39,502 Da for the enzyme P99 alone and together with avibactam, 
respectively. 
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On the other hand, a similar profile to avibactam was not observed for the 
regioisomers of LY2183240. Analyses revealed that the molecular mass of the 
enzyme showed no significant increase in the presence of the 1,5- or 2,5-isomer 
(Figure 5.10).  
However, slight variations in the molecular mass of the enzyme during the analyses 
were noted. In the 1,5-isomer spectrum, for instance, the molecular mass of the 
enzyme was 39,111 Da, 23 Da less than the cephalosporinase alone (Figure 5.10A). 
In the case of the 2,5-isomer, a molecular mass of 39,141 Da was observed, 8 Da 
more than the enzyme alone.  
These minor differences can be attributed to standard analytical variations of the 
technique employed. Typically, there is considerable variability in the baseline, noise 
level, and peak intensities in an assortment of MALDI spectra produced from the 
same sample. Furthermore, variations in ion current are noticed with consecutive 
laser shots fired at the same position on the target protein surface (shot-to-shot 
reproducibility), across different locations on the enzyme surface (region-to-region 
reproducibility) and between identical loadings of the same sample onto different 
targets (sample-to-sample reproducibility) (Duncan et al., 2008). 
Nevertheless, an additional peak in both mass spectra of approximately 200 Da was 
observed. This extra peak correlates with sinapinic acid, which is frequently used as 
matrix for MALDI-TOF analyses, especially for peptides and proteins greater than 
10 kDa in mass (Meetani & Voorhees, 2005).  
These findings indicate that none of the regioisomers gave rise to a covalent bond 
with the catalytic residues of the β-lactamase, under the same conditions of 
avibactam. The detection of non-covalent complexes is difficult and intricate when 
MALDI-TOF is applied, primarily due to the classic matrixes, e.g., sinapinic acid, 
and frequently used organic solvents such as acetonitrile that tend to disrupt weakly 
bound complexes under laser irradiation (Farmer & Caprioli, 1998; Chiang et al., 
2010). 
The results together with findings in above sections suggest that these compounds act 
as competitive non-covalent inhibitors. In addition, these data correlate favorably 
well with the in silico study and further support the type of interaction with the 
enzyme. 
Although the mass spectrometry analysis suggests that both regioisomers of 
LY2183240 have potential non-covalent interactions with the enzyme, as 
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demonstrated in the Section 4.3.4.6, it was not possible to determine the reversibility 
of the compounds tested, including the reference avibactam. The progressive 
inactivation of the cephalosporinase by both isomers revealed to be non-reversible 
after 18 hours of incubation. Generally, enzyme inhibitors can be classified as 
reversible or irreversible. Reversible inhibitors are those that bind to a protein in a 
way that the enzyme activity may be reconditioned. Usually, an equilibrium can be 
established between the enzyme and a reversible, non-covalent inhibitor (Bush, 
1988). On the other hand, irreversible inhibitors can be more efficient than reversible 
inhibitors due to the ultimate permanent inactivation of enzymatic activity. This type 
of inhibition is the effect of a sequence of reactions, including a reversible complex 
that can dissociate to free enzyme and inhibitor or can progress to form a covalent 
complex (inactivated enzyme) (Bush, 1988; Drawz et al., 2010). Nonetheless, 
according to recent reports, there is one exception to these rules. Avibactam presents 
an unusual mechanism of inhibition, whilst it seems to act as a reversible inhibitor, it 
also has a covalent interaction with residue Ser
64
 in the catalytic site of AmpC β-
lactamases (Ehmann et al., 2012; Lahiri et al., 2014).  
As the data revealed non-covalent interactions together with non-reversible 
inhibitory activity (Section 4.3.4.6), these findings may indicate that both 
regioisomers have high affinities towards the cephalosporinase and dissociate very 
slowly from the enzyme. 
This study has gone some way towards enhancing the understanding of the mode of 
action of LY2183240 regioisomers towards class C β-lactamases. Nevertheless, 
further experimental investigations are needed to determine the precise mechanism 
of inhibition mediated by these compounds.  
With this in mind, analysis of crystal structures of the enzyme-bound ligands are 
fundamental in order to confirm the proposed binding mode and provide an accurate 
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Figure 5.10. Mass spectra of β-lactamase from E. cloacae sp. inhibited by 1,5-LY2183240 (A) and 
inhibited by 2,5-LY2183240 (B). 
 
5.3.3 Crystallisation of AmpC with Avibactam and LY2183240 Regioisomers 
 
The use of the three-dimensional structure of biological macromolecules in order to 
understand how they function is one of the most important fields of modern biology. 
To this end, the availability of atomic resolution structures offers a deep and unique 
understanding of protein function, and helps to discover the inner workings of the 
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living cell (Dessau & Modis, 2011). Furthermore, X-ray crystallography permits 
details of covalent and non-covalent interactions to be analyzed quantitatively in 
three dimensions, consequently providing the basis for the comprehension of binding 
of ligands to proteins as well as modes of action such as cell-surface binding (Palmer 
& Niwa, 2003). 
Acquiring appropriate single crystals is the least comprehended step in the X-ray 
structural analysis of a protein. The science of protein crystallisation is still an 
underdeveloped area, although interest is growing, encouraged especially by 
microgravity experiments in space flights (Drenth, 1994). 
Protein crystallisation is mainly a trial-and-error procedure in which the protein is 
slowly precipitated from its solution. The presence of impurities, crystallization 
nuclei, and other unknown factors play a role in this process (Drenth, 1994; Kundrot, 
2004). 
Growth of high quality single crystals is the basis of X-ray structure determination 
and also a limiting step. Protein purity and homogeneity are essential for the growth 
of single protein crystals. Crystallisation of macromolecules is a multi-parametric 
process involving three main steps: nucleation, growth and cessation of growth.  
Nucleation, the initial process that occurs in the formation of a crystal from a 
solution, in which a small number of ions, atoms, or molecules become arranged in a 
pattern characteristic of a crystalline solid, forming a site upon which additional 
particles are deposited as the crystal grows (Uhlmann, 1980; Kashchiev, 2000). 
The cessation of crystal growth can occur for a number of reasons. The most usual 
one is the decrease in concentration of the crystallising solute to the point where the 
solid and solution phases reach exchange equilibrium. In this case, the addition of 
more solute can result in continued crystal growth. Nevertheless, some crystals reach 
a certain size beyond which growth does not proceed, regardless of solute 
concentration. This may be the result of either cumulative lattice strain effects or 
poisoning of the growth surface (Thaller et al., 1981; Sato et al., 1992). 
There are several techniques to crystallise proteins; all of them aim at bringing the 
solution of the protein to a super-saturation state, which will force the 
macromolecules into the solid state, the crystal. 
Among the crystallisation micro-methods, vapor diffusion techniques are the most 
widely used (Benvenuti & Mangani, 2007). A micro-drop of sitting or hanging 
protein solution is mixed with buffer, crystallising or precipitant agent, and 
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eventually also additives, and equilibrated against a reservoir containing a solution of 
precipitant agent at a higher concentration than the droplet (Bunko et al., 2007).  
The Figure 5.11 illustrates one of the many 24-well plates used for the vapor 
diffusion method screening, employing AmpC protein and inhibitor mixtures. 
 
Figure 5.11. Screening for protein crystallization using vapor diffusion method. 
 
There are many reports regarding the conditions of the crystallization of AmpC β-
lactamase from different strains of Enterobacteriaceae species (Lobkovsky et al., 
1993; Knox, 1995; Powers et al., 2002; Nukaga, Kumar, et al., 2003; Nukaga, Abe, 
et al., 2003; Yamaguchi et al., 2009; Lahiri et al., 2013; Lahiri et al., 2014). 
In this current study, several attempts were made to achieve the best conditions to 
grow the crystals of the protein, and most importantly, the complex enzyme and 
inhibitors.  
Table 20 depicts all the conditions undertaken using AmpC, LY2183240 
regioisomers and avibactam. 
The experiments varied in protein/inhibitor concentration ratio, precipitant agents, 





Table 20. Crystallisation screening conditions. 
Precipitant Agents Protein/Inhibitor Ratio pH Temperature (°C) 
10 - 50% PEG 8,000 1:1 and 3:2 4.5 - 8 4 - 18 
0.05 - 0.1M KH2PO4 1:1 and 3:2 4.5 - 8 4 - 18 
0.05 - 0.1M K2HPO4 1:1 and 3:2 4.5 - 8 4 - 18 
50 mM (CH3)2AsO2H 1:1 and 3:2  4.5 - 8  4 - 18  
 
The best conditions established for the co-crystallisation was employed; 20 % PEG 
8,000 and 0.1-M KH2PO4 as precipitant agents at pH 5.0 and 17°C, and with a 
protein/inhibitor ratio of 3:2, as previously reported by Crichlow et al. (1999). The 
crystals appeared after approximately 20 days of incubation (Figure 5.12).  
Surprisingly, the crystals only emerged in solutions containing inhibitors, in other 
words, the AmpC alone with the precipitant agents showed no growth, indicating that 
the presence of inhibitors influenced in the development of the crystals. 
Figure 5.12A shows the crystals of AmpC in complex with the reference standard 
avibactam. The crystals presented with the shape of thin clustered needles, showing a 
similar form of a star. Preliminary X-ray data collection revealed that the size of the 
crystals were comparable to a protein (data not shown). However, due to the size of 
the crystals grown, it was not possible to continue the analysis and determine the 
protein-inhibitor complex structure. In this context, a microseeding technique was 
applied, which is a recognized method of obtaining crystal and is used as an 
optimization step, where seed crystals are transferred into conditions that are similar 
to those previously known to promote crystallisation (Stura & Wilson, 1991; 
Bergfors, 2003; Shaw Stewart et al., 2011). Unfortunately, after several endeavors to 
microseed and create more nuclei in the solution, no suitable crystals have been 
grown so far. One of the possible explanations was the small amount of protein used 
when compared with former studies. Crichlow and coworkers (1999) for instance, 
utilized 13.4 mg of AmpC from E. cloacae P99. Due to the long and laborious 
process of AmpC purification, a limited quantity of enzyme was obtained and 
employed in this crystallography study, making it difficult to reproduce the same 
conditions. Nevertheless, the study is still ongoing. 
Figure 5.12B and 5.12C depict the crystals of AmpC together with 1,5-LY and 2,5-
LY, respectively. Similar to the avibactam, both sets of crystals exhibited a thin 
needle shape, although much longer. Preliminary X-ray analysis revealed that the 
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crystals grown were very small for a protein, strongly suggesting that they are 
crystals of only the ligand, and not in complex with the enzyme. Curiously, the 
crystals of the LY2183240 compounds had grown only in the presence of the AmpC 
enzyme, and not alone as shown in the Figures 3.40D and 3.40E. In these pictures it 
was possible to see potential precipitates, however no crystals were observed under 
the same conditions. 
These findings suggest that the presence of the AmpC helps somehow the growth of 
crystals of LY2183240 regioisomers, however more studies are necessary to 
comprehend better the circumstances of this phenomenon. 
The microseeding technique was again applied for both LY2183240 compounds, 
however using crystals of the enzyme-avibactam complex (Figure 5.12A).  
 
 
Figure 5.12 Crystals of AmpC protein from E. cloacae. (A) AmpC with avibactam, (B) AmpC with 
1,5-LY2183240, (C) AmpC with 2,5-LY2183240, (D) 1,5-LY2183240 alone, (E) 2,5-LY2183240 
alone. 
 
Basically, the crystals were transferred to a solution containing AmpC, precipitant 
agents and the regioisomers, separately. The main objective was to create multiple 
nuclei and increase the chance of growing crystals of the protein-inhibitor complex. 
However, similarly to avibactam, the samples showed no crystals after 25 days 
incubation at 17°C.  
Growing crystals is not an easy task. Not only do crystals need be grown, but they 
also must be of high quality, and suitable for high-resolution X-ray diffraction 
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analysis (McPherson, 1990). The reason that the crystallisation step turned into the 
primary obstacle to increase structural knowledge is the empirical nature of the 
methods employed to overcome it (McPherson, 1982). As mentioned before, 
macromolecules, such as proteins, are extremely complex physical-chemical systems 
whose properties vary as a function of many environmental influences, including 
temperature, pH, ionic strength, contaminants and solvent composition, among 
others. Proteins, in general, are structurally dynamic, heterogeneous and aggregating 
systems, and they can change conformation in the presence of ligands (Schulz & 
Schirmer, 1979; Creighton, 1993). Protein crystallisation is, hence, a matter of 
searching, as systematically as possible, the ranges of the individual parameters that 
impact upon crystal formation, finding a set or multiple sets of these factors that 
yield some kind of crystals, and then optimizing the variable sets to obtain the best 
possible crystals for X-ray analysis. This can be achieved conducting a long series, 
or establishing a vast range, of crystallisation trials, evaluating the results, and using 
information acquired to improve matters in successive rounds of trials. Since the 
number of variables is so large, and their ranges so extensive, intelligence and 
intuition in designing and evaluating the individual and collective trials becomes 
essential (McPherson, 1990). 
It was possible to establish the best conditions and success in generating preliminary 
AmpC crystals was achieved. However the limited availability of purified enzyme 
after multiple trials to find the best crystallization conditions at the time meant the 
optimum protein quantity could not be used to reproduce previous studies (Crichlow 
et al., 1999; Lobkovsky et al., 1993; Lahiri et al., 2014). The crystallisation study is 











The molecular modelling studies corroborate earlier observations suggesting that 
LY2183240 regioisomers bind within the catalytic site of class C β-lactamases, 







by the substrate nitrocefin and standard β-lactamase inhibitors. Also, these results 
substantiate the competitive inhibition model previously determined by enzyme kinetic 
studies on Chapter 4. Furthermore, mass spectrometry data revealed non-covalent 
interactions between AmpC β-lactamase and LY2183240 regioisomers, which together 
with the non-reversible inhibitory activity, may indicate that both regioisomers present 
a high affinity towards this cephalosporinase and dissociate very slowly from the 
enzyme. 
Although it was possible to grow crystals of AmpC enzyme, the size and quality of 
them meant they were not suitable for a high resolution X-ray diffraction analysis. 
Currently, the crystallography study is still in progress and results are being obtained. 
These findings have considerable biological implications once it is largely recognized 
that β-lactamase enzymes are the most widespread resistance mechanisms to β-lactam 
antibiotics. Clinically used inhibitors for these enzymes resemble substrates; both 
contain a β-lactam ring. For this reason, resistance develops rapidly because 
mechanisms that depend on recognition of the lactam ring already exist. A novel non-
β-lactam inhibitor may evade such mechanisms, and, most importantly, it would not be 
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The increase and spread of antimicrobial resistance presents a paramount challenge to 
both science and medicine. This global crisis reflects the worldwide misuse and 
overuse of these drugs and the lack of development of new antibiotic agents by the 
pharmaceutical industry to address the challenge (Brown & Wright, 2016). Amongst 
the many antibiotic resistance mechanisms towards β-lactams, the production of β-
lactamases by bacteria remains one of the most significant threats to the efficacy of 
this life-saving class of antimicrobial agents (Drawz et al., 2014). Multi-drug resistant 
organisms, such as methicillin-resistant S. aureus (MRSA), are also a serious global 
problem; alarming reports from different parts of the world indicate a threat to the 
healthcare system and individual patients (Andersson et al., 2011). More recently, 
evidence that MRSA is becoming resistant to glycopeptides, such as vancomycin, and 
newer therapies raises concern about the use of these therapies in clinical practice 
(Stryjewski & Corey, 2014). Consequently, there is a need to develop new 
antimicrobial agents and resistance-modifying agents such as β-lactamase inhibitors.  
No previous studies on the antimicrobial or resistance-modifying features of 
LY2183240 regioisomers have been reported in the literature, indeed this is the first 
report on the activity of the compound towards prokaryotic systems. This study 
provided an exciting opportunity to advance the knowledge of a potential and novel 
anti-staphylococcal agent with β-lactamase inhibitory properties.  
As such, LY2183240 could be useful as a novel scaffold in the design of future 
antimicrobial drugs as well as inhibitors with improved activities towards class C β-
lactamases (and possibly other enzymes).  
The crystallography study made in collaboration with Dr Gary Parkinson (UCL School 
of Pharmacy) is a work in progress, once the co-crystallization of the cephalosporinase 
and the LY2183240 regioisomers has been achieved insights into the binding of the 
compounds can be made assisting mechanistic elucidation.  
Moreover, future work would also focus on kinetics studies using purified FabI and 
2,5-LY2183240 in order to confirm if this enzyme is indeed the target responsible for 
the antimicrobial activity of the compound. Alternatively, a radioligand binding 
experiment could be performed to identify the target or targets for the anti-
staphylococcal effect. However, the regioisomers of LY2183240 may not have suitable 
groups to add a radioligand. Moore and coworkers (2005), for instance, created a 
radioligand and photoaffinity probe, adding iodo and azido groups to LY2183240. 
However, this alteration in the structure resulted in a modest shift of uptake inhibition 
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potency. In this sense, determination of the primary target responsible for the anti-
staphylococcal activity may be complex as illustrated by this study. 
Another important aspect for future investigation is the synthesis and production of 
analogues of LY2183240 in order to assess and improve the potency of the activities 
already observed. Ortar and coworkers (2007) synthesized a series of 1,5- and 2,5-
disubstituted carbamoyl tetrazoles, evaluating the activity towards anandamide, FAAH 
and other relevant targets. The study demonstrated that changes in the structure could 
improve the potency and selectivity of the effect. Consequently, this is an interesting 
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Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric 
analogs: A new class of selective antitubercular agents active against drug-
susceptible and multidrug-resistant mycobacteria. European Journal of 
Medicinal Chemistry, 82, pp.324–340. 
Karabanovich, G., Roh, J., Soukup, O.R., Avko, I., Eta Pasdioro, M., Ech Tambor, 
V., Rina, J., Iko, S., Vejso, M., Avro, K.R., So, K. & Hra Alek, A., 2015. 
Tetrazole regioisomers in the development of nitro group-containing 
antitubercular agents. Medicinal Chemical Communications, 6, pp.174–181. 
Karabanovich, G., Zemanova, J., Smutny, T., Szeely, R., Vocat, A., Pakova, I., 
Onka, P.C.̌, Ně Meč Ek, J., Ina, J., Íkova, S., Vejsova, M., Ina, K., Vě, V., Ova, 
K., Hrabaíek, A., Paek, P., Cole, S.T., Mikuš Ova, K. & Roh, J., 2016. 
Development of 3,5-dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as 
selective antitubercular agents active against replicating and nonreplicating 
Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 59, pp.2362–
2380. 
Kashchiev, D., 2000. Nucleation : basic theory with applications 1st Ed., Burlington: 
Butterworth Heinemann. 
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., 
 249 
Tarzia, G., Rana, G. La, Calignano, A., Giustino, A., Tattoli, M., Palmery, M., 
Cuomo, V., Piomelli, D., Valio, F., Duranti, A., Tontini, A., Mor, M., Tarzia, 
G., Rana, G. La, Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, 
V. & Piomelli, D., 2002. Modulation of anxiety through blockade of 
anandamide hydrolysis. Nature Medicine, 9(1), pp.76–81. 
Kengatharan, K.M., De Kimpe, S., Robson, C., Foster, S.J. & Thiemermann, C., 
1998. Mechanism of gram-positive shock: identification of peptidoglycan and 
lipoteichoic acid moieties essential in the induction of nitric oxide synthase, 
shock, and multiple organ failure. Journal of Experimental Medicine, 188(2), 
pp.305–15. 
Khalil, A., Hassawi, D.S. & Kharma, A., 2005. Genetic relationship among Salvia 
species and antimicrobial activity of their crude extract against pathogenic 
bacteria. Asian Journal of Plant Sciences, 4(5), pp.544–549. 
King, D.T., King, A.M., Lal, S.M., Wright, G.D. & Strynadka, N.C.J., 2015. 
Molecular mechanism of avibactam-mediated β-lactamase inhibition. ACS 
Infectious Diseases, 1(4), pp.175–184. 
Kirby, W.M.M., 1944. Extraction of a highly potent penicillin inactivator from 
penicillin resistant Staphylococci. Science, 99(2579), pp.452–453. 
Kiriyama, T., Miyake, Y., Sugai, M., Kobayashi, K., Yoshiga, K., Takada, K. & 
Suginaka, H., 1987. Effects of mucopolysaccharides on penicillin-induced lysis 
of Staphylococcus aureus. Journal of Medical Microbiology, 24(4), pp.325–
331. 
Kitchen, D.B., Decornez, H., Furr, J.R. & Bajorath, J., 2004. Docking and scoring in 
virtual screening for drug discovery methods and applications. Nature Reviews 
Drug Discovery, 3, pp.935–949. 
Knox, J.R., 1995. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: 
Mutations, specificity, and three-dimensional structure. Antimicrobial Agents 
and Chemotherapy, 39(12), pp.2593–2601. 
Knox, J.R., Moews, P.C. & Frere, J.-M., 1996. Molecular evolution of bacterial β-
lactam resistance. Chemistry and Biology, 3(11), pp.937–947. 
Koch, H.U., Haas, R. & Fischer, W., 1984. The role of lipoteichoic acid biosynthesis 
 250 
in membrane lipid metabolism of growing Staphylococcus aureus. European 
Journal of Biochemistry, 138(2), pp.357–63. 
Koebnik, R., Locher, K.P. & Van Gelder, P., 2000. Structure and function of 
bacterial outer membrane proteins: barrels in a nutshell. Molecular 
Microbiology, 37(2), pp.239–53. 
Kong, K.-F., Schneper, L. & Mathee, K., 2010. β-lactam antibiotics: from antibiosis 
to resistance and bacteriology. APMIS : Acta Pathologica, Microbiologica, et 
Immunologica Scandinavica, 118(1), pp.1–36. 
Korsak, D., Liebscher, S. & Vollmer, W., 2005. Susceptibility to antibiotics and β-
Lactamase induction in murein hydrolase mutants of Escherichia coli. 
Antimicrobial Agents and Chemotherapy, 49(4), pp.1404–1409. 
Kronvall, G., Giske, C.G. & Kahlmeter, G., 2011. Setting interpretive breakpoints 
for antimicrobial susceptibility testing using disk diffusion. International 
Journal of Antimicrobial Agents, 38(4), pp.281–290. 
Krsta, D., Ku, C., Crosby, I.T., Capuano, B. & Manallack, D.T., 2014. Bacterial fatty 
acid synthesis: effect of Tween 80 on antibiotic potency against Streptococcus 
Agalactiae and Methicillin-Resistant Staphylococcus Aureus. Anti-Infective 
Agents, 12(1), pp.80–84. 
Kumalo, H., Bhakat, S. & Soliman, M., 2015. Theory and applications of covalent 
docking in drug discovery: Merits and pitfalls. Molecules, 20(2), pp.1984–2000. 
Kumar, A. & Schweizer, H.P., 2005. Bacterial resistance to antibiotics: active efflux 
and reduced uptake. Advanced Drug Delivery Reviews, 57(10), pp.1486–513. 
Kumar, C.N.S.S.P., Parida, D.K., Santhoshi, A., Kota, A.K., Sridhar, B., Rao, V.J., 
Jin, Y., Jiang, Y., Bruyère, C., Dubois, J., Mathieu, V., Kornienko, A., Kiss, R., 
Evidente, A., Bountra, C., Evans, D.C., Stapert, D. & Yagi, B.H., 2011. 
Synthesis and biological evaluation of tetrazole containing compounds as 
possible anticancer agents. Medicinal Chemistry Communications, 2(6), p.486. 
Kundrot, C.E., 2004. Which strategy for a protein crystallization project? Cellular 
and Molecular Life Sciences (CMLS), 61(5), pp.525–536. 
Kwon, Y.-J., Fang, Y., Xu, G.-H. & Kim, W.-G., 2009. Aquastatin A, a new 
inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611. 
 251 
Biological and Pharmaceutical Bulletin, 32(12), pp.2061–4. 
Kwon, Y.-J., Sohn, M.-J. & Kim, W.-G., 2011. Aquastatin C, a new glycoaromatic 
derivative from Sporothrix sp. FN611. Journal of Antibiotics, 64156, pp.213–
216. 
Labia, R. & Peduzzi, J., 1978. Kinetics of β-lactamase inhibition by clavulanic acid. 
Biochimica et Biophysica Acta, 526(2), pp.572–9. 
Lahiri, S.D.D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, 
G. & Docquier, J.-D.J.-D., 2013. Structural insight into potent broad-spectrum 
inhibition with reversible recyclization mechanism: avibactam in complex with 
CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases. Antimicrobial 
Agents and Chemotherapy, 57(6), pp.2496–2505. 
Lahiri, S.D., Johnstone, M.R., Ross, P.L., Mclaughlin, R.E., Olivier, N.B. & Alm, 
R.A., 2014. Avibactam and Class C β-Lactamases: Mechanism of inhibition, 
conservation of the binding pocket, and implications for resistance. 
Antimicrobial Agents and Chemotherapy, 58(10), pp.5704–5713. 
Lambert, P. a, 2005. Bacterial resistance to antibiotics: modified target sites. 
Advanced Drug Delivery Reviews, 57(10), pp.1471–85. 
Lamotte-Brasseur, J., Dubus, A. & Wade, R.C., 2000. pKa calculations for class C β-
lactamases: The role of Tyr-150. Proteins: Structure, Function, and Genetics, 
40(1), pp.23–28. 
Land, M., Hauser, L., Jun, S.-R., Nookaew, I., Leuze, M.R., Ahn, T.-H., Karpinets, 
T., Lund, O., Kora, G., Wassenaar, T., Poudel, S. & Ussery, D.W., 2015. 
Insights from 20 years of bacterial genome sequencing. Functional & 
Integrative Genomics, 15(2), pp.141–61. 
Langer, T. & Hoffmann, R., 2001. Virtual Screening An Effective Tool for Lead 
Structure Discovery. Current Pharmaceutical Design, 7(7), pp.509–527. 
Laursen, B.S., Sørensen, H.P., Mortensen, K.K. & Sperling-Petersen, H.U., 2005. 
Initiation of protein synthesis in bacteria. Microbiology and Molecular Biology 
Reviews, 69(1), pp.101–23. 
Lee, C.-R., Lee, J.H., Park, K.S., Kim, Y.B., Jeong, B.C. & Lee, S.H., 2016. Global 
dissemination of carbapenemase-producing Klebsiella pneumoniae: 
 252 
epidemiology, genetic context, treatment options, and detection methods. 
Frontiers in Microbiology, 7, p.895. 
Lee, E.H., Nicolas, M.H., Kitzis, M.D., Pialoux, G., Collatz, E. & Gutmann, L., 
1991. Association of two resistance mechanisms in a clinical isolate of 
Enterobacter cloacae with high-level resistance to imipenem. Antimicrobial 
Agents and Chemotherapy, 35(6), pp.1093–8. 
Lee, G. & Bishop, P., 2012. Microbiology and infection control for health 
professionals 6th Ed., Sydney; Prentice Hall. 
Lefurgy, S.T., De Jong, R.M. & Cornish, V.W., 2007. Saturation mutagenesis of 
Asn152 reveals a substrate selectivity switch in P99 cephalosporinase. Protein 
Science, 16, pp.2636–2646. 
Legendre, D., Vucic, B., Hougardy, V., Girboux, A.-L., Henrioul, C., Van Haute, J., 
Soumillion, P. & Fastrez, J., 2002. TEM-1 β-lactamase as a scaffold for protein 
recognition and assay. Protein Science, 11(6), pp.1506–1518. 
Leggett, H.C., Cornwallis, C.K. & West, S.A., 2012. Mechanisms of Pathogenesis, 
Infective Dose and Virulence in Human Parasites R. Antia, ed. PLoS 
Pathogens, 8(2), p.e1002512. 
Levasseur, P., Girard, A.-M., Claudon, M., Goossens, H., Black, M.T., Coleman, K. 
& Miossec, C., 2012. In vitro antibacterial activity of the ceftazidime-avibactam 
(NXL104) combination against Pseudomonas aeruginosa clinical isolates. 
Antimicrobial Agents and Chemotherapy, 56(3), pp.1606–8. 
Levy, C.W., Roujeinikova, A., Sedelnikova, S., Baker, P.J., Stuitje, A.R., Slabas, 
A.R., Rice, D.W., Rafferty, J.B. & Rafferty, J.B., 1999. Molecular basis of 
triclosan activity. Nature, 398(6726), pp.383–384. 
Levy, S.B., 2002. Factors impacting on the problem of antibiotic resistance. Journal 
of Antimicrobial Chemotherapy, 49(1), pp.25–30. 
Levy, S.B. & Marshall, B., 2004. Antibacterial resistance worldwide: causes, 
challenges and responses. Nature Medicine, 10(12s), pp.S122–S129. 
Lewis, K., 2017. New approaches to antimicrobial discovery. Biochemical 
Pharmacology, 134, pp.87–98. 
 253 
Li, N., Xu, Y., Xia, Q., Bai, C., Wang, T., Wang, L., He, D., Xie, N., Li, L., Wang, 
J., Zhou, H.-G., Xu, F., Yang, C., Zhang, Q., Yin, Z., Guo, Y. & Chen, Y., 
2014. Simplified captopril analogues as NDM-1 inhibitors. Bioorganic and 
Medicinal Chemistry Letters, 24(1), pp.386–389. 
Li, X.-Z. & Nikaido, H., 2009. Efflux-mediated drug resistance in bacteria: an 
update. Drugs, 69(12), pp.1555–1623. 
Liakopoulos, A., Mevius, D. & Ceccarelli, D., 2016. A review of SHV extended-
spectrum β-lactamases: Neglected yet ubiquitous. Frontiers in Microbiology, 7, 
p.1374. 
Liénard, B.M.R., Garau, G., Horsfall, L., Karsisiotis, A.I., Damblon, C., Lassaux, P., 
Papamicael, C., Roberts, G.C.K., Galleni, M., Dideberg, O., Frère, J.-M. & 
Schofield, C.J., 2008. Structural basis for the broad-spectrum inhibition of 
metallo-β-lactamases by thiols. Organic and Biomolecular Chemistry, 6(13), 
p.2282. 
Lister, P.D., Wolter, D.J. & Hanson, N.D., 2009. Antibacterial-resistant 
Pseudomonas aeruginosa: clinical impact and complex regulation of 
chromosomally encoded resistance mechanisms. Clinical Microbiology 
Reviews, 22(4), pp.582–610. 
Livermore, D.M., 1995. β-Lactamases in laboratory and clinical resistance. Clinical 
Microbiology Reviews, 8(4), pp.557–84. 
Livermore, D.M. & Brown, D.F., 2001. Detection of β-lactamase-mediated 
resistance. The Journal of Antimicrobial Chemotherapy, 48 Suppl 1, pp.59–64. 
Livermore, D.M., Mushtaq, S., Warner, M., Miossec, C. & Woodford, N., 2008. 
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-
spectrum β-lactamases and carbapenemases. Journal of Antimicrobial 
Chemotherapy, 62(5), pp.1053–1056. 
Livermore, D.M., Warner, M., Jamrozy, D., Mushtaq, S., Nichols, W.W., Mustafa, 
N. & Woodford, N., 2015. In vitro selection of ceftazidime-avibactam 
resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrobial 
Agents and Chemotherapy, 59(9), pp.5324–30. 
Llosa, M. & de la Cruz, F., 2005. Bacterial conjugation: a potential tool for genomic 
 254 
engineering. Research in Microbiology, 156(1), pp.1–6. 
Lobkovsky, E., Moews, P.C., Liu, H., Zhao, H., Freret, J.-M. & Knox, J.R., 1993. 
Evolution of an enzyme activity: Crystallographic structure at 2-A resolution of 
cephalosporinase from the ampC gene of Enterobacter cloacae P99 and 
comparison with a class A penicillinase (β-lactamase/protein folding/bacterial 
β-lactam resistance). Biochemistry, 90, pp.11257–11261. 
Lobkovsky, E., Billings, E.M., Moews, P.C., Rahil, J., Pratt, R.F. & Knox, J.R., 
1994. Crystallographic structure of a phosphonate derivative of the 
Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-
Lactamase transition-state analog. Biochemistry, 33(22), pp.6762–6772. 
London, N., Miller, R.M., Krishnan, S., Uchida, K., Irwin, J.J., Eidam, O., Gibold, 
L., Cimermančič, P., Bonnet, R., Shoichet, B.K. & Taunton, J., 2014. Covalent 
docking of large libraries for the discovery of chemical probes. Nature 
Chemical Biology, 10(12), pp.1066–1072. 
London, N., Farelli, J.D., Brown, S.D., Liu, C., Huang, H., Korczynska, M., Nawar, 
F.A., Al-Obaidi, F., Babbitt, P.C., Almo, S.C., Allen, K.N. & Shoichet, B.K., 
2015. Covalent docking predicts substrates for haloalkanoate dehalogenase 
superfamily phosphatases. Biochemistry, 54, pp.528–537. 
Lorian, V., 2005. Antibiotics in laboratory medicine 5th Ed., Lippincott Williams & 
Wilkins. 
Lovering, A.L., de Castro, L.H., Lim, D. & Strynadka, C.J., 2007. Structural Insight 
into the Transglycosylation Step of Bacterial Cell-Wall Biosynthesis. Science, 
315, pp.1402–1403. 
Luhavaya, H.M. & Grigorenko, V.G., 2010. Catalytic properties of recombinant 
class a TEM-1 β-lactamase and its inhibition by sulbactam, tazobactam, and 
clavulanic acid. Moscow University Chemistry Bulletin, 65(3), pp.144–147. 
M. Bamberger, D., Goers, M., Quinn, T. & Herndon, B., 2012. Reduction of β-
lactam antimicrobial activity in Staphylococcus aureus abscesses by neutrophil 
alteration of penicillin-binding protein 2. Advances in Infectious Diseases, 2(2), 
pp.48–52. 
Madadlou, A., O’Sullivan, S., Sheehan, D., O’Sullivan, S., Sheehan, D. & Sheehan, 
 255 
D., 2011. Fast Protein Liquid Chromatography. In J. M. Walker, ed. Methods in 
Molecular Biology. Humana Press, pp. 439–447. 
Magaldi, S., Mata-Essayag, S., Hartung de Capriles, C., Perez, C., Colella, M.T., 
Olaizola, C. & Ontiveros, Y., 2004. Well diffusion for antifungal susceptibility 
testing. International Journal of Infectious Diseases, 8(1), pp.39–45. 
Maguire, B.A., 2009. Inhibition of bacterial ribosome assembly: a suitable drug 
target? Microbiology and Molecular Biology Reviews, 73(1), pp.22–35. 
Maione, S., Morera, E., Marabese, I., Ligresti, A., Luongo, L., Ortar, G. & Di Marzo, 
V., 2009. Antinociceptive effects of tetrazole inhibitors of endocannabinoid 
inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. 
British Journal of Pharmacology, 155(5), pp.775–782. 
Malmstrom, R.D. & Watowich, S.J., 2011. Using free energy of binding calculations 
to improve the accuracy of virtual screening predictions. Journal of Chemical 
Information and Modeling, 51(7), pp.1648–55. 
Maltezou, H.C., 2009. Metallo-β-lactamases in Gram-negative bacteria: introducing 
the era of pan-resistance? International Journal of Antimicrobial Agents, 
33(405), pp.1–405. 
Mani, N., Tobin, P. & Jayaswal, R.K., 1993. Isolation and characterization of 
autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ 
mutagenesis. Journal of Bacteriology, 175(5), pp.1493–9. 
Mann, M., Hendrickson, R.C. & Pandey, A., 2001. Analysis of proteins and 
proteomes by mass spectrometry. Annual Review of Biochemistry, 70, pp.437–
73. 
Marchou, B., Bellido, F., Charnas, R., Lucain, C. & Pechère, J.C., 1987. 
Contribution of β-lactamase hydrolysis and outer membrane permeability to 
ceftriaxone resistance in Enterobacter cloacae. Antimicrobial Agents and 
Chemotherapy, 31(10), pp.1589–95. 
Martinez, J.L. & Baquero, F., 2000. Mutation Frequencies and Antibiotic Resistance. 
Journal of Antimicrobial and Chemotherapy, 44(7), pp.1771–1777. 
Martinez, J.L., 2009. Environmental pollution by antibiotics and by antibiotic 
resistance determinants. Environmental Pollution, 157(11), pp.2893–902. 
 256 
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C. & 
Piomelli, D., 1994. Formation and inactivation of endogenous cannabinoid 
anandamide in central neurons. Nature, 372(6507), pp.686–691. 
Massidda, O., Rossolini, G.M. & Satta, G., 1991. The Aeromonas hydrophila cphA 
gene: molecular heterogeneity among class B metallo-β-lactamases. Journal of 
Bacteriology, 173(15), pp.4611–7. 
Matthew, M., 1979. Plasmid-mediated β-lactamases of Gram-negative bacteria: 
properties and distribution. Journal of Antimicrobial Chemotherapy, 5(4), 
pp.349–58. 
Matysiak, J., Niewiadomy, A., Krajewska-Kułak, E. & Mącik-Niewiadomy, G., 
2003. Synthesis of some 1-(2,4-dihydroxythiobenzoyl)imidazoles, -imidazolines 
and -tetrazoles and their potent activity against Candida species. Il Farmaco, 
58(6), pp.455–461. 
Maveyraud, L., Golemi, D., Kotra, L.P., Tranier, S., Vakulenko, S., Mobashery, S. & 
Samama, J.P., 2000. Insights into class D β-lactamases are revealed by the 
crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. 
Structure, 8(12), pp.1289–98. 
Mcconkey, B.J., Sobolev, V. & Edelman, M., 2002. The performance of current 
methods in ligand–protein docking. Current Science, 83(7), pp.845–856. 
McKinney, M.K. & Cravatt, B.F., 2005. Structure and function of fatty acid amide 
hydrolase. Annual Review of Biochemistry, 74, pp.411–32. 
McManus, M.C., 1997. Mechanisms of bacterial resistance to antimicrobial agents. 
American Journal of Health-System Pharmacy, 54(12), pp.1420-33–6. 
McMaster, M.C., 2007. HPLC, a practical user’s guide 2nd Ed., Wiley-Interscience. 
McPherson, A., 1990. Current approaches to macromolecular crystallization. 
European Journal of Biochemistry, 189(1), pp.1–23. 
McPherson, A., 1982. Preparation and analysis of protein crystals, Wiley. 
Meetani, M.A. & Voorhees, K.J., 2005. MALDI mass spectrometry analysis of high 
molecular weight proteins from whole bacterial cells: Pretreatment of samples 
with surfactants. Journal of American Society for Mass Spectrometry, 16, 
 257 
pp.1422–1426. 
Melnyk, A.H., Wong, A. & Kassen, R., 2015. The fitness costs of antibiotic 
resistance mutations. Evolutionary Applications, 8(3), pp.273–83. 
Meng, X.-Y., Zhang, H.-X., Mezei, M. & Cui, M., 2011. Molecular docking: a 
powerful approach for structure-based drug discovery. Current Computer-Aided 
Drug Design, 7(2), pp.146–57. 
Meredith, T.C., Swoboda, J.G. & Walker, S., 2008. Late-stage polyribitol phosphate 
wall teichoic acid biosynthesis in Staphylococcus aureus. Journal of 
Bacteriology, 190(8), pp.3046–3056. 
Michel, J., Tirado-Rives, J. & Jorgensen, W.L., 2009. Prediction of the water content 
in protein binding sites. Journal of Physical Chemistry., 113(40), pp.13337–46. 
Mileni, M., Kamtekar, S., Wood, D.C., Benson, T.E., Cravatt, B.F. & Stevens, R.C., 
2010. Crystal structure of fatty acid amide hydrolase bound to the carbamate 
inhibitor URB597: Discovery of a deacylating water molecule and insight into 
enzyme inactivation. Journal of Molecular Biology, 400(4), pp.743–754. 
Miles, D.L., Miles, D.W. & Eyring, H., 1978. A conformational basis for the 
antiviral inactivity of tetrazole ribonucleosides. Biochimica et Biophysica Acta, 
518(1), pp.17–30. 
Minami, S., Inoue, M. & Mitsuhashi, S., 1980. Purification and properties of a 
cephalosporinase from Enterobacter cloacae. Antimicrobial Agents and 
Chemotherapy, 18(6), pp.853–7. 
Minke, W.E., Diller, D.J., Hol, W.G.J. & Verlinde, C.L.M.J., 1999. The role of 
waters in docking strategies with incremental flexibility for carbohydrate 
derivatives: Heat-labile enterotoxin, a multivalent test case. Journal of 
Medicinal Chemistry, 42(10), pp.1778–1788. 
Minond, D., Saldanha, S., Spicer, T., Qin, L., Mercer, B., Roush, W. & Hodder, P., 
2010. HTS Assay for Discovery of Novel Metallo-β-lactamase (MBL) Inhibitors, 
National Center for Biotechnology Information (US). 
Mirkovic, N., Li, Z., Parnassa, A. & Murray, D., 2006. Strategies for high-
throughput comparative modeling: Applications to leverage analysis in 
structural genomics and protein family organization. Proteins: Structure, 
 258 
Function, and Bioinformatics, 66(4), pp.766–777. 
Miyakawa, S., Suzuki, K., Noto, T., Harada, Y. & Okazaki, H., 1982. 
Thiolactomycin, a new antibiotic. IV. Biological properties and 
chemotherapeutic activity in mice. Journal of Antibiotics, 35(4), pp.411–9. 
Mohamed, M., El-Domany, R. & Abd El-Hameed, R., 2009. Synthesis of certain 
pyrrole derivatives as antimicrobial agents. Acta Pharmaceutica, 59(2), pp.145–
58. 
Mohite, P., Mohite, P.B. & Bhaskar, V.H., 2011. Synthesis and antifungal activity of 
3-aryl-1-(5-phenyl-1H-tetrazol-1-yl)prop-2-en-1-One. Orbital - The Electronic 
Journal of Chemistry, 2(3), pp.311–315. 
Mohite PB & Bhaskar VH, 2011. Potential pharmacological activities of tetrazoles in 
the new millennium. International Journal of PharmTech Research, 3(3), 
pp.1557–1566. 
Moitessier, N., Englebienne, P., Lee, D., Lawandi, J. & Corbeil, C.R., 2009. Towards 
the development of universal, fast and highly accurate docking/scoring 
methods: a long way to go. British Journal of Pharmacology, 153(S1), pp.S7–
S26. 
Mojica, M.F., Bonomo, R.A. & Fast, W., 2016. B1-Metallo-β-Lactamases: Where do 
we stand? Current Drug Targets, 17(9), pp.1029–1050. 
Mollard, C., Moali, C., Papamicael, C., Damblon, C., Vessilier, S., Amicosante, G., 
Schofield, C.J., Galleni, M., Frere, J.M. & Roberts, G.C., 2001. Thiomandelic 
acid, a broad spectrum inhibitor of zinc β-lactamases. Kinetic and spectroscopy 
studies. Journal of Biological Chemistry, 276(48), pp.45015–45023. 
Momose, Y., Maekawa, T., Odaka, H., Ikeda, H. & Sohda, T., 2002. Novel 5-
substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. 
Chemical and Pharmaceutical Bulletin, 50(1), pp.100–11. 
Monnaie, D., Dubus, A., Cooke, D., Marchand-Brynaert, J., Normark, S. & Frère, 
J.M., 1994. Role of residue Lys315 in the mechanism of action of the 
Enterobacter cloacae 908R β-lactamase. Biochemistry, 33(17), pp.5193–201. 
Monnaie, D., Dubus, A., Frère, J.M. & Frere, J.-M., 1994. The role of lysine-67 in a 
class C β-lactamase is mainly electrostatic. Biochemical Journal, 302(1), pp.1–
 259 
4. 
Moore, S.A., Nomikos, G.G., Dickason-Chesterfield, A.K., Schober, D.A., Schaus, 
J.M., Ying, B.-P., Xu, Y.-C., Phebus, L., Simmons, R.M.A., Li, D., Iyengar, S. 
& Felder, C.C., 2005. Identification of a high-affinity binding site involved in 
the transport of endocannabinoids. Proceedings of the National Academy of 
Sciences of the United States of America, 102(49), pp.17852–7. 
Mor, M., Rivara, S., Lodola, A., Plazzi, P.V., Tarzia, G., Duranti, A., Tontini, A., 
Piersanti, G., Kathuria, S. & Piomelli, D., 2004. Cyclohexylcarbamic acid 3′-or 
4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: 
Synthesis, quantitative structure-activity relationships, and molecular modeling 
studies. Journal of Medicinal Chemistry, 47, pp.4998–5008. 
Mushtaq, S., Warner, M. & Livermore, D.M., 2010. In vitro activity of ceftazidime + 
NXL104 against Pseudomonas aeruginosa and other non-fermenters. Journal of 
Antimicrobial Chemotherapy, 65(11), pp.2376–2381. 
Myrianthopoulos, V., Kritsanida, M., Gaboriaud-Kolar, N., Magiatis, P., Ferandin, 
Y., Durieu, E., Lozach, O., Cappel, D., Soundararajan, M., Filippakopoulos, P., 
Sherman, W., Knapp, S., Meijer, L., Mikros, E. & Skaltsounis, A.-L., 2013. 
Novel inverse binding mode of indirubin derivatives yields improved selectivity 
for DYRK kinases. ACS Medicinal Chemistry Letters, 4(1), pp.22–26. 
Naumovski, L., Quinn, J.P., Miyashiro, D., Patel, M., Bush, K., Singer, S.B., Graves, 
D., Palzkill, T. & Arvin ’, A.M., 1992. Outbreak of ceftazidime resistance due 
to a novel extended-spectrum β-lactamase in isolates from cancer patients. 
Antimicrobial Agents and Chemotherapy, 36(9), pp.1991–1996. 
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 NMR Analyses 8.1
 
Figure 8.1. (A) 
13
C and (B) HMQC NMR spectra of 1,5-LY2183240 recorded in MeOH-d4. 
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Figure 8.2. (A) COSY and (B) HMBC NMR spectra of 1,5-LY2183240 recorded in MeOH-d4. 
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Figure 8.3. (A) NOESY and (B) DEPT NMR spectra of 1,5-LY2183240 recorded in MeOH-d4. 
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Figure 8.4. (A) 
13
C and (B) HMQC NMR spectra of 2,5-LY2183240 recorded in MeOH-d4. 
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Figure 8.5. (A) COSY and (B) HMBC NMR spectra of 2,5-LY2183240 recorded in MeOH-d4. 
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Figure 8.6. (A) NOESY and (B) DEPT NMR spectra of 2,5-LY2183240 recorded in MeOH-d4.
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